Document:

EX-4.11

 Exhibit 4.11 

xxxx INDICATES CONFIDENTIAL MATERIAL OMITTED PURSUANT TO A 

REQUEST FOR CONFIDENTIAL TREATMENT AND FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION SEPARATELY WITH A REQUEST 

FOR CONFIDENTIAL TREATMENT. 

K&L GATES 
 Share Sale
Agreement 
 Kilinwata Investments Pty. Ltd. 

ACN 009 641 212 and 
 Mi Ok Chong

 and 
 Paul Hopper 

and 
 Novogen Limited 

ACN 063 259 754 
 K&L Gates 

Melbourne office 
 Ref:
baldij.petranp. 
  
 Confidential material omitted and filed separately
with the Commission. 

 Table of Contents 
  

							
	1.	  	 Definitions and interpretation
	  	 	5	 
	1.1	  	 Definitions
	  	 	5	 
	1.2	  	 Interpretation
	  	 	14	 
			
	2.	  	 Agreement to buy and sell Shares
	  	 	15	 
	2.1	  	 Sale and purchase
	  	 	15	 
	2.2	  	 Date for Completion
	  	 	15	 
	2.3	  	 Encumbrances and rights
	  	 	15	 
	2.4	  	 Title and risk
	  	 	16	 
	2.5	  	 Purchase of all the Shares
	  	 	16	 
	2.6	  	 Waiver of pre-emptive rights
	  	 	16	 
			
	3.	  	 Conditions precedent
	  	 	16	 
	3.1	  	 Conditions precedent to Completion
	  	 	16	 
	3.2	  	 Duties in relation to Conditions
	  	 	16	 
	3.3	  	 Fulfilment by waiver
	  	 	16	 
	3.4	  	 Failure of Condition
	  	 	17	 
			
	4.	  	 Conduct pending Completion
	  	 	17	 
	4.1	  	 Conduct of Business
	  	 	17	 
	4.2	  	 Assistance and access for Buyer
	  	 	17	 
	4.3	  	 Confidentiality
	  	 	18	 
	4.4	  	 Notice of material changes
	  	 	18	 
	4.5	  	 No discussions
	  	 	18	 
			
	5.	  	 Completion
	  	 	18	 
	5.1	  	 Time and place for Completion
	  	 	18	 
	5.2	  	 Sellers’ obligations at Completion
	  	 	18	 
	5.3	  	 Buyer’s obligations at Completion
	  	 	20	 
	5.4	  	 Conditions of Completion
	  	 	20	 
	5.5	  	 Delayed delivery of Completion items
	  	 	20	 
			
	6.	  	 Completion Consideration
	  	 	21	 
	6.1	  	 Completion Cash Amount
	  	 	21	 
	6.2	  	 Completion Shares
	  	 	21	 
			
	7.	  	 Milestone Consideration
	  	 	22	 
	7.1	  	 Milestones
	  	 	22	 
	7.2	  	 Milestone 1
	  	 	22	 
	7.3	  	 Mechanics of issue of Milestone 1 Shares
	  	 	22	 
	7.4	  	 Milestone 2
	  	 	23	 
	7.5	  	 Mechanics of issue of Milestone 2 Shares
	  	 	23	 
	7.6	  	 Milestone 3
	  	 	24	 
	7.7	  	 Mechanics of Milestone 3 Consideration - Shares
	  	 	24	 
	7.8	  	 If approvals not obtained
	  	 	26	 
	7.9	  	 Mechanics of Milestone 3 Consideration - Cash
	  	 	27	 
	7.10	  	 Maximum Payable
	  	 	27	 
	7.11	  	 Milestone 4
	  	 	27	 
	7.12	  	 Mechanics of Milestone 4 Consideration
	  	 	27	 

  
 Table of Contents (ctd) 

 

 Confidential material omitted and filed separately with the Commission. 

  
 2 

							
	8.	  	 Obligations until registration of transfer
	  	 	29	 
	8.1	  	 Buyer's obligation to register
	  	 	29	 
	8.2	  	 Sellers' obligations
	  	 	29	 
			
	9.	  	 Rights and obligations after Completion
	  	 	29	 
	9.1	  	 Novogen Appointment
	  	 	29	 
	9.2	  	 Sellers assistance following Completion
	  	 	29	 
	9.3	  	 Access to Records
	  	 	29	 
			
	10.	  	 Tax matters
	  	 	30	 
	10.1	  	 Completion of Tax returns and calculations
	  	 	30	 
	10.2	  	 Tax enquiries or audits by Government Agency
	  	 	30	 
			
	11.	  	 Sellers’ Warranties
	  	 	31	 
	11.1	  	 Warranties
	  	 	31	 
	11.2	  	 Disclosure Material
	  	 	31	 
	11.3	  	 Separate warranties
	  	 	31	 
	11.4	  	 Sellers must notify breaches
	  	 	32	 
	11.5	  	 Qualification as to knowledge
	  	 	32	 
			
	12.	  	 Indemnities
	  	 	32	 
	12.1	  	 Indemnity for Warranty Claims
	  	 	32	 
	12.2	  	 Tax Indemnity
	  	 	32	 
			
	13.	  	 Claiming under the Sellers’ Warranties and the Indemnities
	  	 	32	 
	13.1	  	 Notice of Claims
	  	 	32	 
	13.2	  	 Seller Warrantors to consider Claims
	  	 	33	 
	13.3	  	 Time limits for Claims
	  	 	33	 
	13.4	  	 Maximum amount the Buyer may recover
	  	 	33	 
	13.5	  	 Benefits received by the Buyer
	  	 	33	 
	13.6	  	 Escrow arrangement where Claim made
	  	 	33	 
	13.7	  	 Reduction in Purchase Price
	  	 	34	 
			
	14.	  	 Buyer’s Warranties
	  	 	34	 
	14.1	  	 Warranties
	  	 	34	 
	14.2	  	 Warranties true on Completion
	  	 	35	 
			
	15.	  	 Termination by Buyer before Completion
	  	 	35	 
	15.1	  	 Termination events
	  	 	35	 
	15.2	  	 Right of Buyer to terminate
	  	 	35	 
	15.3	  	 Remedies cumulative
	  	 	36	 
			
	16.	  	 Public announcements
	  	 	36	 
	16.1	  	 Making announcements
	  	 	36	 
	16.2	  	 Requirements
	  	 	36	 
			
	17.	  	 Confidentiality
	  	 	36	 
	17.1	  	 Obligation of confidentiality
	  	 	36	 
	17.2	  	 Exceptions
	  	 	36	 
	17.3	  	 Disclosure to Recipient
	  	 	37	 
	17.4	  	 Obligations
	  	 	37	 
	17.5	  	 Return or destruction of Confidential Information
	  	 	37	 
	17.6	  	 Post Completion
	  	 	38	 

  
 Table of Contents (ctd) 

 

 Confidential material omitted and filed separately with the Commission. 

  
 3 

							
	18.	  	GST	  	 	38	 
	18.1	  	Definitions	  	 	38	 
	18.2	  	Consideration is GST exclusive	  	 	38	 
	18.3	  	Payment of GST	  	 	38	 
	18.4	  	 Reimbursement of expenses
	  	 	38	 
			
	19.	  	 General
	  	 	39	 
	19.1	  	 Nature of obligations
	  	 	39	 
	19.2	  	 Entire understanding
	  	 	39	 
	19.3	  	 Survival of obligations
	  	 	39	 
	19.4	  	 No adverse construction
	  	 	39	 
	19.5	  	 Further assurances
	  	 	39	 
	19.6	  	 No waiver
	  	 	39	 
	19.7	  	 Severability
	  	 	40	 
	19.8	  	 Successors and assigns
	  	 	40	 
	19.9	  	 No assignment
	  	 	40	 
	19.10	  	 Consents and approvals
	  	 	40	 
	19.11	  	 No variation
	  	 	40	 
	19.12	  	 Costs
	  	 	40	 
	19.13	  	 Duty
	  	 	40	 
	19.14	  	 Governing law and jurisdiction
	  	 	40	 
	19.15	  	 Notices
	  	 	40	 
	19.16	  	 Counterparts
	  	 	41	 
	19.17	  	 Conflicting provisions
	  	 	42	 
	19.18	  	 No merger
	  	 	42	 
	19.19	  	 Operation of indemnities
	  	 	42	 
	19.20	  	 No right of set-off
	  	 	42	 
	19.21	  	 Relationship of parties
	  	 	42	 
		
	 Schedule 1 - Share Details
	  	 	43	 
		
	 Schedule 2 - Corporate Details
	  	 	44	 
		
	 Schedule 3 - Conditions to Completion
	  	 	45	 
		
	 Schedule 4 - The Sellers’ Warranties
	  	 	46	 
		
	 Schedule 5 - The Disclosure Material
	  	 	XX	 
		
	 Annexure 1 - The Accounts
	  	 	XX	 
		
	 Annexure 2 - Escrow Agreement
	  	 	XX	 
		
	 Annexure 3 - Licence Agreement
	  	 	XX	 
		
	 Annexure 4 - Hopper Appointment Agreement
	  	 	XX	 
		
	 Annexure 5 - Chong Appointment Agreement
	  	 	XX	 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 4 

 Share Sale Agreement 

Date 2016 
 Parties 

 

	1.	Kilinwata Investments Pty. Ltd. ACN 009 641 212 of Unit 101 50 McLachlan Avenue Rushcutters Bay NSW 2011 

  

	2.	Mi Ok Chong XXXX 

  

	 	(each a Seller and collectively known as the Sellers) 

  

	3.	Paul Hopper of XXXX 

  

	    	(Warrantor) 

  

	4.	Novogen Limited ACN 063 259 754 of Suite 502, 20 George Street Hornsby NSW 2077 (Buyer) 

Background 
  

	A.	The Shares are owned by the Sellers as set out in Schedule 1. 

  

	B.	The Sellers have agreed to sell to the Buyer and the Buyer has agreed to buy the Shares from the Sellers on the terms and conditions of this Agreement. 

 

	C.	In further consideration of the purchase of the Shares, the Sellers have agreed to facilitate the Buyer’s entry into the Licence Agreement and the entry of Paul Hopper and Mi Ok Chong into consultancy agreements
with the Buyer. 

 Agreed terms 
  

	1.	Definitions and interpretation 

  

	1.1	Definitions 

 In this Agreement: 

Accounting Standards means: 
  

	 	(a)	the accounting standards made by the Australian Accounting Standards Board in accordance with the Corporations Act, and the requirements of that Act relating to the preparation and content of financial statements; and

  

	 	(b)	generally accepted accounting principles that are consistently applied in Australia, except those inconsistent with the standards or requirements referred to in paragraph (a); 

Accounts means: 
  

	 	(a)	the balance sheet of the Company as at the Accounts Date; 

  

	 	(b)	the income statement of the Company for the 12 month period ending on the Accounts Date; 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 5 

	 	(c)	the statement of cash flow of the Company for the 12 month period ending on the Accounts Date; and 

  

	 	(d)	the notes to, and the reports of the directors relating to, those statements, as set out in Annexure 1; 

Accounts Date means 31 August 2016; 

Agreement means this deed including the background, any schedules and any annexures; 

Agreement Date means the date of this Agreement; 

ASIC means the Australian Securities and Investment Commission; 

Associate has the same meaning as “associate” in the Corporations Act and includes a person deemed to be an associate of a
designated body (within the meaning of section 12 of the Corporations Act); 
 ASX means ASX Limited ACN 008 624 691; 

ASX Listing Rules means the rules governing the procedures and behaviour of all entities listed on ASX; 

Business means the business carried on by the Company; 

Business Day means a day that is not a Saturday, Sunday, public holiday or bank holiday in Sydney New South Wales; 

Capital Raising means any capital raising of new Securities in the Buyer during the Milestone 3 Period, provided always that the new
Securities are issued, and funds for such Securities are actually received by the Buyer, during the Milestone 3 Period. The following will not be considered a Capital Raising, nor considered for any contribution to a Capital Raising: 

 

	 	(a)	funds relating to Securities issued before 1 September 2016, even where the funds are actually received during the Milestone 3 Period; 

 

	 	(b)	funds relating to Securities issued during the Milestone 3 Period where funds are actually received after the Milestone 3 Period; 

  

	 	(c)	funds relating to Securities issued pursuant to an option or convertible note issued before 1 September 2016; 

  

	 	(d)	funds relating to Securities issued under this Agreement; and 

  

	 	(e)	funds relating to Securities issued by the Buyer in consideration of any salary, services, or the acquisition of assets or shares; 

Capital Raising Announcement means the announcement of a Capital Raising to the ASX. For the avoidance of doubt, a Capital Raising
Announcement does not include any announcement in relation to the issue of Securities where the funds for such Securities have not been actually received by the Buyer; 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 6 

 Capital Raising Cash Payment means, with respect to each Capital Raising, an amount equal
to 12.35% of the Capital Raising Value with respect to that Capital Raising; 
 Capital Raising Notice means a notice issued in in
accordance with clause 7.6(b); 
 Capital Raising Shares means, with respect to each Capital Raising, the number of Novogen Shares
which is: 
 XXXX 
 and, if a
fractional entitlement, rounded up to the nearest whole number; 
 Capital Raising Value means, with respect to each Capital Raising,
the aggregate value of funds actually received for all new Securities in the Buyer received in that Capital Raising. The following will not be considered in determining the value of any Capital Raising: 

 

	 	(a)	funds relating to Securities issued before 1 September 2016, even where the funds are actually received during the Milestone 3 Period; 

 

	 	(b)	funds relating to Securities issued during the Milestone 3 Period where funds are actually received after the Milestone 3 Period; 

  

	 	(c)	funds relating to Securities issued pursuant to an option or convertible note issued before 1 September 2016; 

  

	 	(d)	funds relating to Securities issued under this Agreement; and 

  

	 	(e)	funds relating to Securities issued by the Buyer in consideration of any salary, services, or the acquisition of assets or shares; 

Chong Appointment Agreement means the agreement to appoint Mi Ok Chong as a consultant of the Buyer including with respect to
development of the Molecule, substantially in the form set out in Annexure 5; 
 Claim includes a claim, notice, demand, action,
proceeding, litigation, prosecution, arbitration, investigation, judgment, award, damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract, tort or statute
and whether involving a Third Party or a party to this Agreement or otherwise; 
 Company means Glioblast Pty Ltd ACN 612 141 625
of Unit 101, 50 McLachlan Avenue Rushcutters Bay NSW 2011, details of which are set out in Schedule 2; 
 Completion means the
completion of the sale and purchase of the Shares; 
 Completion Cash Amount means $600,000; 

Completion Date means the date on which Completion occurs; 

Completion Consideration means: 
  

	 	(a)	the Completion Cash Amount; plus 

  

	 	(b)	the Completion Shares; 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 7 

 Completion Deemed Issue Price means the volume weighted average price of Novogen Shares as
traded on the ASX in the 7 trading days before the date the Agreement is announced to the ASX; 
 Completion Shares means that number
of Novogen Shares calculated as follows: 
 $1,500,000 ÷ Completion Deemed Issue Price, and, if a fractional entitlement, rounded up
to the nearest whole number; 
 Conditions means the conditions referred to in clause 3 and specified in Schedule 3;  

Confidential Information means: 
  

	 	(a)	the terms of this Agreement and its subject matter, including Information submitted or disclosed by a party during negotiations, discussions and meetings relating to this Agreement; 

 

	 	(b)	Information that at the time of disclosure by a Disclosing Party is identified to the Receiving Party as being confidential; and 

  

	 	(c)	all other Information belonging or relating to a Disclosing Party, or any Related Entity of that Disclosing Party, that is not generally available to the public at the time of disclosure other than by reason of a breach
of this Agreement or which the Receiving Party knows, or ought reasonably to be expected to know, is confidential to that Disclosing Party or any Related Entity of that Disclosing Party; 

Control means, in relation to a body corporate, where a person is able to do any of the following things (whether alone or together with
any Associates and whether directly or indirectly or through one or more intervening persons, companies or trusts): 
  

	 	(a)	determine the composition of more than one half of the body’s board of directors; 

  

	 	(b)	determine the outcome of decisions of the body’s board of directors (either because the board is accustomed to act in accordance with that person’s directions or otherwise); 

 

	 	(c)	be in a position to cast, or control the casting of, more than one half of the maximum number of votes that might be cast at a general meeting of the members of the body or its ultimate holding company; or

  

	 	(d)	hold or have a beneficial interest in more than one half of the issued share capital of the body or its ultimate holding company; 

Corporations Act means the Corporations Act 2001 (Cth); 

Disclosing Party means the party to whom Information belongs or relates; 

Disclosure Material means the information made available to the Buyer and/or its representatives and advisors by or on behalf of the
Sellers for the purposes of due diligence into the Company being that information attached to this Agreement in part B of Schedule 5, the index of which is set out in part A of Schedule 5; 

Encumbrance means 
  

	 	(a)	any: 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 8 

	 	(b)	

	 	(i)	legal or equitable interest or power created, arising in or reserved in or over an interest in any property or asset; or 

  

	 	(ii)	security for payment of money, performance of obligations or protection against default (including a mortgage, bill of sale, charge, lien, pledge, trust, power or retention of title arrangement, right of set-off, assignment of income, garnishee order, monetary claim and flawed deposit arrangement); 

  

	 	(c)	any thing or preferential interest or arrangement of any kind giving a person priority or preference over claims or other persons with respect to any property or asset; 

 

	 	(d)	a PPSA Security Interest; or 

  

	 	(e)	any agreement or arrangement (whether legally binding or not) to grant or create anything referred to in paragraphs (a), (b) or (c); 

Environmental Law means a Law (including any determination of any Government Agency) relating to the environment, including in relation to land
use, planning, pollution of air or water, soil or ground water, contamination, chemicals, waste, use of dangerous goods or to any other aspect of protection of the environment, person or property; 

Escrow Agreement means an agreement substantially in the form of the pro-forma restriction agreement
annexed at Annexure 2, which pro-forma is largely based on the pro-forma restriction agreement specified in Appendix 9A of the ASX Listing Rules; 

Financial Market has the meaning given to that term in the Corporations Act; 

Government Agency means any government or any public, statutory, governmental (including a local government), semi-governmental or judicial
body, entity, department or authority and includes any self-regulatory organisation established under statute; 
 GST has the meaning given
to that term in A New Tax System (Goods and Services Tax) Act 1999; 
 Hopper Appointment Agreement means the agreement to appoint
Paul Hopper as a consultant of the Buyer, substantially in the form set out in Annexure 4; 
 Indemnity Claim means a Claim under any of the
indemnities in clause 12; 
 Information means any information, whether oral, graphic, written or in any other form, including: 

 

	 	(a)	forms, memoranda, letters, specifications, processes, procedures, statements, formulae, technology, inventions, trade secrets, research and development information, know how, designs, plans, photographs, microfiche,
business records, notes, accounting procedures or financial information, sales and marketing information, names and details of customers, suppliers and agents, employee details, reports, drawings and data; 

 

	 	(b)	copies and extracts made of or from that information and data, whether translated from the original form, recompiled, partially copied, modified, updated or otherwise altered; and 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 9 

	 	(c)	samples or specimens (if any) disclosed either before or after execution of this Agreement; 

Intellectual Property Rights means all present and future intellectual and industrial property rights conferred by statute, at common law or in
equity and wherever existing, including: 
  

	 	(a)	patents, designs, copyright, rights in circuit layouts, plant breeder’s rights, trade marks, know how, brand names, domain names, inventions, product names, trade secrets and any other rights subsisting in the
results of intellectual effort in any field, whether or not registered or capable of registration; 

  

	 	(b)	any application or right to apply for registration of any of these rights; 

  

	 	(c)	any registration of any of those rights or any registration of any application referred to in paragraph (b); and 

  

	 	(d)	all renewals and extensions of these rights; 

 Law means: 

 

	 	(a)	principles of law or equity established by decisions of courts; 

  

	 	(b)	statutes, regulations or by-laws of the Commonwealth, a State, a Territory or a Government Agency; and 

 

	 	(c)	requirements and approvals (including conditions) of the Commonwealth, a State, a Territory or a Government Agency that have the force of law; 

Liability includes all liabilities, losses, damages, costs, interest, fees, penalties, fines, assessments, forfeiture and expenses of whatever
description (whether actual, contingent or prospective); 
 Licence Agreement means the agreement for the Buyer to licence the Molecule from
Genentech, Inc substantially in the form annexed to this Agreement as Annexure 3; 
 Milestones means each of Milestone 1, Milestone 2,
Milestone 3 and Milestone 4; 
 Milestone 1 means the first patient being ‘dosed’ under a Phase II clinical trial of the Molecule,
conducted in accordance with international standards of good clinical practice; 
 Milestone 1 Shares means that number of Novogen Shares
calculated as follows: 
  

	 	 	$1,250,000 ÷ Milestone Deemed Issue Price 

 and, if a fractional entitlement, rounded up
to the nearest whole number; 
 Milestone 2 means the completion of a Phase II clinical trial of the Molecule conducted in accordance with
the international standards of good clinical practice, where such trial demonstrates a statistically significant improvement in progression-free survival or other approval endpoint indicated by the US Food and Drug Administration; 

Milestone 2 Shares means that number of Novogen Shares calculated as follows: 

 

	 	 	$1,250,000 ÷ Milestone Deemed Issue Price 

 and, if a fractional entitlement, rounded up
to the nearest whole number; 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 10 

 Milestone 3 means the date on which the Buyer has received funds to the value of a minimum of
XXXX in aggregate in new Securities in the Buyer provided always that the new Securities are issued during the Milestone 3 Period and funds for such Securities are actually received by the Buyer during the Milestone 3 Period. The following will not
be considered in determining if an aggregate of XXXX has been received by the Buyer: 
  

	 	(a)	funds relating to Securities issued before 1 September 2016, even where the funds are actually received during the Milestone 3 Period; 

 

	 	(b)	funds relating to Securities issued during the Milestone 3 Period where funds are actually received after the Milestone 3 Period; 

  

	 	(c)	funds relating to Securities issued pursuant to an option or convertible note issued before 1 September 2016; 

  

	 	(d)	funds relating to Securities issued under this Agreement; and 

  

	 	(e)	funds relating to Securities issued by the Buyer in consideration of any salary, services, or the acquisition of assets or shares. 

Milestone 3 may be determined by receipt of funds in a number of tranches over the designated period with the milestone actually achieved
(if at all) at the point an aggregate of XXXX in new Securities have been raised; 
 Milestone 3 Cash Payment means the aggregate of any
Milestone 3 Trigger Cash Payment and Milestone 3 Capital Raising Cash Payment; 
 Milestone 3 Capital Raising Shares means all Capital
Raising Shares issued to the Sellers in accordance with a Capital Raising Notice; 
 Milestone 3 Capital Raising Cash Payment means all
Capital Raising Cash Payments issued to the Sellers with a Capital Raising Notice; 
 Milestone 3 Consideration means either: 

 

	 	(a)	the Milestone 3 Shares; or 

  

	 	(b)	the Milestone 3 Cash Payment, 

 as determined at the sole discretion of the Buyer in accordance
with clause 7.6(c); 
 Milestone 3 Deemed Issue Price with respect to a Capital Raising, means the volume weighted average price of the
Novogen Shares as traded on the ASX in the 7 trading days before the Capital Raising Announcement; 
 Milestone 3 Period means the period
commencing on 1 September 2016 and ending on the date which is 24 months immediately following the Agreement Date; 
 Milestone 3 Shares
means the aggregate of any Milestone 3 Trigger Shares and Milestone 3 Capital Raising Shares issued in accordance with this Agreement; 

Milestone 3 Trigger Cash Payment means an amount equal to the aggregate of the Capital Raising Cash Payment for each Capital Raising during the
Milestone 3 Trigger Period; 
 Milestone 3 Trigger Date means the date on which the Milestone 3 Trigger Notice is issued; 

Milestone 3 Trigger Notice means a notice issued in accordance with clause 7.6(a); 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 11 

 Milestone 3 Trigger Period the period from 1 September 2016 until and including Milestone
Trigger Date; 
 Milestone 3 Trigger Shares means the aggregate of all Capital Raising Shares for each Capital Raising during the Milestone 3
Trigger Period; 
 Milestone 4 means the Buyer voluntarily out-licensing of the Molecule to a Third
Party, other than to any Related Body Corporate of the Buyer, on commercial terms. For the avoidance of doubt, Milestone 4 does not include any licence or divestment of Intellectual Property Rights in or arising out of the Molecule to a Third Party
which occurs as the result of the operation of Law or breach of contract; 
 XXXX 

Milestone 4 Consideration means either: 
  

	 	(a)	the Milestone 4 Shares; or 

  

	 	(b)	the Milestone 4 Cash Payment, 

 as determined at the sole discretion of the Buyer; 

Milestone 4 Shares the number of Novogen Shares which is calculated as follows: 

 

	 	 	XXXX 

 and, if a fractional entitlement, rounded up to the nearest whole number; 

Milestone Consideration means the consideration (if any) payable in accordance with clauses 7.2, 7.4, 7.6 and 7.11; 

Milestone Deemed Issue Price with respect to a Milestone other than Milestone 3, means the volume weighted average price of the Novogen Shares
as traded on the ASX in the 7 trading days before the achievement of the relevant Milestone has been announced to the ASX; 
 Molecule means
the small molecule brain penetrant known as GDC-0084 for glioblastoma multiforme; 
 Novogen Shares
means ordinary fully paid shares in the Buyer; 
 PPSA Security Interest means a security interest as defined in the Personal Property
Securities Act 2009 (Cth); 
 Purchase Consideration means the sum of Completion Consideration and any Milestone Consideration which the
Sellers become entitled to receive in accordance with the terms of this Agreement; 
 Receiving Party means the party to whom Information is
disclosed or who possesses or otherwise acquires Information belonging or relating to a Disclosing Party; 
 Recipient means any Related
Entity, employee, agent, contractor, officer, professional adviser, banker, auditor or other consultant of the Receiving Party; 
 Records
means the originals and copies, in machine readable, electronic, printed or any other readable form, of all files, reports, records, accounts, registers, correspondence, documents and other material relating to or used by the Company or the
Business, including: 
  

	 	(a)	sales literature, market research reports, brochures and other promotional material (including printing blocks, negatives, soundtracks and associated materials); 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 12 

	 	(b)	sales and purchasing records; 

  

	 	(c)	lists of all clients, suppliers and customers; 

  

	 	(d)	financial records and accounts including ledgers, journals and books of account; 

  

	 	(e)	trading records; 

  

	 	(f)	records of wages, employment benefits and other payroll and personnel information; 

  

	 	(g)	records of and relating to the contracts entered into by the Company; 

  

	 	(h)	stationery; and 

  

	 	(i)	all other data, however recorded, owned or used by the Company or the Sellers which relates to the Company or the Business; 

Related Body Corporate has the meaning given to that term in the Corporations Act; 

Related Entity has the meaning given to that term in the Corporations Act; 

Securities has the meaning given to that term in section 92(2) of the Corporations Act; 

Seller Nominee means a person to whom Novogen Shares are to be issued in accordance with the Sellers’ notice under clauses 6.2, 7.3(a),
7.5(a), 7.7(a), 7.7(d) or 7.12(a) (as applicable); 
 Sellers’ Guarantees means any obligation or commitment of any Seller or any of
their Related Entities (other than the Company) in favour of another person to provide money, indemnify or otherwise be responsible for the obligations (whether they relate to financial accommodation or otherwise) of the Company; 

Sellers’ Warranties means the warranties contained in Schedule 4; 

Seller Warrantors means the Sellers and the Warrantor; 

Shares means all the shares (of any class) in the capital of the Company held by the Sellers immediately before Completion, as specified in
Schedule 1; 
 Stamp Duty means any stamp, transaction or registration duty or similar charge imposed by any Government Agency and includes
any interest, fine, penalty, charge or other amount in respect of the above but excludes any goods and services tax; 
 Tax, Taxes or
Taxation means all forms of present and future taxes, excise, stamp or other duties, imposts, deductions, charges, withholdings, rates, levies or other governmental impositions imposed, assessed or charged by any Government Agency, together with all
interest, penalties, fines, expenses and other additional statutory charges relating to any of them, imposed or withheld by a Government Agency; 

Tax Act means the Income Tax Assessment Act 1936 (Cth), the Income Tax Assessment Act 1997 (Cth) or the Taxation Administration Act
1953 (Cth) as the case may be; 
 Tax Claim means any assessment, notice or demand or any other document issued or action taken by or on
behalf of any Government Agency in respect of Tax; 
 Tax Claim Amount means: 

 

	 	(a)	the amount the Company is required to pay in respect of Tax to a Government Agency as a result of a Tax Claim; 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 13 

	 	(b)	the amount the Buyer or the Company is required to pay a Government Agency as a result of a Tax Claim relating to the recovery by the Government Agency of all or part of a Tax incentive, concession or other form of
relief allowed to or applied by the Company before Completion; 

  

	 	(c)	the amount of any credit, rebate or refund of Tax or franking credits lost to or paid by the Buyer or the Company as a result of a Tax Claim; or 

 

	 	(d)	the amount of the loss of any relief, allowance, deduction or loss carried forward, as a result of a Tax Claim, multiplied by the rate of Tax applicable to companies in the year to which the Tax Claim relates,

 plus any associated fines, additional tax, interest or penalties; 

Tax Indemnity means the indemnity given by the Sellers in clause 12.2; 

Tax Indemnity Claim means a Claim under the Tax Indemnity; 

Tax Law means any Law relating to Tax; 

Third Party means a person who is not a party to this Agreement; 

Third Party Claim means a Claim made or threatened by a Third Party against the Buyer or the Company, but excluding any Claim in respect of
which clause 10.2 applies; and 
 Warranty Claim means any Claim by the Buyer (or any person making a Claim through or on behalf of the
Buyer) against the Sellers or any of them for breach of any of the Sellers’ Warranties. 
  

	1.2	Interpretation 

 In this Agreement, unless the context requires otherwise: 

 

	 	(a)	the singular includes the plural and vice versa; 

  

	 	(b)	a gender includes the other genders; 

  

	 	(c)	the headings are used for convenience only and do not affect the interpretation of this Agreement; 

  

	 	(d)	other grammatical forms of defined words or expressions have corresponding meanings; 

  

	 	(e)	a reference to a document includes the document as modified from time to time and any document replacing it; 

  

	 	(f)	a reference to a party is to a party to this Agreement and a reference to a party to a document includes the party’s executors, administrators, successors and permitted assigns and substitutes; 

 

	 	(g)	a reference to a clause, item, schedule or annexure is a reference to a clause, item, schedule or annexure of this Agreement; 

  

	 	(h)	if something is to be or may be done on a day that is not a Business Day then it must be done on the next Business Day; 

  

	 	(i)	the word “person” includes a natural person, partnership, body corporate, association, government or local authority, agency and any body or entity whether incorporated or not; 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 14 

	 	(j)	the word “month” means calendar month and the word “year” means 12 months; 

  

	 	(k)	the words “in writing” include any communication sent by letter, facsimile transmission or email or any other form of communication capable of being read by the recipient; 

 

	 	(l)	a reference to a thing includes a part of that thing; 

  

	 	(m)	a reference to all or any part of a statute, rule, regulation or ordinance (statute) includes that statute as amended, consolidated, re-enacted or replaced from time to time;

  

	 	(n)	wherever “include”, “for example” or any form of those words or similar expression is used, it must be construed as if it were followed by “(without being limited to)”; 

 

	 	(o)	money amounts are stated in Australian currency; 

  

	 	(p)	a reference to time is to Sydney New South Wales, Australia time; 

  

	 	(q)	a reference to any agency or body, if that agency or body ceases to exist or is reconstituted, renamed or replaced or has its powers or functions removed (defunct body), means the agency or body that performs most
closely the functions of the defunct body; 

  

	 	(r)	any agreements, representation, warranty or indemnity in favour of two or more parties (whether those parties are included in the same defined term or not) is for the benefit of them jointly and separately; and

  

	 	(s)	any agreements, representation, warranty or indemnity by two or more parties (whether those parties are included in the same defined term or not) binds them jointly and separately. 

 

	2.	Agreement to buy and sell Shares 

  

	2.1	Sale and purchase 

 On and subject to the terms of this Agreement and in consideration of
the Purchase Consideration: 
  

	 	(a)	each Seller as legal and beneficial owner agrees to sell to the Buyer those Shares listed against that Seller’s name in Schedule 1; and 

 

	 	(b)	the Buyer agrees to purchase the Shares from the Sellers. 

  

	2.2	Date for Completion 

 Completion must occur on the date that is the later of: 

 

	 	(a)	5 Business Days after the first date by which all Conditions have been fulfilled (or waived under clause 3.3); and 

  

	 	(b)	the date on which any period or periods for which the Buyer delays Completion under clause 15.2(e) expires. 

  

	2.3	Encumbrances and rights 

 The Sellers must transfer the Shares to the Buyer at
Completion: 
  

	 	(a)	free from any Encumbrance; and 

  

	 	(b)	together with all benefits and rights, including dividend and voting rights, attached or accrued to them on or after Completion. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 15 

	2.4	Title and risk 

 The title to and the risk of the Shares: 

 

	 	(a)	until Completion, remains solely with the Sellers; and 

  

	 	(b)	on and from Completion, passes from the Sellers to the Buyer. 

  

	2.5	Purchase of all the Shares 

 The Sellers need not complete the sale, and the Buyer need
not complete the purchase, of any of the Shares unless the sale and purchase of all the Shares is completed simultaneously. 
  

	2.6	Waiver of pre-emptive rights 

 Each Seller, by
its execution of this Agreement, consents to the sale and purchase contemplated by clause 2.1 and irrevocably waives in favour of the Buyer any rights of pre-emption that that Seller has, or may have, in
respect of the Shares, whether conferred by the constitution of the Company or otherwise. 
  

	3.	Conditions precedent 

  

	3.1	Conditions precedent to Completion 

 Completion is conditional on each of the Conditions
set out in Schedule 3 being fulfilled, or waived under clause 3.3, on or before 31 December 2016 or any other date agreed by the Sellers and the Buyer in writing. 
  

	3.2	Duties in relation to Conditions 

  

	 	(a)	Each party must use its reasonable endeavours to ensure that the Conditions referred to in clause 3.1 are fulfilled on or before the date specified in that clause. 

 

	 	(b)	Each party must: 

  

	 	(i)	supply each other party with copies of all applications made and documents supplied for the purpose of fulfilling any Condition; 

  

	 	(ii)	not take any action that would, or would be likely to, prevent or hinder the fulfilment of any Condition; and 

  

	 	(iii)	within 2 Business Days of a party becoming aware that a Condition has been fulfilled, notify the other parties in writing of that fact. 

 

	 	(c)	Nothing in this clause 3 requires a party to waive a Condition under clause 3.3 or accept unreasonable conditions or requirements imposed by Third Parties to satisfy any Condition. 

 

	3.3	Fulfilment by waiver 

 A Condition may be waived only: 

 

	 	(a)	where the Condition is expressed to be for the benefit of a particular party, if that party gives notice of waiver of the Condition to the other parties; or 

 

	 	(b)	otherwise, if the Sellers and the Buyer agree in writing to waive the Condition, but only to the extent set out in the waiver. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 16 

	3.4	Failure of Condition 

 Either the Buyer or the Sellers may, if not otherwise in breach of
this Agreement, terminate this Agreement by giving notice to all other parties at any time before Completion if: 
  

	 	(a)	a Condition is not fulfilled (or waived under clause 3.3) before 5.00 pm on 31 December 2016; or 

  

	 	(b)	a Condition having been fulfilled, that Condition does not remain fulfilled in all respects at all times until Completion. 

  

	4.	Conduct pending Completion 

  

	4.1	Conduct of Business 

 Except as otherwise provided in this Agreement, the Sellers must
ensure that from the date of this Agreement until Completion, the Company does not, unless required or contemplated by this Agreement, or unless the Buyer first consents in writing: 

 

	 	(a)	enter into any contract or commitment or terminate or alter any term of any such contract or commitment; 

  

	 	(b)	incur any Liabilities; 

  

	 	(c)	dispose of, agree to dispose of, Encumber or grant an option over any of the Company’s assets or any interest in those assets; 

  

	 	(d)	engage any new employee, terminate the employment of any employee or alter the terms of employment (including the terms of superannuation or any other benefit) of any employee, or offer to do any of those things;

  

	 	(e)	provide or grant any guarantee (including any Sellers’ Guarantee), PPSA Security Interest or any other security to any Third Party; 

 

	 	(f)	borrow money, increase the amount of existing borrowings or draw on any credit lines other than under existing credit facilities; 

  

	 	(g)	issue, agree to issue or grant any option to issue any equity or loan securities or any security convertible into any such securities; 

 

	 	(h)	issue any shares, or options to take up unissued shares, in the capital of the Company; 

  

	 	(i)	declare or pay any dividend, effect a buy back of its shares or make any other distribution of its assets or profits; 

  

	 	(j)	alter or agree to alter its constitution; or 

  

	 	(k)	pass any special resolution. 

  

	4.2	Assistance and access for Buyer 

 Until Completion, the Sellers must: 

 

	 	(a)	supply to the Buyer, and any person who has the Buyer’s written authority, any information or document in their possession or control reasonably requested concerning the Company or the Business; 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 17 

	 	(b)	assist the Buyer, at the Buyer’s request, to gain knowledge concerning and become familiar with the Company, its affairs and the Business; and 

 

	 	(c)	allow the Buyer to investigate the accuracy of the Sellers’ Warranties. 

  

	4.3	Confidentiality 

 Clause 17 applies to any Confidential Information obtained by the Buyer
or any person authorised by it under clause 4.2. 
  

	4.4	Notice of material changes 

 Where before Completion an event occurs that has, or may
have, a material effect on the prospects, operation, profitability or value of the Company or the value of the Shares, the Sellers must, immediately on becoming aware of that event, give notice to the Buyer fully describing the event. Nothing in
this clause limits the Buyer’s rights under clause 15 or otherwise. 
  

	4.5	No discussions 

 Until Completion, the Sellers and the Warrantor must not solicit or
respond to any enquiries or proposals by any person, other than the Buyer, concerning an acquisition of any Shares. 
  

	5.	Completion 

  

	5.1	Time and place for Completion 

 Completion must occur on the date determined under clause
2.2 at: 
  

	 	(a)	the offices of K&L Gates, Level 31, 1 O’Connell St, Sydney NSW 2000 at 11.00 

  

	 	 	am; or 

  

	 	(b)	any other place or time agreed in writing between the Sellers and the Buyer. 

  

	5.2	Sellers’ obligations at Completion  

 On or before Completion the Sellers
must: 
  

	 	(a)	deliver or cause to be delivered to the Buyer: 

  

	 	(i)	a duly executed transfer of the Shares in favour of the Buyer in registrable form; 

  

	 	(ii)	share certificates (or certificate of indemnity for a lost or destroyed certificate in agreed form) in respect of all of the Shares; 

 

	 	(iii)	duly executed written instruments irrevocably waiving in favour of the Buyer all pre-emptive rights (if any) which any person other than a Seller has in respect of any of the
Shares; 

  

	 	(iv)	any consents, waivers or documents necessary to evidence to the Buyer’s satisfaction that each of the Conditions has been and remains fulfilled or waived under clause 3.3; 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 18 

	 	(v)	to the extent they relate to the Company, the constitution, certificate of incorporation or registration (including any certificate of incorporation or registration on change of name), common seal (if any), all
statutory registers, minute books and other records of directors’ and shareholders’ meetings of the Company in proper order and condition, fully entered up to the Completion Date and otherwise complying with all requirements under the Law;

  

	 	(vi)	the ASIC corporate key for the Company; 

  

	 	(vii)	to the extent they relate to the Company, all financial and accounting books and Records, copies of Taxation returns lodged and assessments issued under the Tax Act, fringe benefits tax returns, business activity
statements, land tax assessments, mortgages, leases, agreements, insurance policies, title documents, licences, certificates and all other Records; 

  

	 	(viii)	an original of the Hopper Appointment Agreement duly executed by the Warrantor; 

  

	 	(ix)	an original of the Chong Appointment Agreement duly executed by Mi Ok Chong; and 

  

	 	(x)	a copy of the executed resolution of the Company to adopt a new Constitution; 

  

	 	(b)	cause circulating resolutions of the directors of the Company to be passed in which: 

  

	 	(i)	the registration of the transfer to the Buyer of the Shares is, subject to payment of any Stamp Duty on them, approved; 

  

	 	(ii)	the persons nominated in writing for that purpose by the Buyer and who have consented to so act, are appointed as directors, secretary and public officer of the Company; and 

 

	 	(iii)	the existing directors, alternate directors, secretary and public officer of the Company resign in writing from their respective offices with effect from Completion (without any payment as compensation for loss of
office or otherwise); 

  

	 	(iv)	with effect from Completion, the registered office of the Company is changed to the address requested by the Buyer; and 

  

	 	(v)	all other action necessary to place the Buyer in operating control of the Company with effect from Completion is taken or done; 

  

	 	(c)	deliver to the Buyer a letter (in the form required by the Buyer) signed by each resigning officer (including any alternate directors) of the Company and acknowledging that he or she has no Claim against the Company for
breach of contract, loss of office, redundancy, unfair dismissal, compensation, payment or repayment of loans or otherwise; 

  

	 	(d)	ensure that all matters or actions necessary to give effect to the resolutions of the Company passed in accordance with clause 5.2(b) are done or taken; 

 

	 	(e)	pay to the Company the following amounts (if any) paid by or accrued in the accounts of the Company: 

  

	 	(i)	any commissions or finders fees related to or in any way connected with the transactions contemplated by this Agreement; 

  

	 	(ii)	any legal, accounting or other professional adviser’s costs related to or in any way connected with the transactions contemplated by this Agreement; and 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 19 

	 	(iii)	any other costs of the Sellers relevant to the transactions contemplated by this Agreement that have been paid by or accrued in the accounts of the Company; and 

 

	 	(f)	do all other acts and execute all other documents that this Agreement requires the Sellers to do or execute at Completion. 

  

	5.3	Buyer’s obligations at Completion 

 At Completion the Buyer must: 

 

	 	(a)	provide any consents, waivers or documents necessary to evidence to the Sellers’ satisfaction that each of the Conditions has been and remains fulfilled (or waived under clause 3.3); 

 

	 	(b)	provide the Completion Consideration in accordance with clause 6; 

  

	 	(c)	cause sufficient instruments of consent to be available to allow the Company to pass the resolutions required by clause 5.2(b)(ii); 

  

	 	(d)	deliver or cause to be delivered to the Warrantor an original of the Hopper Appointment Agreement duly executed by the Buyer; 

  

	 	(e)	deliver or cause to be delivered to Mi Ok Chong, an original of the Chong Appointment Agreement duly executed by the Buyer; and 

  

	 	(f)	do all other acts and execute all other documents that this Agreement requires the Buyer to do or execute at Completion. 

  

	5.4	Conditions of Completion 

  

	 	(a)	The obligations of the Buyer and the Sellers under this clause 5 (other than a requirement that has been waived under clause 5.5) are interdependent. Completion is conditional on, and will not be taken to have occurred
until, both the Buyer and the Sellers have complied with all of their respective obligations under this clause 5 (other than a requirement that has been waived under clause 5.5). 

 

	 	(b)	If either the Sellers or the Buyer fail to fully comply with their obligations under this clause 5 and Completion does not occur, then the other of them may, if not otherwise in breach of this Agreement, terminate this
Agreement by giving notice to all other parties and each of the Sellers and the Buyer must promptly: 

  

	 	(i)	return to the other all documents delivered to it under this clause 5; 

  

	 	(ii)	repay to the other all payments received by it under this clause 5; and 

  

	 	(iii)	do everything reasonably required by the other to reverse any action taken under this clause 5, 

  

	 	 	without prejudice to any other rights any party may have in respect of that failure. 

  

	5.5	Delayed delivery of Completion items 

 The Buyer may by notice given to the Sellers on or
before Completion, waive the requirement of the Sellers to comply with one or more of the requirements referred to in clause 5.2, in which case Completion will still occur and the Sellers are not required to comply with the requirements specified in
the notice on or before Completion, but instead must comply with: 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 20 

	 	(a)	those requirements as soon as reasonably possible after Completion; and 

  

	 	(b)	any conditions to the Buyer’s waiver set out in the notice, 

 and the Sellers must
indemnify the Buyer against any Claim or Liability that the Buyer pays, suffers, incurs or is liable for as a result of those requirements not being complied with on or before Completion. 

 

	6.	Completion Consideration 

  

	6.1	Completion Cash Amount 

 On Completion the Buyer must pay the Completion Cash Amount to
the Sellers (or as directed by the Sellers). 
  

	6.2	Completion Shares 

  

	 	(a)	At least 2 Business Days prior to Completion, the Sellers must give notice to the Buyer setting out: 

  

	 	(i)	the details of each Seller Nominee for the Completion Shares; and 

  

	 	(ii)	the proportion of Completion Shares to be issued to each Seller Nominee. 

  

	 	(b)	On Completion the Buyer must: 

  

	 	(i)	issue the Completion Shares to each Seller Nominee in accordance with notice given by the Sellers pursuant to clause 6.2(a). The parties agree and acknowledge that the Completion Shares in the Buyer shall only be issued
if issued to each Seller Nominee subject to an escrow upon the provisions of the Escrow Agreement for the period which is the longer of the following: 

  

	 	(A)	6 months from the date of issue of the Completion Shares; or 

  

	 	(B)	the period which the ASX determines in its absolute discretion; 

  

	 	(ii)	deliver to the Sellers: 

  

	 	(A)	a certified copy of an extract of the minutes of a meeting of the board of directors of the Buyer resolving to issue the Completion Shares to each Seller Nominee; and 

 

	 	(B)	an original counterpart of an Escrow Agreement with respect to each Seller Nominee, duly executed by the Buyer, with respect to the Completion Shares to be issued to that Seller Nominee; and 

 

	 	(iii)	instruct the Buyer’s share registry to record the issue of the Completion Shares to each Seller Nominee in the Buyer’s uncertificated sub-register. 

 

	 	(c)	On Completion the Sellers must deliver or procure the delivery to the Buyer of: 

  

	 	(i)	an accountant’s certificate under section 708(8)(c) of the Corporations Act with respect to each Seller Nominee to whom the Completion Shares are to be issued; 

 

	 	(ii)	an original counterpart of an Escrow Agreement with respect to each Seller Nominee, duly executed by that Seller Nominee, with respect to the Completion Shares to be issued to that Seller Nominee; and 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 21 

	 	(iii)	an application to the Buyer, in a form approved by the Buyer, for the Completion Shares for each Seller Nominee duly executed by that Seller Nominee. 

 

	 	(d)	Within 5 days from the date the Completion Shares are issued the Buyer will give to the ASX a notice under section 708A(6) of the Corporations Act. 

 

	 	(e)	The Completion Shares will rank equally in all respects with the other then existing issued Novogen Shares from the date of issue and will be freely tradeable from the date of lodgement by the Buyer of a notice under
section 708A(6) of the Corporations Act. 

  

	7.	Milestone Consideration 

  

	7.1	Milestones 

 The Sellers will be entitled to the Milestone Consideration in accordance
with this clause 7. For the avoidance of doubt, the Sellers will not be entitled to any consideration where a corresponding Milestone has not been achieved. 
  

	7.2	Milestone 1 

 As soon as practicable after Milestone 1 has been achieved, the Buyer must
give written notice to the Sellers to that effect (Milestone 1 Notice) and the Buyer must cause the Milestone 1 Shares to be issued to the Sellers in accordance with clause 7.3. 

 

	7.3	Mechanics of issue of Milestone 1 Shares 

  

	 	(a)	Within 2 Business Days of the Milestone 1 Notice, the Sellers must give notice to the Buyer setting out: 

  

	 	(i)	the details of each Seller Nominee for the Milestone 1 Shares; and 

  

	 	(ii)	the number of Milestone 1 Shares to be issued to each Seller Nominee. 

  

	 	(b)	Within 40 Business Days of the Milestone 1 Notice the Buyer will: 

  

	 	(i)	issue the Milestone 1 Shares to each Seller Nominee in accordance with the notice issued by the Sellers pursuant to clause 7.3(a). The parties agree and acknowledge that the Milestone 1 Shares in the Buyer shall only be
issued if issued to each Seller Nominee subject to an escrow upon the provisions of the Escrow Agreement for the period which is the longer of the following: 

  

	 	(A)	6 months from the date of issue of the Milestone 1 Shares; or 

  

	 	(B)	the period which the ASX determines in its absolute discretion; 

  

	 	(ii)	deliver to the Sellers: 

  

	 	(A)	a certified copy of an extract of the minutes of a meeting of the board of directors of the Buyer resolving to issue the Milestone 1 Shares to each Seller Nominee; and 

 

	 	(B)	an original counterpart of an Escrow Agreement with respect to each Seller Nominee, duly executed by the Buyer, with respect to the Milestone 1 Shares to be issued to that Seller Nominee; and 

 

	 	(iii)	instruct the Buyer’s share registry to record the issue of the Milestone 1 Shares to each Seller Nominee in the Buyer’s uncertificated sub-register. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 22 

	 	(c)	Within 40 Business Days of the Milestone 1 Notice the Sellers must deliver or procure the delivery to the Buyer of: 

  

	 	(i)	an accountant’s certificate under section 708(8)(c) of the Corporations Act with respect to each Seller Nominee to whom the Milestone 1 Shares are to be issued; 

 

	 	(ii)	an original counterpart of an Escrow Agreement with respect to each Seller Nominee, duly executed by that Seller Nominee, with respect to the Milestone 1 Shares to be issued to that Seller Nominee; and

  

	 	(iii)	an application to the Buyer, in a form approved by the Buyer, for the Milestone 1 Shares for each Seller Nominee duly executed by that Seller Nominee. 

 

	 	(d)	Within 5 days from the date the Milestone 1 Shares are issued the Buyer will give to the ASX a notice under section 708A(6) of the Corporations Act. 

 

	 	(e)	The Milestone 1 Shares will rank equally in all respects with the other then existing issued Novogen Shares from the date of issue and will be freely tradeable from the date of lodgement by the Buyer of a notice under
section 708A(6) of the Corporations Act. 

  

	7.4	Milestone 2 

 As soon as practicable after Milestone 2 has been achieved, the Buyer must
give written notice to the Sellers to that effect (Milestone 2 Notice), and the Buyer must cause the Milestone 2 Shares to be issued to the Sellers in accordance with clause 7.5. 

 

	7.5	Mechanics of issue of Milestone 2 Shares 

  

	 	(a)	Within 2 Business Days of the Milestone 2 Notice, the Sellers must give notice to the Buyer setting out: 

  

	 	(i)	the details of each Seller Nominee for the Milestone 2 Shares; and 

  

	 	(ii)	the number of Milestone 2 Shares to be issued to each Seller Nominee. 

  

	 	(b)	Within 40 Business Days of the Milestone 2 Notice the Buyer will: 

  

	 	(i)	issue the Milestone 2 Shares to each Seller Nominee in accordance with the notice issued by the Sellers pursuant to clause 7.5(a). The parties agree and acknowledge that the Milestone 2 Shares in the Buyer shall only be
issued if issued to each Seller Nominee subject to an escrow upon the provisions of the Escrow Agreement for the period which is the longer of the following: 

  

	 	(A)	6 months from the date of issue of the Milestone 2 Shares; or 

  

	 	(B)	the period which the ASX determines in its absolute discretion; 

  

	 	(ii)	deliver to the Sellers: 

  

	 	(A)	a certified copy of an extract of the minutes of a meeting of the board of directors of the Buyer resolving to issue the Milestone 2 Shares to each Seller Nominee; and 

 

	 	(B)	an original counterpart of an Escrow Agreement with respect to each Seller Nominee, duly executed by the Buyer, with respect to the Milestone 2 Shares to be issued to that Seller Nominee; and 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 23 

	 	(iii)	instruct the Buyer’s share registry to record the issue of the Milestone 2 Shares to each Seller Nominee in the Buyer’s uncertificated sub-register. 

 

	 	(c)	Within 40 Business Days of the Milestone 2 Notice the Sellers must deliver or procure the delivery to the Buyer of: 

  

	 	(i)	an accountant’s certificate under section 708(8)(c) of the Corporations Act with respect to each Seller Nominee to whom the Milestone 2 Shares are to be issued; 

 

	 	(ii)	an original counterpart of an Escrow Agreement with respect to each Seller Nominee, duly executed by that Seller Nominee, with respect to the Milestone 2 Shares to be issued to that Seller Nominee; and

  

	 	(iii)	an application to the Buyer, in a form approved by the Buyer, for the Milestone 2 Shares for each Seller Nominee duly executed by that Seller Nominee. 

 

	 	(d)	Within 5 days from the date the Milestone 2 Shares are issued the Buyer will give to the ASX a notice under section 708A(6) of the Corporations Act. 

 

	 	(e)	The Milestone 2 Shares will rank equally in all respects with the other then existing issued Novogen Shares from the date of issue and will be freely tradeable from the date of lodgement by the Buyer of a notice under
section 708A(6) of the Corporations Act. 

  

	7.6	Milestone 3 

  

	 	(a)	As soon as practicable after Milestone 3 has been achieved, the Buyer must give written notice to the Sellers to that effect (Milestone 3 Trigger Notice), and the Buyer must, subject to clause 7.10, either:

  

	 	(i)	issue the Milestone 3 Trigger Shares in accordance with clause 7.7; or 

  

	 	(ii)	pay the Milestone 3 Trigger Cash Payment in accordance with clause 7.9, as determined by the election of the Buyer in clause 7.6(c). 

 

	 	(b)	Subject to clause 7.10, as soon as practicable after a Capital Raising Announcement with respect to each Capital Raising after the Milestone 3 Trigger Date, the Buyer must give written notice to the Sellers setting out
the consideration payable to the Sellers for that Capital Raising (Capital Raising Notice), and Buyer must either: 

  

	 	(i)	issue the Capital Raising Shares in relation to that Capital Raising in accordance with clause 7.7; or 

  

	 	(ii)	pay the Capital Raising Cash Payment in relation to that Capital Raising in Accordance with clause 7.9, 

as determined at the election of the Buyer in accordance with clause 7.6(c). 

 

	 	(c)	Within 5 Business Days of the Milestone 3 Trigger Notice, the Buyer must elect to pay the Milestone 3 Consideration either by way of shares or cash and must give notice of such election to the Sellers (Election Notice).

  

	7.7	Mechanics of Milestone 3 Consideration - Shares 

 Subject to clauses 7.8 and 7.10, if the
Buyer elects in accordance with clause 7.6(c) to provide the Milestone 3 Consideration by way of shares: 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 24 

	 	(a)	within 2 Business Days of the Election Notice, the Sellers must give notice to the Buyer setting out: 

  

	 	(i)	the details of each Seller Nominee for the Milestone 3 Trigger Shares; and 

  

	 	(ii)	the proportion of Milestone 3 Trigger Shares to be issued to each Seller Nominee; 

  

	 	(b)	within 40 Business Days of the Milestone 3 Trigger Notice the Buyer will: 

  

	 	(i)	issue the Milestone 3 Trigger Shares to each Seller Nominee in accordance with the notice issued by the Sellers pursuant to clause 7.7(a). The parties agree and acknowledge that the Milestone 3 Trigger Shares in the
Buyer shall only be issued if issued to each Seller Nominee subject to an escrow upon the provisions of the Escrow Agreement for the period which is the longer of the following: 

 

	 	(A)	6 months from the date of issue of the Milestone 3 Trigger Shares; or 

  

	 	(B)	the period which the ASX determines in its absolute discretion; 

  

	 	(ii)	deliver to the Sellers: 

  

	 	(A)	a certified copy of an extract of the minutes of a meeting of the board of directors of the Buyer resolving to issue the Milestone 3 Trigger Shares to each Seller Nominee; and 

 

	 	(B)	an original counterpart of an Escrow Agreement with respect to each Seller Nominee, duly executed by the Buyer, with respect to the Milestone 3 Trigger Shares to be issued to that Seller Nominee; and 

 

	 	(iii)	instruct the Buyer’s share registry to record the issue of the Milestone 3 Trigger Shares to each Seller Nominee in the Buyer’s uncertificated subregister; 

 

	 	(c)	within 40 Business Days of the Milestone 3 Trigger Notice the Sellers must deliver or procure the delivery to the Buyer of: 

  

	 	(i)	an accountant’s certificate under section 708(8)(c) of the Corporations Act with respect to each Seller Nominee to whom the Milestone 3 Trigger Shares are to be issued; 

 

	 	(ii)	an original counterpart of an Escrow Agreement with respect to each Seller Nominee, duly executed by that Seller Nominee, with respect to the Milestone 3 Trigger Shares to be issued to that Seller Nominee; and

  

	 	(iii)	an application to the Buyer, in a form approved by the Buyer, for the Milestone 3 Trigger Shares for each Seller Nominee duly executed by that Seller Nominee. 

 

	 	(d)	within 20 Business Days of each Capital Raising Notice, the Sellers must give notice to the Buyer setting out: 

  

	 	(i)	the details of each Seller Nominee for the Capital Raising Shares relevant to the notice; and 

  

	 	(ii)	the proportion of Capital Raising Shares to be issued to each Seller Nominee; 

  

	 	(e)	within 40 Business Days of each Capital Raising Notice the Buyer will: 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 25 

	 	(i)	issue the applicable Capital Raising Shares to each Seller Nominee in accordance with the notice issued by the Sellers pursuant to clause 7.7(d). The parties agree and acknowledge that the Capital Raising Shares in the
Buyer shall only be issued if issued to each Seller Nominee subject to an escrow upon the provisions of the Escrow Agreement for the period which is the longer of the following: 

 

	 	(A)	6 months from the date of issue of the Capital Raising Shares; or 

  

	 	(B)	the period which the ASX determines in its absolute discretion; 

  

	 	(ii)	deliver to the Sellers: 

  

	 	(A)	a certified copy of an extract of the minutes of a meeting of the board of directors of the Buyer resolving to issue the Capital Raising Shares to each Seller Nominee; and 

 

	 	(B)	an original counterpart of an Escrow Agreement with respect to each Seller Nominee, duly executed by the Buyer, with respect to the Capital Raising Shares to be issued to that Seller Nominee; and 

 

	 	(iii)	instruct the Buyer’s share registry to record the issue of the applicable Capital Raising Shares to each Seller Nominee in the Buyer’s uncertificated sub-register;

  

	 	(f)	within 40 Business Days of each Capital Raising Notice the Sellers must deliver or procure the delivery to the Buyer of: 

  

	 	(i)	an accountant’s certificate under section 708(8)(c) of the Corporations Act with respect to each Seller Nominee to whom the applicable Capital Raising Shares are to be issued; 

 

	 	(ii)	an original counterpart of an Escrow Agreement with respect to each Seller Nominee, duly executed by that Seller Nominee, with respect to the Capital Raising Shares to be issued to that Seller Nominee; and

  

	 	(iii)	an application to the Buyer, in a form approved by the Buyer, for the Capital Raising Shares for each Seller Nominee duly executed by that Seller Nominee. 

 

	 	(g)	Within 5 days from the date any Milestone 3 Shares are issued the Buyer will give to the ASX a notice under section 708A(6) of the Corporations Act. 

 

	 	(h)	The Milestone 3 Shares will rank equally in all respects with the other then existing issued Novogen Shares from the date of issue and will be freely tradeable from the date of lodgement by the Buyer of a notice under
section 708A(6) of the Corporations Act. 

  

	7.8	If approvals not obtained 

  

	 	(a)	If: 

  

	 	(i)	the Buyer elects in accordance with clause 7.6(c) to provide the Milestone 3 Consideration by way of shares; and 

  

	 	(ii)	the Buyer is unable to obtain all necessary consents and approvals for the issue of the relevant Novogen Shares within 35 Business Days of a Milestone 3 Trigger Notice or a Capital Raising Notice (as applicable),

 the Buyer must pay the Sellers the applicable portion of the Milestone 3 Consideration by cash and clause 7.7 will not
apply. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 26 

	 	(b)	If clause 7.8(a) applies: 

  

	 	(i)	in relation to the Milestone 3 Trigger Shares, the Buyer will pay the Milestone 3 Trigger Cash Payment to the Sellers (or as the Sellers direct) within 40 Business Days of the Milestone 3 Trigger Notice; or

  

	 	(ii)	in relation to Capital Raising Shares, the Buyer will pay the Capital Raising Cash Payment applicable to the relevant Capital Raising to the Sellers (or as the Sellers direct) within 40 Business Days of the relevant
Capital Raising Notice. 

  

	 	(c)	For the avoidance of doubt, the Sellers will only ever be entitled to payment with respect to a particular Capital Raising in either cash or shares. 

 

	7.9	Mechanics of Milestone 3 Consideration - Cash 

 Subject to clause 7.10, if the Buyer
elects to provide the Milestone 3 Consideration by way of cash: 
  

	 	(a)	within 7 Business Days of the Milestone 3 Trigger Notice, the Buyer will pay the Milestone 3 Trigger Cash Payment to the Sellers (or as the Sellers direct); and 

 

	 	(b)	within 7 Business Days of each Capital Raising Notice, the Buyer will pay the Capital Raising Cash Payment for that Capital Raising to the Sellers (or as the Sellers direct). 

 

	7.10	Maximum Payable 

 Despite any other provision of this Agreement, the maximum Milestone 3
Consideration payable is: 
  

	 	(a)	If the Buyer elects to provide the Milestone 3 Consideration by way of cash, XXXXX; or 

  

	 	(b)	If the Buyer elects to provide the Milestone 3 Consideration by way of shares, the amount of Novogen Shares equal to XXXX determined by reference to the value of the Capital Raising Shares as at the time of issue to the
Seller Nominees. 

  

	7.11	Milestone 4 

 As soon as practicable after the Buyer announces to the ASX that Milestone
4 has been achieved, the Buyer must give written notice to the Sellers to that effect (Milestone 4 Notice), and the Milestone 4 Consideration will be payable in accordance with clause 7.12. 

 

	7.12	Mechanics of Milestone 4 Consideration 

  

	 	(a)	Subject to clause 7.12(c), if the Buyer elects to provide the Milestone 4 Consideration by way of the Milestone 4 Shares: 

  

	 	(i)	within 2 Business Days of the Milestone 4 Notice, the Sellers must give notice to the Buyer setting out: 

  

	 	(A)	the details of each Seller Nominee for the Milestone 4 Shares; and 

  

	 	(B)	the number of Milestone 4 Shares to be issued to each Seller Nominee; 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 27 

	 	(ii)	within 40 Business Days of the Milestone 4 Notice the Buyer will: 

  

	 	(A)	issue the Milestone 4 Shares to each Seller Nominee in accordance with the notice issued by the Sellers pursuant to clause 7.12(a)(i). The parties agree and acknowledge that the Milestone 4 Shares in the Buyer shall
only be issued if issued to each Seller Nominee subject to an escrow upon the provisions of the Escrow Agreement for the period which is the longer of the following: 

 

	 	(a)	6 months from the date of issue of the Milestone 4 Shares; or 

  

	 	(b)	the period which the ASX determines in its absolute discretion; 

  

	 	(B)	deliver to the Sellers: 

  

	 	(a)	a certified copy of an extract of the minutes of a meeting of the board of directors of the Buyer resolving to issue the Milestone 4 Shares to each Seller Nominee; and 

 

	 	(b)	an original counterpart of an Escrow Agreement with respect to each Seller Nominee, duly executed by the Buyer, with respect to the Milestone 4 Shares to be issued to that Seller Nominee; and 

 

	 	(C)	instruct the Buyer’s share registry to record the issue of the Milestone 4 Shares to each Seller Nominee in the Buyer’s uncertificated sub-register; and

  

	 	(iii)	within 40 Business Days of the Milestone 4 Notice the Sellers must deliver or procure the delivery to the Buyer of: 

  

	 	(A)	an accountant’s certificate under section 708(8)(c) of the Corporations Act with respect to each Seller Nominee to whom the Milestone 4 Shares are to be issued; 

 

	 	(B)	an original counterpart of an Escrow Agreement with respect to each Seller Nominee, duly executed by each that Seller Nominee with respect to the Milestone 4 Shares to be issued to that Seller Nominee; and

  

	 	(C)	an application to the Buyer, in a form approved by the Buyer, for the Milestone 4 Shares for each Seller Nominee, duly executed by that Seller Nominee. 

 

	 	(iv)	Within 5 days from the date the Milestone 4 Shares are issued the Buyer will give to the ASX a notice under section 708A(6) of the Corporations Act. 

 

	 	(v)	The Milestone 4 Shares will rank equally in all respects with the other then existing issued Novogen Shares from the date of issue and will be freely tradeable from the date of lodgement by the Buyer of a notice under
section 708A(6) of the Corporations Act. 

  

	 	(b)	If the Buyer elects to provide the Milestone 4 Consideration by way of the Milestone 4 Cash Payment, within 7 Business Days of the Milestone 4 Notice the Buyer will pay the Milestone 4 Cash Payment to the Sellers (or as
the Sellers direct). 

  

	 	(c)	If: 

  

	 	(i)	the Buyer elects in accordance with clause 7.12(a) to provide the Milestone 4 Consideration by way of Milestone 4 Shares; and 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 28 

	 	(ii)	the Buyer is unable to obtain all necessary consents and approvals for the issue of the Milestone 4 Shares within 35 Business Days of the Milestone 4 Notice, 

the Buyer must pay to the Sellers the Milestone 4 Consideration by way of the Milestone 4 Cash Payment within 40 Business Days of the
Milestone 4 Notice, and clause 7.12(a) will not apply. 
  

	 	(d)	For the avoidance of doubt, the Sellers will only ever be entitled to payment of the Milestone 4 Consideration in either cash or shares. 

 

	8.	Obligations until registration of transfer 

  

	8.1	Buyer’s obligation to register 

 The Buyer must ensure that registration of the
transfer of the Shares to the Buyer takes place as soon as possible after Completion. 
  

	8.2	Sellers’ obligations 

 After Completion and until the Shares are registered in the
name of the Buyer, the Sellers must convene and attend meetings of the Company, vote at those meetings and take all other action as registered holder of the Shares as the Buyer may lawfully require from time to time by notice to the Sellers. 

 

	9.	Rights and obligations after Completion 

  

	9.1	Novogen Appointment 

  

	 	(a)	Within 28 days of Completion, the Buyer must use its best endeavours to appoint Dr Alan Olivero to the scientific board of the Buyer. 

 

	 	(b)	For the avoidance of doubt, nothing in clause 9.1(a) requires the Buyer to take any action which does not comply with any Laws (including any ASX Listing Rules) or the Buyer’s constitution. 

 

	9.2	Sellers assistance following Completion 

  

	 	(a)	During the period from Completion to the date which is 3 months after Completion (Transition Period), the Sellers must at their own expense provide all assistance to the Buyer as reasonably necessary to facilitate a
smooth and complete transition of the management of the Company to the Buyer, including to: 

  

	 	(i)	provide the Buyer with any information in the possession or control of the Sellers concerning the matters relating to the Company or the Business; 

 

	 	(ii)	if so requested, attend at an address nominated by the Buyer to assist the Buyer to gain knowledge concerning the Business and its conduct; and 

 

	 	(iii)	liaise with any Third Parties with respect to the transfer of the Company and Business to the Buyer. 

  

	 	(b)	The Sellers will not be required to incur any Third Party expense in the course of providing reasonable assistance during the Transition Period. 

 

	9.3	Access to Records 

  

	 	(a)	The Sellers may retain after Completion copies of any Records necessary for the Sellers to comply with any applicable Law (including Tax Law) and to prepare Tax and other returns required of the Sellers by Law.

  
 Confidential material
omitted and filed separately with the Commission. 

  
 29 

	 	(b)	The Buyer must ensure that the Company retains all Records required to be retained by Law existing at Completion for the period that they are required to be retained by Law after Completion. 

 

	 	(c)	Without limiting clause 9.3(a), the Buyer must ensure that the Sellers are promptly afforded reasonable access to the Records referred to in clause 9.3(b) on reasonable request by the Sellers for the purpose of enabling
the Sellers to do all or any of the following: 

  

	 	(i)	comply with any applicable Law (including a Tax Law); 

  

	 	(ii)	prepare any financial statement or Tax return; and 

  

	 	(iii)	defend or deal with any Claim against the Sellers. 

  

	10.	Tax matters 

  

	10.1	Completion of Tax returns and calculations 

  

	 	(a)	As soon as practicable after Completion, the Buyer must procure that the Company prepares all Tax returns that have not been lodged for periods of account concluded before Completion and deliver a copy in draft form to
the Sellers. 

  

	 	(b)	For any period of account which commences before but ends on or after Completion, the Buyer must as soon as practicable after the end of that period, procure that the Company prepares a Tax return for that period and
deliver a copy in draft form to the Sellers. 

  

	 	(c)	Both the Sellers and the Buyer must co-operate fully with each other in the preparation of each Tax return referred to in clauses 10.1(a) and 10.1(b). 

 

	 	(d)	A Tax return referred to in clause 10.1(a) must not be filed with the relevant Government Agency until: 

  

	 	(i)	the Sellers have agreed to the substance of the Tax return, and in this regard, the Sellers have 10 Business Days from receipt of the Tax return (Revision Period) to notify the Buyer of any revisions sought (Revision
Notice); 

  

	 	(ii)	the Revision Period lapses and no Revision Notice has been received by the Buyer; or 

  

	 	(iii)	the Revision Period lapses after the Sellers gives a Revision Notice but any revision suggested has not been agreed to by the Buyer within 5 Business Days after the end of the Revision Period, in which case the Tax
return must be lodged adopting the least favourable tax treatment for the Company. 

  

	10.2	Tax enquiries or audits by Government Agency 

  

	 	(a)	If the Buyer or the Company receives any written communication or notice from any Government Agency of any enquiry, including any request for information, notice to produce documents, audit, review or request for a
meeting (Tax Enquiry): 

  

	 	(i)	relating to the Company; 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 30 

	 	(ii)	wholly or partially in relation to the period before Completion; and 

  

	 	(iii)	that is likely to lead to a circumstance as a result of which the Buyer, would, or would be likely to, make a Warranty Claim, 

then the Buyer or the Company must promptly notify the Sellers of that fact in writing within 10 Business Days after receipt of the Tax
Enquiry. 
  

	 	(b)	Where a Tax Enquiry relates wholly to the period before Completion, the Sellers may: 

  

	 	(i)	control all discussions and communications with the relevant Government Agency in relation to the Tax Enquiry; and 

  

	 	(ii)	conduct, defend and settle any issue against or in respect of the Company, and the Buyer and the Company must, at the request of the Sellers, provide all such assistance as is reasonably necessary to defend or assist in
the defence of the Tax Enquiry. 

  

	 	(c)	Where a Tax Enquiry concerns both the period before and the period after Completion, then the Sellers and the Buyer must, and the Buyer must cause the Company to, co-operate fully
with each other to: 

  

	 	(i)	undertake discussions and communications with the relevant Government Agency in relation to the Tax Enquiry; and 

  

	 	(ii)	conduct, defend and settle any issue against the Company. 

  

	 	(d)	The rights of the Sellers under clauses 10.2(b) and 10.2(c) are conditional on the Sellers having confirmed in writing that they will indemnify the Buyer and the Company against any loss or reasonable costs and expenses
that they may suffer or incur as a result of them providing assistance to the Sellers under those clauses. 

  

	 	(e)	For the avoidance of doubt, the Buyer and the Company have full control of all other Tax Enquiries concerning the Company for periods of account commenced on or after Completion. 

 

	11.	Sellers’ Warranties 

  

	11.1	Warranties 

 The Seller Warrantors warrant and represent to the Buyer and the Company as
an inducement to the Buyer to enter into this Agreement that, subject to the limitations in this clause 11 and clause 13, each of the Sellers’ Warranties is true and accurate, and not misleading or deceptive, at the date of this Agreement and,
except as expressly stated, will be true, accurate and not misleading or deceptive at Completion. 
  

	11.2	Disclosure Material 

 The Buyer acknowledges that, where applicable, the Sellers’
Warranties are qualified by all information fully and fairly disclosed in the Disclosure Material. 
  

	11.3	Separate warranties 

 Each of the Sellers’ Warranties is a separate warranty and is
not limited or restricted by any other warranty, except if that limit or restriction is clearly stated in the relevant Sellers’ Warranty. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 31 

	11.4	Sellers must notify breaches 

 The Seller Warrantors must (whether before or after
Completion) disclose to the Buyer anything which has or will constitute a breach of a Sellers’ Warranty or cause a Sellers’ Warranty to be untrue or inaccurate, as soon as practicable after the Seller Warrantors becomes aware of it. 

 

	11.5	Qualification as to knowledge 

 Where any statement in the Sellers’ Warranties is
qualified by a person’s awareness or knowledge, that statement will be deemed to include an additional statement that it has been made after reasonable enquiries of the officers, employees and advisers of the Seller Warrantors and the Company,
and includes all matters, events or circumstances of which any of the Seller Warrantors or the Company should reasonably be aware or know. 
  

	12.	Indemnities 

  

	12.1	Indemnity for Warranty Claims 

  

	 	(a)	Subject to clauses 11 and 13, if the Buyer makes a Warranty Claim and notifies the Seller Warrantors to that effect, then the Seller Warrantors must jointly and severally indemnify the Buyer from and against any Claim
or Liability that the Buyer or the Company pays, suffers, incurs or is liable for as a direct or indirect result of the Sellers’ Warranty the subject of the Warranty Claim being untrue, inaccurate, misleading or deceptive. 

 

	 	(b)	Clause 12.1(a) does not apply to the extent that the Buyer is able to be indemnified from and against the relevant Claim or Liability under an indemnity in clause 12.2. 

 

	12.2	Tax Indemnity 

 The Seller Warrantors must indemnify the Buyer and the Company for: 

 

	 	(a)	the Tax Claim Amount in respect of any Tax Claim, to the extent that it: 

  

	 	(i)	relates to any period or part period that ends on or before Completion ; or 

  

	 	(ii)	arises as a result of or in respect of, or by reference to, any event, act or failure to act that occurs, or is deemed to occur, on or before or because of Completion; and 

 

	 	(b)	any Liability that the Buyer or the Company may suffer or incur as a result of the Buyer and the Company complying with clause 10.2. 

 

	13.	Claiming under the Sellers’ Warranties and the Indemnities 

  

	13.1	Notice of Claims 

  

	 	(a)	If the Buyer becomes aware of any matter that may give rise to a Warranty Claim or an Indemnity Claim, the Buyer must notify the Seller Warrantors in writing with details of the matter and an estimate of the amount of
the claim as soon as practicable after the Buyer becomes aware of the matter. 

  

	 	(b)	If after Completion the Buyer becomes aware of a matter that may give rise to a Warranty Claim or an Indemnity Claim as a result of a Third Party Claim made or threatened by a Third Party against the Buyer, the Company
or the Sellers, then the Buyer must notify the Seller Warrantors of the Third Party Claim in writing with details of the matter and an estimate of the amount involved as soon as practicable after the Buyer becomes aware of the matter.

  
 Confidential material
omitted and filed separately with the Commission. 

  
 32 

	 	(c)	If the Buyer intends to make a Warranty Claim or an Indemnity Claim, it must notify the Seller Warrantors in writing of that Warranty Claim or Indemnity Claim with details of the matter giving rise to the Claim and the
amount claimed (Claim Notice). A Claim Notice in respect of a Warranty Claim will be deemed to constitute notice of a corresponding Indemnity Claim under clause 12.1. 

 

	13.2	Seller Warrantors to consider Claims 

  

	 	(a)	The Seller Warrantors must notify the Buyer within 10 Business Days after receipt of a Claim Notice, indicating whether they admit or denies the relevant Claim (in whole or in part). 

 

	 	(b)	If the Seller Warrantors do not notify the Buyer within the period specified in clause 13.2(a), they will be taken to have admitted the Claim in full. 

 

	13.3	Time limits for Claims 

 The Buyer may not make a Warranty Claim or an Indemnity Claim
unless it provides a Claim Notice to the Seller Warrantors in respect of the relevant Claim on or before the expiration of 7 years after the date of Completion. 
  

	13.4	Maximum amount the Buyer may recover 

  

	 	(a)	The maximum total amount the Buyer may recover for all Warranty Claims (other than Warranty Claims relating to items 9, 10, 11 or 12 of Schedule 4, fraud or wilful concealment, which are excluded from this amount) must
not exceed the Purchase Consideration. 

  

	 	(b)	For the avoidance of doubt, no limit applies to Warranty Claims arising from fraud or wilful concealment. 

  

	13.5	Benefits received by the Buyer 

  

	 	(a)	The Buyer must reimburse the Seller Warrantors if: 

  

	 	(i)	the Buyer recovers an amount under this Agreement in respect of a Warranty Claim or an Indemnity Claim; and 

  

	 	(ii)	the Buyer or the Company then receives an amount from a Third Party, under a final judgment or award (which cannot be appealed) or under an enforceable settlement, and this amount would have reduced the amount recovered
by the Buyer if it had been received before the recovery. 

  

	 	(b)	The amount the Buyer must reimburse to the Seller Warrantors is equal to the amount the Buyer or the Company receives from the Third Party (less any costs incurred by the Buyer in obtaining the amount). However, the
amount to be reimbursed may not exceed the amount the Buyer recovered from the Seller Warrantors under the relevant Warranty Claim or Indemnity Claim. 

  

	13.6	Escrow arrangement where Claim made 

 Without limiting the operation of this Agreement,
where a Claim under this Agreement is made by the Buyer prior to the expiry of any escrow period under an Escrow Agreement executed pursuant to this Agreement, then, subject to the ASX providing its consent if such consent is necessary to be
obtained: 
  

	 	(a)	the Buyer may in writing extend the relevant escrow period until resolution of the Claim; 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 33 

	 	(b)	the Sellers must procure the agreement of any Seller Nominee under a relevant Escrow Agreement to the extension of the relevant escrow period in accordance with clause 13.6(a); and 

 

	 	(c)	where agreed by the parties, or determined by a court, that an amount with respect to the Claim is due to the Buyer from the Sellers or the Warrantor, without limitation to or waiving any of the Buyer’s rights:

  

	 	(i)	the Buyer may as agent for the relevant Seller Nominee(s) sell the Novogen Shares which are the subject of the relevant Escrow Agreement and apply the proceeds from the sale to the amount due to the Buyer in respect of
the Claim, with any excess to be paid to the relevant Seller Nominee; and 

  

	 	(ii)	the Sellers must procure any Seller Nominee under a relevant Escrow Agreement agrees to, and executes all necessary documents to enable, the operation of clause 13.6(c)(i) 

 

	13.7	Reduction in Purchase Price 

 To the maximum extent permitted by Law, any amount paid by
the Seller Warrantors to the Buyer or the Company under clause 12 or this clause 13 operates as a decrease in the Purchase Price. 
  

	14.	Buyer’s Warranties 

  

	14.1	Warranties 

 The Buyer warrants and represents to the Sellers that: 

 

	 	(a)	the execution and delivery of this Agreement has been properly authorised by all necessary corporate action of the Buyer; 

  

	 	(b)	the Buyer has full corporate power and lawful authority to execute and deliver this Agreement and to perform, or cause to be performed, its obligations under this Agreement; 

 

	 	(c)	this Agreement constitutes a legal, valid and binding obligation on the Buyer enforceable in accordance with its terms by appropriate legal remedy; 

 

	 	(d)	none of the following has occurred and is subsisting, or is threatened, in relation to the Buyer: 

  

	 	(i)	an application or order made, proceeding commenced, resolution passed or proposed in a notice of meeting, petition presented, meeting convened or other step taken for: 

 

	 	(A)	the winding up, dissolution, bankruptcy or administration of the Buyer; or 

  

	 	(B)	the Buyer entering into an arrangement, compromise or composition with or assignment for the benefit of its creditors or a class of them; 

 

	 	(ii)	the Buyer: 

  

	 	(A)	being (or being taken to be under applicable legislation) unable to pay its debts as and when they fall due; or 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 34 

	 	(B)	stopping or suspending, or threatening to stop or suspend, payment of all or a class of its debts; or 

  

	 	(iii)	the appointment of an administrator, receiver, receiver and manager, liquidator, provisional liquidator or similar person to the Buyer or any of its assets; 

 

	 	(e)	this Agreement does not conflict with or result in the breach of or default under any provision of its constitution or any material term or provision of any agreement, deed, writ, order or injunction, judgment or Law to
which it is a party or a subject or by which it is bound; and 

  

	 	(f)	there are no Claims pending or threatened against it or to its knowledge by, against or involving any person which may have a material effect on the sale and purchase of the Shares in accordance with this Agreement.

  

	14.2	Warranties true on Completion 

 The Buyer warrants and represents to the Sellers that
each of the warranties set out in clause 14.1 is true and accurate, and not misleading or deceptive, at the date of this Agreement and, except as expressly stated, will be true, accurate and not misleading or deceptive at Completion. 

 

	15.	Termination by Buyer before Completion 

  

	15.1	Termination events 

 Each of the following is a termination event for the purposes of
this clause 15: 
  

	 	(a)	the Sellers materially breach a term of this Agreement; 

  

	 	(b)	any Sellers’ Warranty is or becomes false, misleading or incorrect when made or regarded as made under this Agreement (except to the extent fully and fairly disclosed in the Disclosure Material); and

  

	 	(c)	a material adverse change occurs in the Business, assets of the Company or the financial or trading position of the Company since the Accounts Date that was not disclosed in the Disclosure Material. 

 

	15.2	Right of Buyer to terminate 

 If: 

 

	 	(a)	a termination event occurs under clause 15.1; 

  

	 	(b)	the Buyer notifies the Sellers of that event within 5 Business Days after becoming aware of it, giving reasonable details of the relevant event; and 

 

	 	(c)	the Sellers are unable to remedy the termination event within 5 Business Days after receiving the notice (or such longer period or periods as may be allowed by the Buyer under clause 15.2(e)), 

then the Buyer may by giving notice to the Sellers at any time before Completion elect to: 

 

	 	(d)	terminate its obligation to buy the Shares and to perform its other obligations under this Agreement, in which event this Agreement terminates at the time the Buyer gives the notice; or 

 

	 	(e)	without affecting its rights to subsequently give notice under clause 15.2(d), delay Completion for a period or periods nominated by the Buyer to determine whether any of the matters referred to in clauses 15.1(a),
15.1(b) and 15.1(c) are remedied or cured within that period. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 35 

	15.3	Remedies cumulative 

 The Buyer may exercise its right of termination under this clause
15 without affecting any of its other rights and remedies. 
  

	16.	Public announcements 

  

	16.1	Making announcements 

 A party must not make, or authorise or cause to be made, any
public announcement relating to the negotiations between the parties or the subject matter of this Agreement unless: 
  

	 	(a)	it has the prior written consent of each other party; or 

  

	 	(b)	it is required to do so by Law or by the rules of any Financial Market to which a party, or a Related Body Corporate of a party, is subject. 

 

	16.2	Requirements 

 If the Sellers or the Warrantor are required to make a public announcement
under clause 16.1(b), they must before doing so, to the extent practicable and as soon as reasonably possible: 
  

	 	(a)	notify the Buyer of the proposed announcement; 

  

	 	(b)	consult with each the Buyer as to its content; and 

  

	 	(c)	use reasonable endeavours to consider any reasonable request by the Buyer concerning the proposed announcement. 

  

	17.	Confidentiality 

  

	17.1	Obligation of confidentiality 

 Subject to clauses 17.2 and 17.3, the Receiving Party
must: 
  

	 	(a)	keep the Confidential Information of or relating to the Disclosing Party confidential and not directly or indirectly disclose, divulge or communicate any of that Confidential Information to, or otherwise place that
Confidential Information at the disposal of, any other person without the prior written approval of the Disclosing Party; 

  

	 	(b)	take all reasonable steps to secure and keep secure all Confidential Information of or relating to the Disclosing Party which comes into its possession or control; and 

 

	 	(c)	not memorise, use, modify, reverse engineer or make copies, notes or records of that Confidential Information for any purpose other than in connection with the performance by the Receiving Party of its obligations under
this Agreement. 

  

	17.2	Exceptions 

 The obligations of confidentiality under clause 17.1 do not apply to: 

 

	 	(a)	any Confidential Information that: 

  

	 	(i)	is disclosed to the Receiving Party by a third party entitled to do so, whether before or after the date of this Agreement; 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 36 

	 	(ii)	was already lawfully in the Receiving Party’s possession when it was given to the Receiving Party and was not otherwise acquired from the Disclosing Party directly or indirectly; or 

 

	 	(iii)	is generally available to the public at the date of this Agreement or subsequently becomes so available other than by reason of a breach of this Agreement; or 

 

	 	(b)	any disclosure of Confidential Information by the Receiving Party that is necessary to comply with any court order, law, or the applicable rules of any Financial Market if, to the extent practicable and as soon as
reasonably possible, the Receiving Party: 

  

	 	(i)	notifies the Disclosing Party of the proposed disclosure; 

  

	 	(ii)	consults with the Disclosing Party as to its content; and 

  

	 	(iii)	uses reasonable endeavours to comply with any reasonable request by the Disclosing Party concerning the proposed disclosure. 

  

	17.3	Disclosure to Recipient 

 A Receiving Party may disclose Confidential Information to a
Recipient only if the disclosure is made to the Recipient strictly on a “need to know basis” and, prior to the disclosure: 
  

	 	(a)	the Receiving Party notifies the Recipient of the confidential nature of the Confidential Information to be disclosed; and 

  

	 	(b)	the Recipient has given an undertaking to the Receiving Party, for the benefit of the Disclosing Party, to be bound by the obligations in this Agreement as if the Recipient were a Receiving Party in relation to the
Confidential Information to be disclosed. 

  

	17.4	Obligations 

  

	 	(a)	The Receiving Party must take all reasonable steps to ensure that any person to whom the Receiving Party is permitted to disclose Confidential Information under clause 17.3 complies at all times with the terms of this
Agreement as if that person were a Receiving Party. 

  

	 	(b)	The Receiving Party is liable for all acts or omissions of a Recipient which constitute a breach of this clause 18 as if such acts or omissions were acts or omissions of the Receiving Party. 

 

	17.5	Return or destruction of Confidential Information 

 Immediately on the written request of
the Disclosing Party or on the termination of this Agreement for any reason, the Receiving Party must: 
  

	 	(a)	cease using all Confidential Information of or relating to the Disclosing Party (or any Related Entity of the Disclosing Party); 

  

	 	(b)	deliver to the Disclosing Party all documents and other materials in its possession or control containing, recording or constituting that Confidential Information or, at the option of the Disclosing Party, destroy, and
certify to the Disclosing Party that it has destroyed, those documents and materials; and 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 37 

	 	(c)	for Confidential Information stored electronically, permanently delete that Confidential Information from all electronic media on which it is stored, so that it cannot be restored. 

 

	17.6	Post Completion 

 On and from Completion: 

 

	 	(a)	all Information in the possession or control of the Sellers relating to or in any way connected with the Company will be deemed to be “Confidential Information” of or relating to the Buyer for the purposes of
this clause 17 and the Sellers must comply with the provisions of this clause 17 as if the Sellers were a “Receiving Party” of that Confidential Information; and 

 

	 	(b)	the Buyer may make use of the Confidential Information of or relating to the Company as it sees fit and without restriction under this Agreement. 

 

	18.	GST 

  

	18.1	Definitions 

 In this clause 18: 

 

	 	(a)	the expressions Consideration, GST, Input Tax Credit, Recipient, Supply, Tax Invoice and Taxable Supply have the meanings given to those expressions in the A New Tax System (Goods and Services Tax) Act 1999 (GST
Act); and 

  

	 	(b)	Supplier means any party treated by the GST Act as making a Supply under this Agreement. 

  

	18.2	Consideration is GST exclusive 

 Unless otherwise expressly stated, all prices or other
sums payable or Consideration to be provided under or in accordance with this Agreement are exclusive of GST. 
  

	18.3	Payment of GST 

  

	 	(a)	If GST is imposed on any Supply made under or in accordance with this Agreement, the Recipient of the Taxable Supply must pay to the Supplier an additional amount equal to the GST payable on or for the Taxable Supply,
subject to the Recipient receiving a valid Tax Invoice in respect of the Supply at or before the time of payment. 

  

	 	(b)	Payment of the additional amount must be made at the same time as payment for the Taxable Supply is required to be made in accordance with this Agreement. 

 

	18.4	Reimbursement of expenses 

 If this Agreement requires a party (the First Party) to pay
for, reimburse, set off or contribute to any expense, loss or outgoing (Reimbursable Expense) suffered or incurred by the other party (the Other Party), the amount required to be paid, reimbursed, set off or contributed by the First Party will be
the sum of: 
  

	 	(a)	the amount of the Reimbursable Expense net of Input Tax Credits (if any) to which the Other Party is entitled in respect of the Reimbursable Expense (Net Amount); and 

 

	 	(b)	if the Other Party’s recovery from the First Party is a Taxable Supply, any GST payable in respect of that Supply, such that after the Other Party meets the GST liability, it retains the Net Amount.

  
 Confidential material
omitted and filed separately with the Commission. 

  
 38 

	19.	General 

  

	19.1	Nature of obligations 

  

	 	(a)	Any provision in this Agreement which binds more than one person binds all of those persons jointly and each of them severally. 

  

	 	(b)	Each obligation imposed on a party by this Agreement in favour of another is a separate obligation. Unless specified otherwise, the performance of one obligation is not dependent on the performance of any other
obligation. 

  

	19.2	Entire understanding 

  

	 	(a)	This Agreement and the Licence Agreement and each executed Escrow Agreement contain the entire understanding between the parties concerning the subject matter of the Agreement and supersedes, terminates and replaces all
prior agreements and communications between the parties. 

  

	 	(b)	Each party acknowledges that, except as expressly stated in this Agreement, that party has not relied on any representation, warranty or undertaking of any kind made by or on behalf of another party in relation to the
subject matter of this Agreement. 

  

	19.3	Survival of obligations 

  

	 	(a)	Despite any other provision of this Agreement, any indemnity or obligation of confidence under this Agreement survives Completion or the termination of this Agreement, however arising, including clauses 1, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, and 19. 

  

	 	(b)	On termination under clause 3.4 or clause 15, no party has any obligation or liability to any other party, except in connection with claims that arose before termination. 

 

	19.4	No adverse construction 

 This Agreement, and any provision of this Agreement, is not to
be construed to the disadvantage of a party because that party was responsible for its preparation. 
  

	19.5	Further assurances 

 A party, at its own expense (unless otherwise provided in this
Agreement) and within a reasonable time of being requested by another party to do so, must do all things and execute all documents that are reasonably necessary to give full effect to this Agreement. 

 

	19.6	No waiver 

  

	 	(a)	A failure, delay, relaxation or indulgence by a party in exercising any power or right conferred on the party by this Agreement does not operate as a waiver of the power or right. 

 

	 	(b)	A single or partial exercise of the power or right does not preclude a further exercise of it or the exercise of any other power or right under this Agreement. 

 

	 	(c)	A waiver of a breach does not operate as a waiver of any other breach. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 39 

	19.7	Severability 

 Any provision of this Agreement which is invalid in any jurisdiction must
in relation to that jurisdiction: 
  

	 	(a)	be read down to the minimum extent necessary to achieve its validity, if applicable; and 

  

	 	(b)	be severed from this Agreement in any other case, 

 without invalidating or affecting the
remaining provisions of this Agreement or the validity of that provision in any other jurisdiction. 
  

	19.8	Successors and assigns 

 This Agreement binds and benefits the parties and their
respective successors and permitted assigns under clause 19.9. 
  

	19.9	No assignment 

 A party cannot assign or otherwise transfer the benefit of this Agreement
without the prior written consent of each other party. 
  

	19.10	Consents and approvals 

 Where anything depends on the consent or approval of a party
then, unless this Agreement provides otherwise, that consent or approval may be given conditionally or unconditionally or withheld, in the absolute discretion of that party. 
  

	19.11	No variation 

 This Agreement cannot be amended or varied except in writing signed by the
parties. 
  

	19.12	Costs 

 Each party must pay its own legal costs of and incidental to the preparation and
completion of this Agreement. 
  

	19.13	Duty 

  

	 	(a)	Any duty (including related interest or penalties) payable in respect of this Agreement or any instrument created in connection with it must be paid by the Buyer. 

 

	 	(b)	The Buyer undertakes to keep the Sellers indemnified against all liability relating to the duty, fines and penalties. 

  

	19.14	Governing law and jurisdiction 

  

	 	(a)	This Agreement is governed by and must be construed in accordance with the Law of New South Wales. 

  

	 	(b)	The parties submit to the non-exclusive jurisdiction of the courts of that State or Territory and the Commonwealth of Australia in respect of all matters arising out of or
relating to this Agreement, its performance or subject matter. 

  

	19.15	Notices 

 Any notice or other communication to or by a party under this Agreement: 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 40 

	 	(a)	may be given by personal service, post or facsimile; 

  

	 	(b)	must be in writing, legible and in English addressed (depending on the manner in which it is given) as shown below: 

  

	 	(i)	If to the Sellers or (before Completion) the Company: 

Address:      Unit 101 50 McLachlan Avenue Rushcutters Bay NSW 2011 

Attention:    Paul Hopper 

Facsimile: 
  

	 	(ii)	If to the Buyer or (after Completion) the Company: 

Address:      P.O. Box 2333, Hornsby Westfield, NSW 1635 

Attention:    Dr James Garner 

Facsimile:    +61 2 9476 0388 
  

	 	(iii)	If to the Warrantor: 

 Address:      Unit 101 50 McLachlan Avenue
Rushcutters Bay NSW 2011 
 Attention:    Paul Hopper 

Facsimile: 
 or to any other
address last notified by the party to the sender by notice given in accordance with this clause; 
  

	 	(c)	must be signed: 

  

	 	(i)	in the case of a corporation registered in Australia, by any authorised representative or by the appropriate office holders of that corporation under section 127 of the Corporations Act; or 

 

	 	(ii)	in the case of a corporation registered outside of Australia, by a person duly authorised by that corporation under the laws governing the place of registration of that corporation; and 

 

	 	(d)	is deemed to be given by the sender and received by the addressee: 

  

	 	(i)	if delivered in person, when delivered to the addressee; 

  

	 	(ii)	if posted, at 9.00 am on the second business day after the date of posting to the addressee, whether delivered or not; 

  

	 	(iii)	if sent by facsimile transmission, on the date and time shown on the transmission report by the machine from which the facsimile was sent which indicates that the facsimile was sent in its entirety and in legible form
to the facsimile number of the addressee notified for the purposes of this clause, 

 but if the delivery or receipt is on a
day which is not a business day or is after 4.0 pm (addressee’s time), it is deemed to have been received at 9.00 am on the next business day. In this clause 19.15, ‘business day’ means a day which is not a Saturday, Sunday, public
holiday or bank holiday in the place of receipt of a communication. 
  

	19.16	Counterparts 

 If this Agreement consists of a number of signed counterparts, each is an
original and all of the counterparts together constitute the same document. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 41 

	19.17	Conflicting provisions 

 If there is any conflict between the main body of this Agreement
and any schedules or annexures comprising it, then the provisions of the main body of this Agreement prevail. 
  

	19.18	No merger 

 A term or condition of, or act done in connection with, this Agreement or
Completion does not operate as a merger of any of the undertakings, warranties and indemnities in this Agreement or the rights or remedies of the parties under this Agreement which continue unchanged. 

 

	19.19	Operation of indemnities 

 Unless this Agreement expressly provides otherwise: 

 

	 	(a)	each indemnity in this Agreement survives the expiry or termination of this Agreement; and 

  

	 	(b)	a party may recover a payment under an indemnity in this Agreement before it makes the payment in respect of which the indemnity is given. 

 

	19.20	No right of set-off 

 Unless this Agreement
expressly provides otherwise, a party has no right of set-off against a payment due to another party. 
  

	19.21	Relationship of parties 

 Unless this Agreement expressly provides otherwise, nothing in
this Agreement may be construed as creating a relationship of partnership, of principal and agent or of trustee and beneficiary. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 42 

 Schedule 1-Share Details 

(Clause 1.1) 

																	
	 Sellers

(registered holder)
	  	 Beneficial

owner
	 	  	
No. and class of
Shares
	 	  	 Paid-up

amount
	 	  	 Unpaid

amount
	 
	 Kilinwata Investments Pty. Ltd.
	  	 	Yes	 	  	 	750	 	  	$	0.75	 	  	 	Nil	 
	 Mi Ok Chong
	  	 	Yes	 	  	 	250	 	  	$	0.25	 	  	 	Nil	 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 43 

 Schedule 2-Corporate Details 

(Clause 1.1) 
 Details of the Company 

 

			
	 Name:
	  	Glioblast Pty Ltd
		
	 ACN:
	  	612 141 625
		
	 Registered Office:
	  	Unit 101, 50 McLachlan Avenue, Rushcutters Bay NSW 2011
		
	 Date and place of incorporation:  
	  	2 May 2016, New South Wales
		
	 Issued capital:
	  	$1
		
	 Directors:
	  	Deborah Anne Coleman
		
	 Secretary:
	  	None appointed
		
	 Public Officer:
	  	None appointed

  
 Confidential material
omitted and filed separately with the Commission. 

  
 44 

 Schedule 3 - Conditions to Completion 

(clause 3.1) 
  

			
	 Condition
	  	 Party entitled to
benefit

	1.      Execution of the Licence Agreement by the Buyer and by Genentech, Inc	  	The Buyer
		
	2.      Completion of Buyer due diligence into the Company	  	The Buyer
		
	3.      All consents and waivers the Buyer deems necessary or relevant for the sale and purchase of the Shares, the Buyer and/or its nominee(s) to be registered as holder of any and all of the Shares
and all other applicable transactions contemplated by this Agreement to take place in accordance with the terms of this Agreement and without breaching any Law or agreement are granted and received, or if only granted subject to conditions, such
conditions being satisfactory to the Buyer in its sole and absolute discretion	  	The Buyer
		
	4.      The Company obtains all necessary consents (on terms and conditions in all respects satisfactory to the Buyer) all third party consents, licences, approvals, authorisations or waivers
required for the acquisition of the Shares	  	The Buyer
		
	5.      All consents, waivers and approvals (including shareholder approvals) required by Law (including the ASX Listing Rules) and the Buyer’s constitution with respect to the issue of the
Completion Shares and Milestone Consideration to the Sellers are obtained on terms reasonably satisfactory to the Buyer	  	The Buyer
		
	6.      Replacement of the Company’s constitution with a form of constitution approved by the Buyer	  	The Buyer
		
	7.      Appointment of Paul Hopper as a consultant to the Buyer on the terms of the Hopper Appointment Agreement	  	The Buyer
		
	8.      Appointment of Mi Ok Chong as a consultant to the Buyer on the terms of the Chong Appointment Agreement	  	The Buyer

  
 Confidential material
omitted and filed separately with the Commission. 

  
 45 

 Schedule 4 - The Sellers’ Warranties 

(Clause 11) 
  

	1.	The Sellers’ authority to sell 

  

	 	(a)	The Sellers are the registered holder and beneficial owner of the Shares and such shares are all of the issued shares in the capital of the Company. 

 

	 	(b)	The Shares are not subject to any Encumbrance in favour of any person or company. 

  

	 	(c)	Kilinwata Investments Pty. Ltd. and the Company are both validly existing under the Law of their place of incorporation. 

  

	 	(d)	Each of the Sellers and the Company has the power to enter into and perform its obligations under this Agreement and to carry out the transactions contemplated by this Agreement. 

 

	 	(e)	Each of the Sellers and the Company has taken all necessary action to authorise its entry into and performance of this Agreement and to carry out the transactions contemplated by this Agreement. 

 

	 	(f)	The obligations of the Sellers and the Company under this Agreement are valid and binding and enforceable against the Sellers and the Company (respectively) in accordance with their terms. 

 

	2.	The Company 

  

	 	(a)	The Company has full corporate power to own its properties, assets and business and to carry on its business as now conducted. 

  

	 	(b)	The Company does not hold or beneficially own shares or other securities in the capital of another corporation. 

  

	 	(c)	The Company has not bought or agreed to buy any securities in another corporation. 

  

	 	(d)	The Company is not, and has not agreed to become, a member of any partnership, unincorporated association, joint venture or consortium. 

 

	 	(e)	No meeting has been convened, resolution proposed, petition presented or order made for the winding up of the Company and no receiver, receiver and manager, provisional liquidator, liquidator, administrator or other
officer of the court has been appointed or threatened to be appointed in relation to the Company or any part of its undertaking or assets. 

  

	3.	Share capital of the Company 

  

	 	(a)	The Shares: 

  

	 	(i)	as set out in Schedule 1 comprise all of the share capital of the Company; 

  

	 	(ii)	are held and beneficially owned and are paid as set out in Schedule 1; and 

  

	 	(iii)	were all properly issued. 

  

	 	(b)	There is no restriction on the sale or transfer of the Shares to the Buyer (whether contained in the constitution of the Company or otherwise) except for the consent of the directors of the Company to the registration
of the transfers of the Shares. 

  

	 	(c)	There are no securities convertible into shares of the Company. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 46 

	 	(d)	There are no options or other entitlements of any kind over any shares of the Company or to have shares in the Company issued. 

  

	 	(e)	There are no restrictions on the transfer of any Shares (including any rights of pre-emption exercisable by any person) or on the effective change of control of the Company as a
result of the transactions contemplated by this Agreement. 

  

	4.	Information 

  

	 	(a)	The information set out in this Agreement is true, accurate and not misleading or deceptive (whether by omission or otherwise) in any material respect. 

 

	 	(b)	A true and correct copy of the constitution of the Company will be provided to the Buyer on Completion. 

  

	 	(c)	All information which the Seller Warrantors, the Company or any of their respective employees, agents or advisers have given before the date of this Agreement to the Buyer or its advisers relating to the Business, the
activities, affairs, assets and Liabilities of the Company and the subject matter of this Agreement was prepared with reasonable care and is, and was when given, complete and accurate in all material respects. 

 

	 	(d)	All information that is: 

  

	 	(i)	known to the Seller Warrantors relating to the Shares, the Company, the Business or otherwise relevant to the subject matter of this Agreement; and 

 

	 	(ii)	material to a buyer of the Shares, 

 has been fully and fairly disclosed in writing to the Buyer
before the date of this Agreement. 
  

	 	(e)	The Seller Warrantors have not withheld from providing to the Buyer before the date of this Agreement any information that is material to or would reasonably be required for the purpose of making an informed assessment
of the assets and liabilities, financial position and performance of the Company or would otherwise have a material adverse effect on the value of the Business or the Shares. 

 

	5.	Financial statements 

  

	 	(a)	The Accounts disclose a true and fair view of the affairs, financial position and assets and liabilities of the Company as at the Accounts Date and of the income, expenses, results of operations and cash flow of the
Company. 

  

	 	(b)	The Accounts were prepared in accordance with the Accounting Standards, the requirements of the Corporations Act and all other applicable Laws. 

 

	 	(c)	The Accounts contain proper and adequate provision for and full disclosure of all liabilities of the Company as at the Accounts Date. 

 

	 	(d)	All financial arrangements of or relating to the Company and the Business are fully and accurately reflected in the Accounts. 

  

	 	(e)	Any budget, forecast or projection relating to the Company provided to the Buyer by or on behalf of the Sellers before the date of this Agreement, has been prepared carefully, on a reasonable basis and is arithmetically
correct, and there are no facts or circumstances known to the Sellers which would cause a prudent manager to change the budget, forecast or projection. 

  

	 	(f)	The income and profits of the Company disclosed in the Accounts have not resulted from: 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 47 

	 	(i)	transactions entered into other than on normal commercial terms; 

  

	 	(ii)	other factors rendering the profits for the relevant period abnormally high. 

  

	 	(g)	The Accounts are not affected by any unusual, abnormal, extraordinary, exceptional or non-recurring items. 

 

	 	(h)	Since the Accounts Date there has been no material change in the assets, liabilities, turnover, earnings, financial condition, trading position or affairs of the Company. 

 

	6.	No operation 

  

	 	(a)	No dividend or distribution of capital or income has been declared, made or paid in respect of any capital of the Company, whether of cash, specific assets or otherwise. 

 

	 	(b)	The Company has conducted its internal affairs with all reasonable care and in accordance with normal and prudent practice (having regard to the nature of the Business and past practice and so as to comply with all
applicable Laws). 

  

	 	(c)	The Company has not entered into any material contracts or arrangements, or terminated or altered any term of any material contracts or arrangements, other than in accordance with this Agreement. 

 

	 	(d)	The Company has no turnovers or earnings and has not incurred or undertaken any material Liabilities or obligations (actual or contingent), including Taxation. 

 

	 	(e)	The Company has not acquired or disposed of or dealt with any assets nor has it entered into any agreement or option to acquire or dispose of any assets. 

 

	 	(f)	Since the Agreement Date, the rights attaching to any shares in the Company have not altered and no alteration has been made to the capital structure of the Company. 

 

	 	(g)	No loans have been made or bonuses paid by the Company to any person. 

  

	 	(h)	The Company has not issued, agreed to issue or granted any option to issue any equity or loan securities or any security convertible into any such securities. 

 

	 	(i)	Other than the Shares, the Company has not issued any shares, or options to take up unissued shares, in the capital of the Company. 

  

	 	(j)	No resolutions have been passed by the members or directors of the Company except in the ordinary course of the Business and those necessary to give effect to this Agreement. 

 

	7.	Liabilities and commitments 

  

	 	(a)	The Company has not borrowed money, increased the amount of existing borrowings or drawn on any credit lines other than under existing credit facilities. 

 

	 	(b)	The Company has not granted or created any Encumbrance over the Shares or any of its assets or inventory. 

  

	 	(c)	The Company has not provided any guarantee or other security to any Third Party. 

  

	 	(d)	No Sellers’ Guarantees have been provided to any Third Party. 

  

	 	(e)	The Company does not have any material commitments or unusual Liabilities that are not disclosed in the Accounts. 

  

	 	(f)	The Company does not owe any money or have any outstanding liability to the Sellers. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 48 

	 	(g)	No Sellers nor any Related Entity of any Sellers owes, or will owe at Completion, any money, or has any outstanding liability, to the Company. 

 

	 	(h)	The Company is not directly or indirectly obliged in any way to guarantee, assume or provide funds to satisfy any obligation of any person, and has not given a letter of comfort to any person. 

 

	 	(i)	No offer, tender or quotation given or made by the Company is capable of giving rise to a contract merely by any unilateral act of a Third Party. 

 

	 	(j)	The transfer of the Shares in accordance with this Agreement does not and will not constitute a breach of any obligation (including any statutory, contractual or fiduciary obligation), or default under any agreement or
undertaking, by which the Company is or may become bound. 

  

	 	(k)	There are no outstanding commitments of the Company for capital expenditure. 

  

	 	(l)	The Company is not party to any agreement in terms of which it is, or will be, bound to share its profits or pay any royalties. 

  

	 	(m)	There are no debts owed to or accounts receivable of the Company at Completion. 

  

	8.	Records 

 The Records of the Company: 

 

	 	(a)	are in the possession or under the control of the Company; 

  

	 	(b)	have been fully, properly and accurately kept and maintained and are up to date; 

  

	 	(c)	accurately record the details of all of the transactions, finances, assets and liabilities of the Company; and 

  

	 	(d)	as far as necessary, have been prepared in accordance with the requirements of the Corporations Act and the Accounting Standards. 

  

	9.	Taxation 

  

	 	(a)	All Tax and other revenue returns, including income tax, fringe benefits tax, payroll tax, superannuation guarantee, land tax, rates, customs duty, franking account returns and business activity statements (Returns)
lodged by the Company: 

  

	 	(i)	have been lodged by the due date for filing those Returns, and no Returns remain un-lodged; 

  

	 	(ii)	have been made taking reasonable care and with full and true disclosure; and 

  

	 	(iii)	do not contain any statement that is false or misleading, whether by omission or otherwise. 

  

	 	(b)	All assessments, whether original or amended, made by a Government Agency in respect of the Company and all Returns of the Company accurately reflect any Liability for Tax of the Company for the period to which the
assessment or Return relates. 

  

	 	(c)	All notices and elections required to be given or made by the Company have been given or made by the Company and support the position taken in the Returns. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 49 

	 	(d)	All information required to be retained under any relevant Tax legislation is currently held by the Company, including any information that may be required to calculate or verify the adjustable value and any capital
gain or loss on disposal of any asset held at Completion. 

  

	 	(e)	The Company has paid all Taxes which the Company is liable to pay prior to Completion and the Accounts fully provide for, all Taxes which the Company is or may become liable to pay for the period up to and including the
Completion Date. 

  

	 	(f)	The Company will have no liability in respect of unpaid or unassessed Taxes referrable to any time before Completion in excess of the provision for Tax in the Accounts. 

 

	 	(g)	There is no difference between the amounts incurred for acquisition, improvements and incidental costs of acquisition of any Company assets and their cost base for Tax purposes. 

 

	 	(h)	The costs bases of the Company’s assets have not been reduced from the amounts of money actually incurred for acquisition, improvements and incidental costs of acquisition on account of: 

 

	 	(i)	any transfers of assets; 

  

	 	(ii)	any transfers of losses; 

  

	 	(iii)	any forgiveness of debt; or 

  

	 	(iv)	any transactions which shift value. 

  

	 	(i)	The Company is not involved in any audit by a Government Agency or aware of any pending audit of any of its Returns or its Tax affairs and there are no outstanding disputes, questions or demands as between the Company
and any Government Agency relating to a Tax matter. The Sellers are not aware of any circumstances that may give rise to such audit or dispute. 

  

	 	(j)	Complete copies of all rulings, private binding rulings, advices, consents and clearances (Rulings) affecting the Company from any Government Agency have been supplied to the Buyer, and any transactions carried into
effect in reliance on any of those Rulings have been implemented in the manner disclosed in the application for it. 

  

	 	(k)	The Company has not taken any action which has or might alter or prejudice any arrangement or Ruling which has previously been negotiated with or obtained from the relevant Government Agency under any Tax Law.

  

	 	(l)	The Company has not acted otherwise than in accordance with any advance opinion or private binding ruling issued to it by any Government Agency and has otherwise taken “reasonable care” and adopted
“reasonably arguable positions” (within the meaning of those terms in the Tax Act) in relation to its liability to Tax. 

  

	 	(m)	The Company has not participated in schemes or transactions or made any payments to which Part IVA, section 82KK or section 82KL of the Tax Act applies or might apply. 

 

	 	(n)	The Company has not participated in: 

  

	 	(i)	any dividend stripping or dividend or capital streaming or franking credit trading schemes (or schemes of substantially the same effect) within the meaning of the Tax Act or which are subject to the operation of
sections 45 to 45D, former sections 46B, and 160AQCBA and section 177E or 177EA of the Tax Act; or 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 50 

	 	(ii)	any scheme or arrangement within the meaning of Division 204 of Part 3-6 of the Tax Act to exploit the benchmark franking percentage of another entity, stream franked
distributions or tax-exempt bonus shares or stream distributions to shareholders or former shareholders of the Company that derive greater benefit from franking credits than other shareholders or former
shareholders, and nor will the sale itself, or in conjunction with other events before Completion, constitute such a scheme. 

  

	 	(o)	No dividend has been paid by the Company: 

  

	 	(i)	in respect of which the franking amount has exceeded the benchmark franking percentage or the maximum franking credit within the meaning of Part 3-6 of the Tax Act; or

  

	 	(ii)	in respect of which an application has been made to the Commissioner of Taxation for permission to depart from the benchmark franking percentage within the meaning of Part 3-6 of
the Tax Act. 

  

	 	(p)	The Company has provided, or will provide before Completion, distribution statements within the meaning of section 202-80 of the Tax Act to shareholders in respect of all
dividends paid by the Company before Completion. 

  

	 	(q)	The Company does not hold any assets to which Subdivision 104-J of the Tax Act may apply. 

  

	 	(r)	Nothing has occurred to cause a disallowance of carried forward income or capital losses of the Company as at Completion (other than the transfer of Shares as contemplated by this Agreement). 

 

	 	(s)	The Company has not been required to reduce losses or the tax attributes of assets (for capital allowances purposes or capital gains tax purposes) as contemplated by Division 245 of Schedule 2C of the Tax Act.

  

	 	(t)	The share capital account of the Company is not tainted within the meaning of section 197-50 of the T ax Act. 

 

	 	(u)	All amounts of Tax required by Law to be deducted by the Company from the salary or wages of employees, servants and agents or payments to contractors have been deducted and remitted to the relevant Government Agency
within the time allowed by the relevant Tax Law. 

  

	 	(v)	Any withholding tax that is required to be withheld from any payment made by the Company has been duly withheld and remitted to the relevant Government Agency within the time allowed by the relevant Tax Law and the
Company has not been a party to a scheme to which section 177CA of the Tax Act applies. 

  

	 	(w)	The Company has not entered into a transaction or arrangement that attracts the operation of any of section 108, section 109 or the provisions of Division 7A of the Tax Act. 

 

	 	(x)	Subject to the Company satisfying the conditions in Subdivision 165-C of the Tax Act, a bad debt deduction will be available in respect of the write off of any trade debts shown
in the Accounts which have not previously been written off. 

  

	 	(y)	The Company has not entered into any arrangement that: 

  

	 	(i)	will give rise to any adjustment to its taxable income as a result of the operation of the provisions in Division 13 of Part III of the Tax Act; or 

 

	 	(ii)	results in it obtaining a “transfer pricing benefit” as that term is defined in Division 815 of the Tax Act 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 51 

	 	(z)	The Company is not and will not become liable to pay, reimburse or indemnify any person in respect of any Tax relating to an act or omission occurring before Completion or because of the failure of that other person to
discharge the Tax Liability. 

  

	 	(aa)	The Company has not issued or created any: 

  

	 	(i)	non-share equity interest (as defined in section 995-1 of the Tax Act); or 

 

	 	(ii)	non-equity share (as defined in section 6(1) of the Tax Act). 

  

	 	(bb)	The Company has valued trading stock using an accepted methodology under Subdivision 70-C of the Tax Act. 

 

	 	(cc)	The Company is not a member of a Consolidated Group (as defined in section 703-5 of the Tax Act) and the Sellers will not form, and will procure that no Related Body Corporate
forms, a Consolidated Group including the Company, whether before or after the date of this Agreement. 

  

	10.	GST 

  

	 	(a)	In this warranty 10: 

  

	 	(i)	expressions which are not defined, but which have a defined meaning in GST Law, have the same meaning; and 

  

	 	(ii)	GST Law has the meaning given to that expression in the A New Tax System (Goods and Services Tax) Act 1999 (Cth). 

  

	 	(b)	The Company is not: 

  

	 	(i)	a member of any GST group, GST joint venture or partnership; or 

  

	 	(ii)	liable to pay GST in respect of supplies made by any other entity. 

  

	 	(c)	The Company has not participated in any schemes or transactions or made any payments to which Division 165 of the A New Tax System (Goods and Services Tax) Act 1999 (Cth) applies or might apply.

  

	 	(d)	The Company has not lodged any Business Activity Statements. 

  

	11.	Stamp Duty 

  

	 	(a)	All Stamp Duty arising under a Tax Law in relation to any transaction or document to which the Company is or has been a party or by which the Company derives, or has or will derive, a benefit has been paid or will be
paid before Completion in accordance with the relevant Tax Law (irrespective of whether the Company or a Third Party is liable for that Stamp Duty). 

  

	 	(b)	The Company has not been a party to a transaction or document with a Related Body Corporate of the Company (or an entity that was a Related Body Corporate of the Company at the time) in the 6 years preceding Completion
that would have been liable to Stamp Duty under a Tax Law but for relief granted in writing by a Government Agency. 

  

	 	(c)	No liability for Stamp Duty will be triggered in respect of events occurring before Completion as a result of any change of ownership or control on Completion. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 52 

	12.	Non-resident CGT withholding 

 The Buyer is not required
under a Tax Law to withhold any amount otherwise payable to the Sellers under this Agreement for remittance to the Commissioner of Taxation as a foreign resident capital gains withholding payment under subsection
14-200(3) of Schedule 1 of the Tax Act. 
  

	13.	Plant and Equipment 

  

	 	(a)	The Company does not and will not on Completion own, lease, licence or use any plant, equipment (including computer equipment), motor vehicles, machinery, furniture, fixtures and fittings. 

 

	 	(b)	The Company has not entered into any hire purchase, leasing or credit sale agreement in respect of, and has not sold or agreed to sell, any items of plant, equipment (including computer equipment), motor vehicles,
machinery, furniture, fixtures and fittings. 

  

	 	(c)	The Company does not use any computer hardware of software whether owned by or licensed to the Company. 

  

	 	(d)	All Records of the Company stored by electronic means have been provided to the Buyer in a downloadable form which the Buyer may access without specialised software. 

 

	 	(e)	The Company does not, and will not on Completion hold or own any stock of finished goods, including packaging. 

  

	14.	Real Property 

  

	 	(a)	The Company does not and will not on Completion own, occupy, lease or licence any real property. 

  

	 	(b)	The Company does not owe any rent, rates, Taxes (including land tax), outgoings, levies and contributions with respect to any real property. 

 

	15.	Insurance 

  

	 	(a)	The Company has not entered into any contract under which the Company or its officers are an insured party (including in respect of directors indemnity insurance or workers’ compensation insurance) (Insurance
Contract). 

  

	 	(b)	There are no outstanding claims or insurance premiums payable under any Insurance Contracts. 

  

	16.	Intellectual Property Rights 

  

	 	(a)	The Company does not own, use or require in the Business any business names, trade marks, service marks, trade names, copyright, patents, patent applications, confidential information or other Intellectual Property
Rights. 

  

	 	(b)	The Company has not dealt with or granted to any person any rights in respect of any Intellectual Property Rights by way of licence or in any other way. 

 

	 	(c)	The Company has not infringed the Intellectual Property Rights of any other person. 

  

	 	(d)	The Sellers are not aware of any allegation or basis on which an allegation could be made that the Company has infringed the Intellectual Property Rights of any person. 

 

	 	(e)	There are no royalties, licence fees or other similar fees payable by the Company in connection with the use of any Intellectual Property Rights. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 53 

	17.	Contracts and commercial matters 

  

	 	(a)	The Company has not entered into or is not bound by any contract, arrangement or understanding with a Third Party that has not been fully and fairly disclosed in writing to the Buyer. 

 

	 	(b)	No employee or director of the Company has entered into or agreed to be bound by a contract, arrangement or understanding with a Third Party purportedly on behalf of the Company, in circumstances where the employee or
director has acted wrongfully, against the intention or instructions of the Company or otherwise outside the scope of his or her authority. 

  

	 	(c)	The Company has not made any offer, tender or quotation made which is outstanding and capable of acceptance by a Third Party. 

  

	18.	Defective products 

 The Company has not manufactured, sold or supplied any products or services
that: 
  

	 	(a)	are or were or will become faulty or defective in any material respect; or 

  

	 	(b)	do not comply, in any material respect, with any warranties or representations expressly or impliedly made or given by the Company or with all applicable regulations, standards and requirements. 

 

	19.	Compliance with applicable Laws 

  

	 	(a)	The Company has at all times complied with all Laws, including all: 

  

	 	(i)	planning Laws, agreements and permits; 

  

	 	(ii)	employment and industrial relations Laws and agreements; 

  

	 	(iii)	occupational health and safety Laws; and 

  

	 	(iv)	Environmental Laws, 

  

	 	 	and no contravention or allegation of any contravention of any applicable Law is known to the Sellers. 

  

	 	(b)	As far as the Seller Warrantors are aware: 

  

	 	(i)	there is no fact or matter that might prejudice the continuance or renewal, or result in the revocation or variation in any material respect, of any statutory permit or licence; and 

 

	 	(ii)	the Company is not being investigated for any breach or alleged breach of any Law. 

  

	 	(c)	The Company has not received any notice that any statutory permit or licence will be revoked, suspended, modified or will not be renewed. 

 

	20.	Litigation 

  

	 	(a)	Neither the Company nor any person for whose acts or defaults the Company may be vicariously liable is involved in, or threatened with, any Claim in any court, tribunal or otherwise and there are no facts or
circumstances likely to give rise to any such Claim. 

  

	 	(b)	There are no unsatisfied Claims against the Company. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 54 

	 	(c)	There are no facts or circumstances known to the Sellers that may result in a material industrial dispute between the Company and any third party and no material pay claims have been made, or are likely to be made,
against it. 

  

	21.	Employees, officers and sub-contractors 

  

	 	(a)	The Company has not engaged: 

  

	 	(i)	any employees whether current or in the past; or 

  

	 	(ii)	consultants or contractors to provide services to the Company, whether current or in the past. 

  

	 	(b)	The Company does not operate any bonus, profit share or employee incentive plans or schemes for its employees or officers. 

  

	 	(c)	No money is payable to any director of the Company and the Company is not under any present, future or contingent liability to pay compensation for loss of office or employment to any
ex-officer. 

  

	 	(d)	Since the Agreement Date, no remuneration or fees have been paid or agreed by the Company to be paid to any director of the Company. 

 

	22.	Superannuation 

 As at Completion, the Company has no employer superannuation obligations in
respect of any person. 
  

	23.	Effect of sale of Shares 

 The entry into and performance of this Agreement does not and will
not: 
  

	 	(a)	result in the breach of any of the terms, conditions or provisions of any agreement or arrangement to which the Company is a party; 

  

	 	(b)	relieve any person from any obligation to the Company; 

  

	 	(c)	result in the creation, imposition, crystallisation or enforcement of any Encumbrance on the Company or any of its assets; or 

  

	 	(d)	result in any indebtedness of the Company becoming due and payable. 

  

	24.	Delegations and finder’s fees 

  

	 	(a)	No power of attorney given by the Company will be in force after Completion. 

  

	 	(b)	Neither the Sellers nor the Company has taken any action under which                      any person is or may be
entitled to a finder’s fee, brokerage or commission in connection with the acquisition of the Shares under this Agreement 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 55 

 Executed as a deed 
  

	Sellers	

 Executed by Kilinwata Investments Pty. Ltd. 

ACN 009 641 212 in accordance with its constitution: 

	
	Signature of sole director
	
	Name (please print)

 Signed Sealed and Delivered by Mi Ok Chong in the presence of: 

	
	 /s/ Mi Ok Chong

	Signature

 Signature of witness 

Name of witness 
 (please
print) 
  

	
	Address of witness
	(please print)

  
 Confidential material
omitted and filed separately with the Commission. 

  
 56 

 Warrantor 
  

			
	Signed Sealed and Delivered by Paul Hopper in the presence of:	 	
		
		 	 /s/ Paul Hopper

	Signature of witness	 	Signature
		
	 Name of witness

(please print)
	 	
		 	
	 Buyer
	 	
	 101/50 McLachlan Ave, Rushcutters Bay
	 	
	Address of witness	 	
	(please print)	 	
	Executed by Novogen Limited ACN 063 259 754 in accordance with section 127(1) of the Corporations Act 2001 (Cth):	 	
	*-----DocuSigned by:	 	
		
	 /s/ James Garner
	 	DocuSigned by:
	Signature of director	 	 /s/ Kate Hill

		 	Name (please print)
		
	James Garner	 	 Signature of director or company

secretary*

	Name (please print)	 	*delete whichever does not apply
		
	31 OCT 2016	 	Kate Hill

  
 Confidential material
omitted and filed separately with the Commission. 

  
 57 

 EXHIBIT A 

LICENSED PATENT RIGHTS 
  

							
	 Country
	  	 Patent Number
	  	 Application Number
	  	 Status

	Argentina	  		  	P110104706	  	Filed
				
	Austria	  	E696957	  	11808454.0	  	Granted
				
	Australia	  	2011343712	  	2011343712	  	Granted
				
	Australia	  		  	2015268776	  	Filed
				
	Belgium	  	2651951	  	11808454.0	  	Granted
				
	Bulgaria	  	2651951	  	11808454.0	  	Granted
				
	Brazil	  		  	BR112013014914-0	  	Filed
				
	Canada	  		  	2820078	  	Filed
				
	Switzerland	  	2651951	  	11808454.0	  	Granted
				
	Chile	  		  	01093-2013	  	Filed
				
	China P.R.	  	ZL201180060597.3	  	201180060597.3	  	Granted
				
	China P.R.	  		  	201610206179.5	  	Filed
				
	Colombia	  	5835	  	13-105848	  	Granted
				
	Costa Rica	  		  	2013-0247	  	Filed
				
	Cyprus	  	2651951	  	11808454.0	  	Granted
				
	Czech Republic	  	2651951	  	11808454.0	  	Granted
				
	Germany	  	602011011639.8	  	11808454.0	  	Granted
				
	Denmark	  	2651951	  	11808454.0	  	Granted
				
	Algeria	  	8698	  	130447	  	Granted
				
	Eurasian Patent Convention	  		  	201390879	  	Filed
				
	Ecuador	  		  	SP-2013-12692	  	Filed
				
	Estonia	  	2651951	  	11808454.0	  	Granted
				
	Egypt	  		  	PCT1034/2013	  	Filed
				
	European Patent Convention	  	2651951	  	11808454.0	  	Granted
				
	European Patent Convention	  	2813506	  	14177962.9	  	Granted

  

Confidential material omitted and filed separately with the Commission. 

							
	 Country
	  	 Patent Number
	  	 Application Number
	  	 Status

	European Patent Convention	  		  	16151410.4	  	Filed
				
	Spain	  	2651951	  	11808454.0	  	Granted
				
	Finland	  	2651951	  	11808454.0	  	Granted
				
	France	  	2651951	  	11808454.0	  	Granted
				
	Great Britain	  	2651951	  	11808454.0	  	Granted
				
	 Gulf Cooperation
 Council
	  		  	GC2011-20037	  	Filed
				
	Greece	  	3085435	  	11808454.0	  	Granted
				
	Hong Kong	  		  	13113223.7	  	Filed
				
	Croatia	  	P20150127	  	11808454.0	  	Granted
				
	Hungary	  	2651951	  	11808454.0	  	Granted
				
	Indonesia	  		  	W-00201302646	  	Filed
				
	Ireland	  	2651951	  	11808454.0	  	Granted
				
	Israel	  		  	225778	  	Filed
				
	India	  		  	4538/CHENP/2013	  	Filed
				
	Italy	  	2651951	  	502015902331728	  	Granted
				
	Japan	  	5775171	  	2013-544769	  	Granted
				
	Republic of Korea	  	10-1548439	  	2013-7018489	  	Granted
				
	Republic of Korea	  		  	2014-7020819	  	Filed
				
	Lithuania	  	2651951	  	11808454.0	  	Granted
				
	Luxembourg	  	2651951	  	11808454.0	  	Granted
				
	Latvia	  	2651951	  	11808454.0	  	Granted
				
	Morocco	  	35795	  	36026	  	Granted
				
	Monaco	  	2651951	  	11808454.0	  	Granted
				
	Malta	  	2651951	  	11808454.0	  	Granted
				
	Mexico	  	335308	  	MX/A/2013/006858	  	Granted
				
	Malaysia	  		  	PI2013701009	  	Filed
				
	Netherlands	  	2651951	  	11808454.0	  	Granted
				
	Norway	  	EP2651951	  	11808454.0	  	Granted
				
	New Zealand	  	609448	  	609448	  	Granted
				
	Peru	  		  	1418.2013	  	Filed

  

Confidential material omitted and filed separately with the Commission. 

							
	 Country
	  	 Patent Number
	  	 Application Number
	  	 Status

	Philippines	  	1-2013-501243	  	1-2013-501243	  	Granted
				
	Poland	  	2651951	  	11808454.0	  	Granted
				
	Portugal	  	2651951	  	11808454.0	  	Granted
				
	Romania	  	2651951	  	11808454.0	  	Granted
				
	Republic of Serbia	  	53768	  	P-2015/0034	  	Granted
				
	Sweden	  	2651951	  	11808454.0	  	Granted
				
	Singapore	  	190890	  	201304056-3	  	Granted
				
	Singapore	  		  	10201510347Q	  	Filed
				
	Slovenia	  	2651951	  	11808454.0	  	Granted
				
	Slovak Republic	  	2651951	  	11808454.0	  	Granted
				
	Thailand	  		  	1301003262	  	Filed
				
	Turkey	  	TR201501621T4	  	11808454.0	  	Granted
				
	Taiwan	  	I441824	  	100146570	  	Granted
				
	Taiwan	  		  	103111141	  	Inactive
				
	Ukraine	  	109688	  	A201308951	  	Granted
				
	United States	  		  	61/423694	  	Inactive
				
	United States	  	8883799	  	13/326524	  	Granted
				
	United States	  		  	14/524204	  	Filed
				
	United States	  		  	61/423,694	  	Inactive
				
	United States	  		  	62/268,149	  	Filed
				
	United States	  		  	62/288,832	  	Filed
				
	United States	  		  	62/291,248	  	Filed
				
	Venezuela	  		  	1773-11	  	Filed
				
	Vietnam	  		  	1-2013-02191	  	Filed
				
	 Patent Cooperation
 Treaty
	  		  	 PCT/US2011/065101
 (WO2012/082997)
	  	Inactive
				
	South Africa	  	2013/04128	  	2013/04128	  	Granted

  
 Confidential material omitted and filed
separately with the Commission. 

 EXHIBIT B 

STRUCTURE OF GDC-0084 
  

 
 5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[3,4-e]purin-2-yl)pyrimidin-2- amine 

 
 Confidential material omitted and filed separately with the Commission.

  

 EXHIBIT C 

TECHNOLOGY TRANSFER PLAN 
 Genentech shall
provide the following materials and information to Novogen within three (3) months following the Effective Date: 
 Clinical Sciences: 

XXXXX 
 Regulatory 

XXXXX 
 Research 

XXXXX 
 IP/Legal 

XXXXX 
 CMC 

XXXXX 
 45 kg of API 

XXXXX 
 API to be shipped within ten (10) days of
receipt of upfront payment by Genentech. 
  
 Confidential
material omitted and filed separately with the Commission. 

 Drug Product 

XXXXX 
 XXXXX 

 
 Confidential material omitted and filed separately with the Commission.

 EXHIBIT D 

Novogen Clinical Study Design 

Preliminary, and Subject to Consultation with Regulatory Agencies and Key Opinion Leaders 

 

			
	

	  	 CLINICAL TRIAL
PROTOCOL CONCEPT
  
 Proposed Phase II Study of
GDC-0084 in Glioblastoma Multiforme

  

	I.	STUDY OBJECTIVE 

 This study is intended to demonstrate safety and efficacy of
GDC-0084 in the treatment of glioblastoma multiforme (GBM) in the adjuvant setting, following surgical resection and radiotherapy. 

The study is designed to maximise the potential for accelerated approval of the product following completion. 

 

	II.	STUDY POPULATION 

 All subjects will have a histologically-confirmed diagnosis of GBM (WHO Grade IV), and an
unmethylated MGMT status, as confirmed by PCR or alternative genomic analysis. Prior to study entry, subjects will have had optimal surgical resection and subsequent treatment with radiotherapy and temozolomide, in accordance with the ‘Stupp
regimen’. Subjects who have had disease progression or recurrence subsequent to radiotherapy treatment will not be eligible. 
 Other
eligibility criteria will be as commonly deployed for oncology studies. Both male and female subjects will be recruited. 
  

	III.	STUDY DESIGN 

 The study is a multicentre, two-arm, randomised,
double-blind clinical trial, using temozolomide as an active comparator. 
 Following completion of radiotherapy treatment according to the
‘Stupp regimen’, subjects will be assigned to one of two treatment groups, in a 1:1 ratio. The first group will receive temozolomide, in accordance with the labelled dose and schedule. The second group will receive GDC-0084 at a dose of 45mg, once daily. 
  

	IV.	ENDPOINTS 

 Primary Endpoint Progression-Free Survival (PFS) 

Secondary Endpoints Overall Survival (OS) 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 D-1 

 Safety and Tolerability Pharmacokinetics 

Exploratory Endpoints 
 Biomarkers (as predictors
of response) 
 Exploratory Imaging 
 Neurological
and Behavioural Instruments (MDASI-BT, neuro-cognitive tests, etc.) 
 Quality of Life (HRQoL) 

 

	V.	STATISTICAL CONSIDERATIONS 

 Sample Size 

It is expected that approximately 160 subjects will be recruited to the study (80 subjects in each of two arms). Subjects may be stratified according to the
Karnofsky Performance Status (KPS) and age. 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 D-2 

 EXHIBIT F 

PROPOSED PUBLICATIONS 
 1: Clinical
Pharmacokinetics and Brain Penetration of GDC-0084, an Oral PI3K/mTOR Inhibitor, in Patients with High-Grade Glioma 

Status: Draft in preparation - submission by end of 2016 (Lead author Kari Morrissey) 

Poster presented at ASCPT meeting in March 2016, with the addition of the clinical imaging data from one subject. 

2. First-in-human Phase I study to evaluate the brain-penetrant PI3K/mTOR
inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma 
 Timothy Cloughesy,1 Patrick Y. Wen,2 Alan Olivero,1 Xuyang Lu,3 Lars Mueller,3 Alexandre Fernandez Coimbra,3 Elizabeth Gerstner,2 Jordi Rodon5 

Status: Draft in preparation 
 Poster presented at
ASCO 
  
  

	1 	CMC Article and a book chapter on the API synthesis - (Lead author Andy Stumf) 

 Status: Draft in
preparation 

  
 Confidential material
omitted and filed separately with the Commission. 

  
 D-3EX-4.13

 Exhibit 4.13 

xxxx INDICATES CONFIDENTIAL MATERIAL OMITTED PURSUANT TO A 

REQUEST FOR CONFIDENTIAL TREATMENT AND FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION SEPARATELY WITH A REQUEST 

FOR CONFIDENTIAL TREATMENT. 
  

					
		 		  	Department of Industry, Innovation and Science
		 	
		 		  	CRC Project Funding Agreement CRC-P53981
		 	
		 		  	Targeting Tropomyosin as a Novel Anti-Cancer Therapy
		 		  	 
		 	
		 		  	 Commonwealth of Australia (Commonwealth)
  

Novogen Ltd (Recipient)

 Version 2.1 (CRC-P SR2, Dec 2016) 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 1	 

 Details 

 
  

			
	Date	  	
    21    /    March    /  
  2017    

    day            month         
   year

 Parties 
  

			
	Name	  	The Commonwealth of Australia as represented by the Department of Industry, Innovation and Science
	Short form name	  	Commonwealth
		  	ABN 74 599 608 295
		
	Name	  	Novogen Ltd
	Short form name	  	Recipient
		  	ABN 37 063 259 754

 Background 
  

	A	This Agreement is made pursuant to the projects stream of the Programme. The objective of the projects stream is to support industry-identified and industry-led collaborative
research to develop products, services or processes that will solve industry problems and deliver tangible outcomes. 

  

	B	The Commonwealth provides the Funds to the Recipient under this Agreement to support the Project, Targeting Tropomyosin as a Novel Anti-Cancer Therapy, to be undertaken by the Participants. The Participants have,
or will have within the time period stipulated in this Agreement, entered into a Participants Agreement to undertake the Project. 

  

	C	The Participants will, wherever appropriate, engage on an ongoing basis with one or more relevant Industry Growth Centres in order to share knowledge, experience and resources and achieve common goals.

  

	D	The Commonwealth is required by law to ensure accountability for the Funds and accordingly the Recipient is required to be accountable for all Funds received. 

 

	E	The Commonwealth has agreed to provide the Funds to the Recipient for the purposes of the Project, subject to the terms and conditions of this Agreement. 

 

	F	The Recipient accepts the Funds for the purposes of the Project, and subject to the terms and conditions of this Agreement. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 2	 

 Funding Agreement 
  

 
  

							
	 Details
	 		  	 	2	
		
	 Agreed terms
	  	 	5	
		
	 Part 1 – Project and Funds
	  	 	5	
			
	 1.
	 	Definitions and interpretation	  	 	5	
			
	 2.
	 	Priority of documents	  	 	10	
			
	 3.
	 	Duration of Agreement	  	 	10	
			
	 4.
	 	Project	  	 	10	
			
	 5.
	 	Participant obligations	  	 	11	
			
	 6.
	 	Participant Contributions	  	 	14	
			
	 7.
	 	Funds	  	 	15	
			
	 8.
	 	GST and R&D Tax Incentive	  	 	15	
			
	 9.
	 	Use of Funds	  	 	16	
			
	 10.
	 	Repayment	  	 	17	
			
	 11.
	 	Monitoring progress	  	 	18	
			
	 12.
	 	Performance	  	 	18	
		
	 Part 2 – General requirements
	  	 	21	
			
	 13.
	 	Subcontractors and Personnel	  	 	21	
			
	 14.
	 	Assets	  	 	22	
			
	 15.
	 	Intellectual Property Rights	  	 	22	
			
	 16.
	 	Moral Rights	  	 	24	
			
	 17.
	 	Indemnity	  	 	25	
			
	 18.
	 	Insurance	  	 	25	
			
	 19.
	 	Publicity	  	 	26	
			
	 20.
	 	Confidentiality	  	 	26	
			
	 21.
	 	Work health and safety	  	 	28	
			
	 22.
	 	Protection of personal information	  	 	28	
			
	 23.
	 	Conflict of interest	  	 	30	
			
	 24.
	 	Books and records	  	 	30	
			
	 25.
	 	Audit and access	  	 	31	
			
	 26.
	 	Dispute resolution	  	 	32	
			
	 27.
	 	Reduction, suspension and termination	  	 	33	

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 3	 

							
	28.	 	Survival	  	 	37	
			
	29.	 	Notices and other communications	  	 	37	
			
	30.	 	Miscellaneous	  	 	38	
		
	Schedule 1 – Agreement Details	  	 	41	
		
	Schedule 2 – Project	  	 	45	
		
	Schedule 3 – Reporting	  	 	49	
		
	Schedule 4 – Funds, contributions and budget	  	 	50	
		
	Signing page	  	 	53	

  
  

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 4	 

 Agreed terms 

 
 Part 1 – Project and Funds 

 

	1.	Definitions and interpretation 

  

	1.1	Defined terms 

 In this Agreement, except where the contrary intention is expressed, the
following definitions are used: 
  

					
		 	Accounting Standards	  	the standards of that name maintained by the Australian Accounting Standards Board (created by section 226 of the Australian Securities and Investments Commission Act 2001 (Cth)) or other accounting standards which are
generally accepted and consistently applied in Australia.
			
		 	Advisers	  	 (a)    the financial or legal advisers of a party; and

 
 (b)    the respective
officers and employees of those financial or legal advisers.

			
		 	Agreed Terms	  	clauses 1 to 30 of this Agreement, which set out terms and conditions agreed by the parties.
			
		 	Agreement	  	this funding agreement between the Commonwealth and the Recipient, as varied from time to time in accordance with clause 30.4, and includes its schedules and any attachments.
			
		 	Agreement Material	  	any Material created on or following the Commencement Date, for the purpose of or as a result of the Recipient performing its obligations under this Agreement.
			
		 	Agreement Period	  	the period from the Commencement Date to the End Date.
			
		 	Asset	  	any item of tangible property purchased, leased, created or otherwise brought into existence either wholly or in part with use of the Funds, but does not include Agreement Material.
			
		 	Budget	  	the budget set out in Schedule 4, as varied from time to time in accordance with this Agreement.
			
		 	Business Day	  	a day that is not a Saturday, Sunday, public holiday or bank holiday in the place where the act is to be performed or where the Notice is received.

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 5	 

					
		 	Change in Control	  	 in relation to an entity, a change in the direct or indirect power or capacity of a person to:

 
 a)      determine
the outcome of decisions about the financial and operating policies of the  entity; or
  

b)      control the membership of the board of directors of the entity,

 
 whether or not the power has statutory, legal or equitable force or is based on
statutory, legal or equitable rights and whether or not it arises by means of trusts, agreements, arrangements, understandings, practices, the ownership of any interest in shares or stock of the entity or otherwise, not including a change in control
resulting from ordinary course trading on a stock exchange in the shares of the entity.

			
		 	Commencement Date	  	the date on which this Agreement commences, as specified in item 7 of Schedule 1.
			
		 	Commonwealth	  	the Commonwealth as specified in item 1 of Schedule 1.
			
		 	Commonwealth Material	  	any Material provided to the Recipient by the Commonwealth, including the Material (if any) specified in item 14 of Schedule 1.
			
		 	Commonwealth Representative	  	the person identified in item 3 of Schedule 1.
			
		 	Confidential Information	  	 information that is by its nature confidential and:
  

(a)    is designated by a party as confidential and is described in item 19 of Schedule 1;
or
  
 (b)    a party knows
or ought to know is confidential,
  
 but does not include:

 
 (c)    information that is or
becomes public knowledge otherwise than by breach of this Agreement or any other confidentiality obligation.

			
		 	Corporations Act	  	the Corporations Act 2001 (Cth).
			
		 	CRC Advisory Committee	  	the Cooperative Research Centres Advisory Committee is a committee of Innovation Australia established under the Industry Research and Development Act 1986.
			
		 	CRC Indicia	  	the terms “CRC”, “CRC Projects”, “CRC-P”, “Cooperative Research Centre” and the Programme logo and any additional items specified by the Commonwealth
from time to time.
			
		 	CRC Project (CRC-P)	  	the collaboration between the Participants to undertake the Project as determined by the arrangements set out in the Participants Agreement.
			
		 	Department	  	the Department of Industry, Innovation and Science and its successors that administer the Programme.
			
		 	End Date	  	the date on which this Agreement will end (unless terminated earlier), as specified in item 8 of Schedule 1.

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 6	 

					
		 	Financial Year	  	the Australian financial year beginning 1 July and ending 30 June.
			
		 	Funds	  	the amounts payable by the Commonwealth under this Agreement as specified in Schedule 4 and any interest earned on those amounts.
			
		 	Guidelines	  	the Programme Guidelines listed under item 9 of Schedule 1, and any other guidelines issued by the Commonwealth from time to time in relation to the Programme and its administration.
			
		 	Industry Entity	  	an entity where the majority of its revenue is not derived from any government, capable of deploying research outputs in a commercial context, excluding a Research Organisation, and excluding entities where the primary function is
administrative or to provide support services to a CRC-P.
			
		 	Industry Growth Centres	  	not-for-profit companies limited by guarantee responsible for delivering the ‘Industry Growth Centres Initiative’.
			
		 	Intellectual Property Rights	  	 all intellectual property rights, including:
  

(a)    copyright, patents, trademarks (including goodwill in those marks), designs, trade secrets,
know how, rights in circuit layouts, domain names and any right to have confidential information kept confidential;
  

(b)    any application or right to apply for registration of any of the rights referred to in
paragraph (a); and
  

(c)    all rights of a similar nature to any of the rights in paragraphs (a) and (b) which
may subsist in Australia or elsewhere,
  
 whether or not such rights are registered or
capable of being registered.

			
		 	Law	  	any applicable statute, regulation, by-law, ordinance or subordinate legislation in force from time to time in Australia, whether made by a State, Territory, the Commonwealth, or a local
government, and includes the common law and rules of equity as applicable from time to time.
			
		 	Material	  	includes property, information, software, firmware, documented methodology or process, documentation or other material in whatever form, including any reports, specifications, business rules or requirements, user manuals, user
guides, operations manuals, training materials and instructions, and the subject matter of any category of Intellectual Property Rights.
			
		 	Milestone	  	a stage of completion of the Project as set out in Schedule 2.
			
		 	Moral Rights	  	the right of integrity of authorship (that is, not to have a work subjected to derogatory treatment), the right of attribution of authorship of a work, and the right not to have authorship of a work falsely attributed, as defined in
the Copyright Act 1968 (Cth).
			
		 	Notice	  	a notice, demand, consent, approval or communication issued under this Agreement.

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 7	 

					
		 	Outcomes	  	the outcomes of the Project, as set out in Schedule 2.
			
		 	Outputs	  	the end products of a Project, which may include products, publications, patents, prototypes and student completions.
			
		 	Participants	  	the Recipient and Project Partners collectively, being those persons, or bodies who have agreed to support the Project and provide Participant Contributions to the Project, and are signatories to the Participants
Agreement.
			
		 	Participants Agreement	  	the agreement(s) entered into by the Participants for the purposes of carrying out the Project.
			
		 	Participant Contributions	  	the cash, personnel, facilities and services to be provided by Participants to the CRC-P, from their own resources, for the purposes of undertaking the Project as specified in
Schedule 4.
			
		 	Personnel	  	in relation to a party, any employee, officer, agent, or professional adviser of that party, and in the case of the Recipient, of any subcontractor.
			
		 	Pre-existing Material	  	Material owned by a party before execution of this Agreement, including any Material specified in item 15 of Schedule 1.
			
		 	Privacy Act	  	Privacy Act 1988 (Cth) as amended from time to time.
			
		 	Programme	  	the programme referred to in item 6 of Schedule 1.
			
		 	Project	  	the project set out in Schedule 2.
			
		 	Project Partners	  	all the Participants, other than the Recipient.
			
		 	Quarter	  	a period of 3 months or, where the context necessitates part or multiples of that period, ending on 31 March, 30 June, 30 September or 31 December.
			
		 	R&D Tax Incentive	  	is established by Division 355 of the Income Tax Assessment Act 1997 with functions relating to its administration included in the Industry Research and Development Act 1986 (Cth).
			
		 	Recipient	  	the party specified in item 2 of Schedule 1. Also known as the Lead Participant.
			
		 	Recipient Representative	  	the person identified in item 4 of Schedule 1.
			
		 	Reports	  	the reports to be provided under clause 11.2.
			
		 	Research Organisation	  	all higher education providers listed at Table A and Table B of the Higher Education Support Act 2003, as amended from time to time, as well as Federal, State and Territory government departments or agencies which undertake
publicly funded research. This includes, but is not limited to the Commonwealth Scientific and Industrial Research Organisation, Defence Science and Technology Organisation, Australian Institute of Marine Science and Australian Nuclear Science and
Technology Organisation.
			
		 	Resolution Institute	  	the dispute resolution association with that name and the Australian Business Number 69 008 651 232.

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 8	 

					
		 	Schedules	  	the schedules to this Agreement.
			
		 	Shortfall	  	any deficit in the total contributions received by the Recipient during a Financial Year and the contributions which should have been received by the Recipient during that Financial Year as specified in Schedule 4.
			
		 	SME	  	a small to medium sized business with fewer than 200 employees.
			
		 	Specified Personnel	  	the Personnel (if any) specified in item 13 of Schedule 1.
			
		 	Third Party Material	  	 Material owned by a third party that is:
  

(a)    included, embodied in or attached to the Agreement Material; or

 
 (b)    used in undertaking
the Project.

			
		 	Utilisation	  	technology transfer and take-up and use of research Outputs. Commercial utilisation includes the manufacture, sale, hire or other exploitation of a product or process, or the provision of a
service, incorporating Agreement Material, or licensing of any third party to do any of those things, or otherwise licensing or assigning Agreement Material.
			
		 	WHS Act	  	the Work Health and Safety Act 2011 (Cth) and any corresponding WHS law as defined in that Act.
			
		 	WHS Laws	  	the WHS Act, regulations made under the WHS Act and any Code of Practice approved for the purpose of the WHS Act.

  

	1.2	Interpretation 

 In this Agreement, except where the contrary intention is expressed:

  

	 	(a)	the singular includes the plural and vice versa, and a gender includes other genders; 

  

	 	(b)	another grammatical form of a defined word or expression has a corresponding meaning; 

  

	 	(c)	a reference to a clause, paragraph or schedule is to a clause or paragraph of, or schedule to, this Agreement; 

  

	 	(d)	a reference to a document or instrument includes the document or instrument as novated, altered, supplemented or replaced from time to time; 

 

	 	(e)	a reference to A$, $A, dollar or $ is to Australian currency; 

  

	 	(f)	a reference to time is to Canberra, Australia time; 

  

	 	(g)	a reference to a party is to a party to this Agreement, and a reference to a party to a document includes the party’s executors, administrators, successors and permitted assignees and substitutes;

  

	 	(h)	a reference to a person includes a natural person, partnership, body corporate, association, governmental or local authority or agency or other entity; 

 

	 	(i)	a reference to a statute, ordinance, code or other law includes regulations and other instruments under it and consolidations, amendments, re-enactments or replacements of any of
them; 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 9	 

	 	(j)	the meaning of general words is not limited by specific examples introduced by including, for example or similar expressions; 

  

	 	(k)	any agreement, representation, warranty or indemnity by two or more parties (including where two or more persons are included in the same defined term) binds them jointly and severally; 

 

	 	(l)	any agreement, representation, warranty or indemnity in favour of two or more parties (including where two or more persons are included in the same defined term) is for the benefit of them jointly and severally;

  

	 	(m)	a rule of construction does not apply to the disadvantage of a party because the party was responsible for the preparation of this Agreement or any part of it; 

 

	 	(n)	if a day on or by which an obligation must be performed or an event must occur is not a Business Day, the obligation must be performed or the event must occur on or by the next Business Day; 

 

	 	(o)	headings are for ease of reference only and do not affect interpretation. 

  

	1.3	Completion of Schedules 

 To the extent that the parties have not completed items in a
Schedule, unless otherwise stated in the Schedule, those items will be taken to be ‘not applicable’ for the purpose of this Agreement. 
  

	2.	Priority of documents 

 If there is inconsistency between any of the documents forming part of
this Agreement, those documents will be interpreted in the following order of priority to the extent of any inconsistency: 
  

	 	(a)	Agreed Terms; 

  

	 	(b)	Schedules; 

  

	 	(c)	any attachments to the Schedules; 

  

	 	(d)	Guidelines; and 

  

	 	(e)	documents incorporated by reference in this Agreement. 

  

	3.	Duration of Agreement 

 This Agreement begins on the Commencement Date and continues until the
End Date or the date on which the Recipient has completed all reporting obligations to the Commonwealth, whichever is the later, unless terminated earlier in accordance with clause 27. 

 

	4.	Project 

  

	4.1	Undertaking the Project 

 The Recipient, in collaboration with the Project Partners,
must: 
  

	 	(a)	undertake the Project to achieve the Outcomes; 

  

	 	(i)	undertake the Project diligently, effectively, to a high professional standard and in accordance with: 

  

	 	(ii)	all applicable Laws; 

  

	 	(iii)	any guidelines specified in item 9 of Schedule 1; and 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 10	 

	 	(iv)	any Commonwealth policies and specific requirements set out in item 10 of Schedule 1; 

  

	 	(b)	complete the Project within the Agreement Period; and 

  

	 	(c)	meet the due dates for the Milestones, as specified in Schedule 2. 

  

	4.2	Acknowledgement of support 

 The Recipient must, and must ensure that all Project
Partners, in all: 
  

	 	(a)	publications (including reprints, and despite whether published by the Recipient or other persons) that are a result of the Project; 

 

	 	(b)	products, processes or inventions produced as a direct result of the Project activities; and 

  

	 	(c)	promotional and advertising materials, public announcements, events and activities in relation to the Project; 

acknowledge the financial and other support received from the Commonwealth: 

 

	 	(d)	through reference to the Programme; 

  

	 	(e)	in relation to 4.2 (c), through prominent display of the CRC Indicia; and 

  

	 	(f)	by reference to any acknowledgement specified in item 11 of Schedule 1 or as otherwise approved by the Commonwealth prior to its use. 

 

	4.3	Warranties 

 The Recipient represents and warrants that: 

 

	 	(a)	it has the right to enter into this Agreement; 

  

	 	(b)	it and its subcontractors and Personnel, including its Specified Personnel, have the necessary experience, skill, knowledge, expertise and competence to undertake the Project and (where appropriate) will hold such
licences, permits or registrations as are required under any State, Territory or Commonwealth legislation to undertake the Project, and are fit and proper people; 

 

	 	(i)	if the Recipient is a trustee, it enters this Agreement personally and in its capacity as trustee and has the power to perform its obligations under this Agreement. 

 

	 	(c)	if relevant and applicable, it is compliant with the Workplace Gender Equality Act 2012 (Cth) (WGE Act) and that: 

  

	 	(i)	if it becomes non-compliant with the WGE Act during the Agreement Period, the Recipient must notify the Commonwealth as soon as practicable; 

 

	 	(ii)	if the Agreement Period exceeds 18 months, the Recipient must provide a current letter of compliance under the WGE Act within 18 months from the Commencement Date and following this, annually to the Commonwealth; and

  

	 	(iii)	compliance with the WGE Act does not relieve the Recipient from its responsibility to comply with its other obligations under this Agreement. 

 

	5.	Participant obligations 

  

	5.1	Participants Agreement 

 All Participants must enter into a Participants Agreement to
undertake the Project. For the entire term of this Agreement, the Participants Agreement will require the Participants to: 
  

	 	(a)	undertake the Project at the times and in the manner specified in the Schedules to this Agreement; 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 11	 

	 	(b)	make the Participant Contributions to the Recipient which are specified in Schedule 4 of this Agreement; 

  

	 	(c)	cooperate with and provide to the Recipient any information about the Participant Contributions and other activities reasonably required by the Recipient; 

 

	 	(d)	be bound to equivalent terms and conditions to those of this Agreement, except where due to the context it is not relevant to do so; and 

 

	 	(e)	where terms of this Agreement are expressed to survive termination or expiry of this Agreement, the equivalent terms used in the Participants Agreement will also be expressed to survive termination or expiry of the
Participants Agreement. 

  

	5.2	In the event the Recipient is unable to meet obligations 

 The Recipient must notify the
Commonwealth immediately upon becoming aware of any circumstances that are likely to adversely affect the Recipient’s ability to comply with the terms of this Agreement, in particular its solvency or ability to ensure that the Project is
carried out in accordance with this Agreement. The giving of Notice by the Recipient pursuant to this clause 5.2, will not, in any way, limit the obligations of the Recipient under this Agreement or excuse the Recipient in any way from the
performance of those obligations. 
  

	5.3	Participants Agreement to be consistent with obligations under this Agreement 

 The
Recipient must: 
  

	 	(a)	ensure the Participants Agreement and any other contractual arrangements allow the Recipient to meet its obligations under this Agreement, and ensure the Participants Agreement requires the Project Partners to comply
with obligations consistent with those contained in: 

  

	 	(i)	Clause 5.4 (Breach of the Participants Agreement); 

  

	 	(ii)	Clause 15.3 (Intellectual Property Rights in Agreement Material); 

  

	 	(iii)	Clause 18 (Insurance); 

  

	 	(iv)	Clause 20 (Confidentiality); 

  

	 	(v)	Clause 21 (Work health and safety); 

  

	 	(vi)	Clause 22 (Protection of personal information); 

  

	 	(vii)	Clause 23 (Conflict of interest); 

  

	 	(viii)	Clause 24 (Books and records); 

  

	 	(ix)	Clause 25 (Audit and access); 

  

	 	(x)	Clause 28 (Survival); 

  

	 	(xi)	Clause 30.14 (Relationship); 

  

	 	(xii)	Clause 30.16 (False or misleading information); 

  

	 	(xiii)	Clause 30.17 (Safe and ethical research); and 

  

	 	(xiv)	Clause 30.18 (Responsible conduct of research). 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 12	 

	 	(b)	make reasonable endeavours to enforce any rights the Commonwealth may have in the Participants Agreement, including but not limited to those rights arising as a result of clause 5.3(a), where directed to do so by the
Commonwealth; 

  

	 	(c)	ensure no variation or alteration is made to any arrangement described in clause 5.3(a) that is, or may be, inconsistent with this Agreement without the prior written consent of the Commonwealth; and 

 

	 	(d)	provide the Commonwealth with a copy of any proposed alteration or variation described under clause 5.3(c) within 10 Business Days of completion of the change. 

 

	5.4	Breach of the Participants Agreement 

 The Recipient must, within 5 Business Days of
becoming aware of a breach or suspected breach of the Participants Agreement that would affect the Recipient’s ability to comply with its obligations under this Agreement: 

 

	 	(a)	provide Notice to the Commonwealth of that breach or suspected breach; 

  

	 	(b)	provide all information reasonably required by the Commonwealth in relation to the breach or suspected breach; 

  

	 	(c)	identify to the Commonwealth the steps the Recipient intends to take to remedy the matter; 

  

	 	(d)	keep the Commonwealth informed of any action it takes to remedy the breach; and 

  

	 	(e)	provide Notice to the Commonwealth once the breach is remedied. 

  

	5.5	Project Partners 

 The Recipient must ensure that all Project Partners are listed in item
5 of Schedule 1 and must ensure that at all times it has among the Participants, and approved by the Commonwealth, at least: 
  

	 	(a)	Two Australian Industry Entities (including at least one SME); and 

  

	 	(b)	One Australian Research Organisation. 

  

	5.6	Change of Project Partners 

 Subject to clauses 5.5 and 5.7 and any further obligations
under this Agreement, the Recipient may substitute or change Project Partners during the Agreement Period, with the Commonwealth’s prior written approval. 
  

	5.7	Notification of change of Project Partners 

 Payment of Commonwealth Funds is dependent
on the ongoing support of the Project by Project Partners. The Recipient must notify the Commonwealth 30 days prior to any proposed substitution or change of a Project Partner. This Notice must include: 

 

	 	(a)	the details of the exiting Project Partner and their reason for leaving, and details of any incoming Project Partner and a breakdown comparison of their contributions to enable side by side comparison of component
parts; 

  

	 	(b)	the amount of any Shortfall for that Financial Year, or any future Financial Years that is anticipated to arise from the substitution or change in Project Partner, and any steps the Recipient proposes to take to resolve
or otherwise deal with the Shortfall; 

  

	 	(c)	an assessment as to the degree to which the viability or capacity to undertake the Project and achieve the Milestones is likely to be affected. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 13	 

 If after receiving a Notice under this clause 5.7, the Commonwealth is reasonably satisfied that
the proposed substitution or change of a Project Partner is likely to impact on the Recipient’s capacity to undertake the Project or achieve the Milestones, the Commonwealth, at its sole discretion and on 10 Business Days’ Notice to
the Recipient, may without limiting any of its other rights under this Agreement, reduce or suspend payment of the Funds until the Commonwealth is satisfied that a suitable substitute or replacement Project Partner is proposed. 

 

	5.8	Other government funding 

  

	 	(a)	The Recipient must give the Commonwealth full details of any financial assistance for activities in connection with the Project which a Participant receives from another Commonwealth, State or Territory government
source or agency after the Commencement Date of this Agreement, (Other Financial Assistance) including the amount and source of the funding and the name of the programme under which it was provided, within 30 days of the Participant receiving
notice that the Other Financial Assistance has been approved. 

  

	 	(b)	The Commonwealth may reduce, suspend or defer its payments as set out in Schedule 4 in the event a Participant receives Other Financial Assistance, but only to the extent that this financial assistance duplicates
Commonwealth Funds. 

  

	6.	Participant Contributions 

  

	6.1	Participant Contributions 

 The Participants must provide the Participant Contributions
to the Project as specified in Schedule 4. 
  

	6.2	Shortfall in Participant Contributions 

 The Recipient must notify the Commonwealth, as
part of each Report provided to the Commonwealth under clause 11.2, of any Shortfall in the Participant Contributions, as specified in Schedule 4, for the corresponding period. The notification of any Shortfall in a Report must include the
following: 
  

	 	(a)	the amount and value of the Shortfall; 

  

	 	(b)	the reasons for the Shortfall; 

  

	 	(c)	any remedial action proposed or undertaken; and 

  

	 	(d)	any impact the Shortfall is expected to have on the current or future capacity of the Recipient to undertake the Project and/or meet its obligations under this Agreement. 

 

	 	(e)	The Commonwealth will not require notification under this clause 6.2 or issue a Notice under clause 6.3, unless the Shortfall is equal to, or exceeds 10% of the: 

 

	 	(i)	cash contributions specified in Schedule 4; or 

  

	 	(ii)	value of the non-staff in-kind contributions specified in Schedule 4; or 

 

	 	(iii)	staff in-kind (FTE) contributions, specified in Schedule 4; 

for that reporting period. 
  

	6.3	Recipient to make good any Shortfall in Participant Contributions 

  

	 	(a)	Where the Recipient is required to provide notification of a Shortfall under clause 6.2 the Commonwealth may, by Notice, require the Recipient to make good the Shortfall and/or take other remedial action and to report
on any matters specified in the Notice within the period specified in the Notice (or if not specified within 10 Business Days). The Recipient must comply with any such Notice issued by the Commonwealth within the time period specified.

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 14	 

	 	(b)	If the Recipient is unable to obtain Participant Contributions to make good the Shortfall and/or does not take other remedial action as specified in the Notice to the Commonwealth’s satisfaction within the period
specified in the Notice, or does not report on any matters specified in the Notice, the Commonwealth may in its absolute discretion, and without limiting any of its other rights under this Agreement or at law, reduce the total amount of Funds by all
or a part of the value of the Shortfall. 

  

	 	(c)	Nothing in clause 6.3 affects the Commonwealth’s rights under clause 27 [Reduction, Suspension and Termination]. 

  

	6.4	Calculation of Shortfall 

 When calculating the total amount of a Shortfall under
clause 6, the value of any staff in-kind contributions which were not provided by a Participant, and which therefore contributed to the Shortfall, will be calculated based on the FTE value specified in
Schedule 4. 
  

	7.	Funds 

  

	7.1	Payment 

 Subject to: 

 

	 	(a)	clauses 8.4, 27.1 and 27.2; 

  

	 	(b)	sufficient funding being available for the Programme; and 

  

	 	(c)	the Recipient complying with this Agreement, 

 the Commonwealth will pay the Funds to the
Recipient as set out in Schedule 4. 
  

	7.2	Due date for payment 

 The Commonwealth must make quarterly payments within 30 days of
the Commonwealth’s acceptance and approval of satisfactory, relevant Reports, as per Schedule 4. 
  

	7.3	Taxes 

 The Recipient must pay all: 

 

	 	(a)	stamp duty (including penalties and interest) assessed or payable in respect of this Agreement and the Project; and 

  

	 	(b)	subject to clause 8, all taxes, duties and government charges imposed or levied in Australia or overseas in connection with the performance of this Agreement. 

 

	8.	GST and R&D Tax Incentive 

  

	8.1	Construction 

 In this clause 8 words and expressions which are not defined in this
Agreement but which have a defined meaning in the GST Law have the same meaning as in the GST Law. 
  

	8.2	Consideration GST exclusive 

 Unless otherwise expressly stated, all prices or other sums
payable or consideration to be provided under this Agreement are exclusive of GST. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 15	 

	8.3	Payment of GST 

 If GST is payable by a supplier on any supply made under this Agreement,
the recipient of the supply will pay to the supplier an amount equal to the GST payable on the supply, in addition to and at the same time that the consideration for the supply is to be provided under this Agreement. 

 

	8.4	Recipient Created Tax Invoice 

  

	 	(a)	The Recipient agrees to allow the Commonwealth to issue it with a Recipient Created Tax Invoice (RCTI) for any taxable supplies it makes in relation to the Project. 

 

	 	(b)	The Recipient agrees not to issue tax invoices in respect of any taxable supplies. 

  

	 	(c)	The parties acknowledge that they are registered for GST and will notify the other party if they cease to be registered for GST. 

  

	8.5	R&D Tax Incentive 

 To assist certain Participants claim the R&D Tax Incentive,
the Recipient must expend (or allocate) contributions from Participants on (or to) R&D activities, as defined under subdivision 355B section 355-20 of the Income Tax Assessment Act 1997 and maintain
records of the date when such expenditure on which R&D activities occurred. 
  

	9.	Use of Funds 

  

	9.1	What Funds can be used for 

  

	 	(a)	The Recipient must spend the Funds only for the purposes of undertaking the Project. 

  

	 	(b)	The Recipient must spend the Funds and the Participant Contributions only in accordance with the Budget. 

  

	 	(c)	Subject to clause 9.1(d), the Recipient may vary the Budget by re-allocating expenditure between heads of expenditure specified in the Budget. 

 

	 	(d)	Any variation under clause 9.1(c) which increases or decreases the amount allocated to a head of expenditure by more than 10% cannot be made without the Commonwealth’s prior written approval. 

 

	9.2	What Funds cannot be used for 

 The Recipient must not spend the Funds: 

 

	 	(a)	for capital works or for the purchase or construction of facilities such as buildings or laboratories; 

  

	 	(b)	for renovation or extension of buildings and facilities unless approved by the Commonwealth in writing; 

  

	 	(c)	for any activities for which the Participants have previously been funded, or are currently being funded by the Australian Government or a State or Territory government either directly or indirectly through any other
funding scheme; 

  

	 	(d)	to reimburse a Participant for the costs associated with existing staff or other resources committed by the Participant to the Project as in-kind contributions under this
Agreement; 

  

	 	(e)	to pay a Participant for the indirect support costs of research in relation to cash-funded Project staff located in their organisation; or 

 

	 	(f)	for the indirect support costs of research conducted overseas. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 16	 

	9.3	When Funds cannot be used 

  

	 	(a)	Without limiting any other right or remedy of the Commonwealth, the Commonwealth may by Notice direct the Recipient not to spend Funds if: 

 

	 	(i)	the Recipient has not completed a Report that was due before the date of notification; 

  

	 	(ii)	the Recipient has not achieved a Milestone that was due to be achieved before the date of notification; or 

  

	 	(iii)	the Recipient is otherwise in breach of this Agreement. 

  

	 	(b)	The Recipient must not spend any Funds after it receives Notice from the Commonwealth under clause 9.3(a) unless and until the Commonwealth notifies the Recipient otherwise. 

 

	9.4	Bank account 

 The Recipient must ensure that: 

 

	 	(a)	proper accounting standards and controls are exercised in respect of the Funds and the Participant Contributions; 

  

	 	(b)	all Funds are held in an account (the Account) with an authorised deposit-taking institution authorised under the Banking Act 1959 (Cth) to carry on banking business in Australia; 

 

	 	(c)	the Account is held in the name of the Recipient, which the Recipient solely controls and which is separate from the Recipient’s other operational accounts, for the purpose of accounting for, and administering any
Funds paid to the Recipient; 

  

	 	(d)	identify the receipt and expenditure of the Funds separately within the Recipient’s accounting records so that at all times the Funds are identifiable and ascertainable; 

 

	 	(e)	the Account bears a rate of interest reasonably required by the Commonwealth and that any interest on the balance is credited to the Account; 

 

	 	(f)	the Commonwealth is notified, prior to the receipt of any Funds, of details sufficient to identify the account, and on notification from the Commonwealth, provide the Commonwealth and the authorised deposit-taking
institution with an authority for the Commonwealth to obtain any details relating to the use of the account; 

  

	 	(g)	any money forming part of the Funds or Participant Contributions is deposited in the Account; and 

  

	 	(h)	if the Account changes, that it complies with 9.4(c) and (d) above and notify the Commonwealth within 7 days of any changes to the Account, providing details of the new account. 

 

	9.5	No additional Funds 

 The Commonwealth is not responsible for the provision of additional
money to meet any expenditure in excess of the Funds. 
  

	10.	Repayment 

  

	10.1	During the Agreement Period 

 The Commonwealth is entitled to recover from the Recipient
any amount of money which, at any time, in the Commonwealth’s opinion, has been spent other than in accordance with this Agreement. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 17	 

	10.2	At the end of the Agreement Period 

 After the End Date, the Commonwealth is entitled to
recover from the Recipient: 
  

	 	(a)	any Funds which have not been spent, or legally committed for expenditure by the Recipient in accordance with this Agreement and payable by the Recipient as a current liability (written evidence of which will be
required); and 

  

	 	(b)	the amount of any Funds which, in the Commonwealth’s opinion, have been spent other than in accordance with this Agreement. 

  

	10.3	Repayment Notice 

  

	 	(a)	The Commonwealth may give the Recipient a Notice requiring the Recipient to repay to the Commonwealth (or deal with as specified by the Commonwealth) an amount which the Commonwealth is entitled to recover under clause
10.1 or 10.2. 

  

	 	(b)	If the Commonwealth gives a Notice under clause 10.3(a), the Recipient must repay the amount specified in the Notice in full (or deal with it as specified by the Commonwealth) within 30 days of the date of the Notice.

  

	11.	Monitoring progress 

  

	11.1	Progress meetings 

 The parties will meet at the times and in the manner reasonably
required by the Commonwealth to discuss any issues in relation to this Agreement or the Project. The Recipient must ensure that the Recipient Representative, and the Commonwealth must ensure the Commonwealth Representative, are reasonably available
to attend such meetings and answer any queries relating to the Project raised by either party. 
  

	11.2	Reporting 

 The Recipient must provide the Commonwealth with Reports in accordance with
Schedule 3. 
  

	11.3	Contents of Reports 

 The Recipient must comply with any direction the Commonwealth may
issue in writing to the Recipient in respect of a Report the Recipient is required to provide under clause 11.2 specifying: 
  

	 	(a)	a format for the Report (or for part of the Report); and 

  

	 	(b)	information the Recipient is to include in the Report (or part of the Report); and 

  

	 	(c)	the person or persons who are to certify that information contained in a Report (or part of a report) is accurate. 

For the purposes of clause 11.3, the Commonwealth will be taken to have issued a direction in writing concerning a matter referred to in
clause 11.3 if it includes that information in a Guideline or any similar document and that document is available to the Recipient. 
  

	12.	Performance 

  

	12.1	Reviews of the CRC Project 

  

	 	(a)	Ad hoc reviews may be undertaken or required by the Commonwealth from time to time, including but not limited to cases where substantial changes to the Project are proposed, or Milestones are not being met.

  

	 	(b)	The Commonwealth will bear the cost of any review under clause 12.1, subject to the Recipient meeting its own costs in accordance with the Guidelines. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 18	 

	 	(c)	The Commonwealth may, by Notice, require the Recipient to take actions in relation to the outcomes or recommendations of any review under clause 12.1, or recommendations of the CRC Advisory Committee, in accordance
with: 

  

	 	(i)	the timeframe (if any) specified in the Notice; 

  

	 	(ii)	any requirements in the Guidelines; or 

  

	 	(iii)	any reasonable directions of the Commonwealth. 

  

	12.2	Evaluation 

 Without limiting any of its obligations under this Agreement the Recipient
must assist the Commonwealth with and participate in, within the timeframe and in the manner required by the Commonwealth in accordance with the Guidelines , any: 
  

	 	(a)	evaluation of the: 

  

	 	(i)	performance of the CRC Project; 

  

	 	(ii)	conduct of the Project; 

  

	 	(iii)	Recipient’s compliance with this Agreement; 

  

	 	(b)	surveys, questionnaires and other evaluation procedures related to the performance of the Recipient, the CRC-P or the Programme; and 

 

	 	(c)	preparation of reports reasonably required under this clause 12.2. 

  

	12.3	Cooperation 

 In relation to any review or evaluation under clause 12, the Recipient
must: 
  

	 	(a)	provide all reasonable assistance to; 

  

	 	(b)	respond to all reasonable requests of; and 

  

	 	(c)	provide any information reasonably required by; 

 the Commonwealth or its authorised
representative. 
  

	12.4	Commonwealth rights 

  

	 	(a)	If the Recipient does not: 

  

	 	(i)	meet any of the obligations under clause 12; 

  

	 	(ii)	comply with a Notice given under clause 12.1(c) within the specified timeframe; or 

  

	 	(iii)	comply with the Guidelines in relation to a review or evaluation under clause 12; 

 to the
satisfaction of the Commonwealth, the Commonwealth may at its sole discretion, without limiting any of its other rights under this Agreement or at law, exercise its right to reduce or suspend payment of the Funds, or terminate the Agreement, under
clause 27. 
  

	 	(b)	Without limiting any of the Commonwealth’s rights arising elsewhere under this Agreement, if the Commonwealth determines, in its sole discretion, whether pursuant to a review or evaluation under clause 12 or
otherwise, that the Recipient is not performing satisfactorily under this Agreement, the Commonwealth may by Notice take any action it considers appropriate, including but not limited to: 

 

	 	(i)	requiring the Recipient to undergo further reviews; 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 19	 

	 	(ii)	requiring the Recipient to comply with additional reporting and/or monitoring requirements; or 

  

	 	(iii)	reducing or suspending payment of the Funds, or terminating the Agreement, under clause 27. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 20	 

 Part 2 – General requirements 
  

	13.	Subcontractors and Personnel 

  

	13.1	Subcontracting 

  

	 	(a)	The Recipient must: 

  

	 	(i)	not subcontract the performance of any of its obligations under this Agreement other than to those entities set out in item 12 of Schedule 1 without the prior written approval of the Commonwealth, which will not be
unreasonably withheld; 

  

	 	(ii)	not, in any event, enter into a subcontract under this Agreement with a subcontractor named by the Director of the Workplace Gender Equality Agency in a report to the responsible Minister as an employer currently not
complying with the reporting requirements of the WGE Act; and 

  

	 	(iii)	ensure that any subcontractor approved under this Agreement is contractually required to comply with obligations consistent with those contained in: 

 

	 	(A)	Clause 18 (Insurance); 

  

	 	(B)	Clause 20 (Confidentiality); 

  

	 	(C)	Clause 21 (Work health and safety); 

  

	 	(D)	Clause 22 (Protection of personal information); 

  

	 	(E)	Clause 23 (Conflict of interest); 

  

	 	(F)	Clause 24 (Books and records); 

  

	 	(G)	Clause 25 (Audit and access); 

  

	 	(H)	Clause 28 (Survival); 

  

	 	(I)	Clause 30.16 (False or misleading information); 

  

	 	(J)	Clause 30.17 (Safe and ethical research); and 

  

	 	(K)	Clause 30.18 (Responsible conduct of research). 

  

	 	(b)	When granting written approval under clause 13.1(a)(i), and without limiting considerations the Commonwealth may have regard to, the Commonwealth will have regard to whether the proposed subcontractor is a related body
corporate. 

  

	 	(c)	The Recipient is fully responsible for undertaking the Project even if the Recipient subcontracts any aspect of the Project and for the performance of all of the Recipient’s obligations under this Agreement.

  

	13.2	Use of Specified Personnel 

 The Recipient must: 

 

	 	(a)	undertake the Project or any part of the Project to which their particular expertise relates, with the active involvement of, and using the expertise of, the Specified Personnel or any persons who are appointed to
replace them in accordance with clause 13.3(b); and 

  

	 	(b)	ensure that each of the Specified Personnel is aware of and complies with the Recipient’s obligations in undertaking the Project. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 21	 

	13.3	If the Specified Personnel are not available 

 Where one or more of the Specified
Personnel is or will become unable or unwilling to be involved in the Project, the Recipient must: 
  

	 	a)	notify the Commonwealth in writing immediately of any change to the Specified Personnel; and 

  

	 	b)	when replacing Specified Personnel, ensure that any such replacement personnel directly involved in the Project has the time commitment, qualifications and competency to undertake the Project to the standard required by
the Agreement and have similar or better suited expertise and ability to those of the Specified Personnel they are replacing. 

  

	13.4	Commonwealth may request replacement of Personnel 

 The Commonwealth may at any time request the
Recipient to remove from work in respect of this Agreement any of the Specified Personnel or any of the Recipient’s subcontractors or Personnel. The Recipient must promptly arrange for the removal of such subcontractors or Personnel, and
arrange for a replacement in accordance with the requirements under clause 13.3 (b). 
  

	14.	Assets 

  

	14.1	Ownership 

 Subject to the terms of any lease or other arrangement, the Recipient owns
any Asset. 
  

	14.2	Use and dealings 

  

	 	(a)	During the Agreement Period, the Recipient must use any Asset only for the purposes of the Project, or other purposes consistent with the Outcomes. 

 

	 	(b)	During the Agreement Period, the Recipient must: 

  

	 	(i)	not encumber, dispose or deal with any Asset valued at $50,000 (excluding GST) or above other than in accordance with this clause 14, without the Commonwealth’s prior approval; 

 

	 	(ii)	hold all Assets securely and safeguard them against theft, loss, damage, or unauthorised use and ensure they are adequately insured as described in clause 18; 

 

	 	(iii)	maintain all Assets in good working order; and 

  

	 	(iv)	be fully responsible for, and bear all risks relating to, the use or disposal of all Assets. 

  

	15.	Intellectual Property Rights 

  

	15.1	Pre-existing Material and Third Party Material 

This clause 15 does not affect the ownership of the Intellectual Property Rights in any Pre-existing
Material or Third Party Material. 
  

	15.2	Third Party Material 

  

	 	(a)	The Recipient must obtain all necessary copyright and other Intellectual Property Rights permissions before making any Third Party Material available for the purpose of this Agreement or the Project. 

 

	 	(b)	The Recipient must specify which parts (if any) of the Intellectual Property Rights are Third Party Material and who owns the Intellectual Property Rights in that material. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 22	 

	15.3	Intellectual Property Rights in Agreement Material 

  

	 	(a)	The Intellectual Property Rights in the Agreement Material vest in the Recipient and/or the Project Partners on creation, as determined and agreed in the Participants Agreement. 

 

	 	(b)	To the extent that: 

  

	 	(i)	the Commonwealth needs to use any of the Agreement Material in connection with this Agreement or the Programme, or for any other legitimate carriage of its responsibilities, including but not limited to:

  

	 	(A)	the use of Reports provided by the Recipient to the Commonwealth; or 

  

	 	(B)	the exercise of its rights under clause 25; 

 the Recipient grants to, or must obtain for, the
Commonwealth a perpetual, world-wide, royalty free, non-exclusive licence (including the right to sublicense) to use, reproduce, adapt, modify and communicate that Material; or 

 

	 	(ii)	the Recipient needs to use any of the Commonwealth Material (excluding the CRC Indicia) for the purpose of performing its obligations under this Agreement, the Commonwealth grants to the Recipient, subject to any
conditions, directions or restrictions of the Commonwealth specified in item 14 of Schedule 1, a world-wide, royalty free, non-exclusive, non-transferable licence
(including the right to sublicence) to use, reproduce, adapt, modify and communicate the Commonwealth Material solely for the purpose of undertaking the Project, or 

 

	 	(iii)	the Recipient needs to use any of the CRC Indicia for the purposes of clause 4.2, the Commonwealth grants to the Recipient, subject to any conditions, directions or restrictions of the Commonwealth specified in item 14
of Schedule 1, a world-wide, royalty free, non-exclusive, non-transferable licence (including the right to sublicense, with the exception of the Recipient being
able to grant a sublicense to the Project Partners) to use, reproduce and communicate the CRC Indicia solely for the purposes of undertaking the Project. 

  

	 	(c)	The licence granted to the Commonwealth under clause 15.3(b)(i) does not include a right to exploit the Agreement Material, Pre-existing Material or Third Party Material for the
Commonwealth’s commercial purposes. 

  

	 	(d)	The Recipient must, or where the Agreement Material vests in the Project Partner must ensure that, at all times during the Agreement Period, the Recipient and/or Project Partner has in place and adheres to documented
procedures to ensure that, before any Agreement Material is published or disclosed to any person other than the Commonwealth or a Participant, consideration is given to the potential prejudice to the subsistence or Utilisation of the Agreement
Material, including the possibility that publication or disclosure might preclude the grant of a patent or cause the loss of Intellectual Property Rights. 

  

	 	(e)	The Recipient must, or where the Agreement Material vests in the Project Partner must ensure that, the Recipient and/or Project Partner uses its best endeavours to ensure Utilisation of Agreement Material (but not
including reports or other such material to be provided to the Commonwealth for the Commonwealth’s benefit) by the Participants. 

  

	 	(f)	The Recipient must, or where the Agreement Material vests in the Project Partner must ensure that, any Utilisation of Agreement Material, including by any third party, is consistent with any Milestones, the nature of
the Project and the objectives of the Programme, including the maximisation of benefits accruing to Australia. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 23	 

	 	(g)	The Recipient must ensure that in order to maximise the benefits from research, after appropriate commercialisation and Utilisation decisions have been taken, consideration is given, where relevant, to dissemination of
the results from the Project. 

  

	 	(h)	If at any time, the Commonwealth is of the reasonable view that the Utilisation of the Agreement Material by the Recipient and/or Project Partner, including any third party, is not consistent with clause 15.3(f), the
Commonwealth may, by Notice at its sole and unfettered discretion: 

  

	 	(i)	require the Recipient to repay some or all of the Funds spent Utilising the Agreement Material; 

  

	 	(ii)	reduce or suspend payment of the Funds, or terminate the Agreement, under clause 27; or 

  

	 	(iii)	exercise any other right it may have under this Agreement. 

  

	15.4	Commonwealth Material 

 The Commonwealth will provide to the Recipient the Commonwealth Material and the
Recipient must ensure that the Commonwealth Material is used strictly in accordance with any conditions or restrictions specified in item 14 of Schedule 1 and any direction by the Commonwealth. 

 

	16.	Moral Rights 

  

	16.1	Obtaining consents 

 To the extent permitted by applicable Laws and for the benefit of
the Commonwealth, the Recipient must: 
  

	 	(a)	give, where the Recipient is an individual, in a form acceptable to the Commonwealth; 

  

	 	(b)	use its best endeavours to ensure that each of the Personnel used by the Recipient in the production or creation of the Agreement Material gives, in a form acceptable to the Commonwealth; and 

 

	 	(c)	use its best endeavours to ensure that any holder of Moral Rights in Third Party Material included in the Agreement Material gives, 

genuine consent in writing to the use of the Agreement Material for the Specified Acts, even if such use would otherwise be an infringement of
its or their Moral Rights and notify the Commonwealth if this consent is not obtained. 
  

	16.2	Specified Acts 

  

	 	(a)	In this clause 16, unless otherwise specified in item 17 of Schedule 1, Specified Acts means: 

  

	 	(i)	falsely attributing the authorship of any Agreement Material, or any content in the Agreement Material (including literary, dramatic, artistic works and cinematograph films within the meaning of the Copyright Act
1968 (Cth)); 

  

	 	(ii)	materially altering the style, format, colours, content or layout of the Agreement Material and dealing in any way with the altered Agreement Material; 

 

	 	(iii)	reproducing, communicating, adapting, publishing or exhibiting any Agreement Material; and 

  

	 	(iv)	adding any additional content or information to the Agreement Material. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 24	 

	 	(b)	For the purposes of clause 16.2(a), Agreement Material includes any Pre-existing Material and Third Party Material to the extent that it is included in, forms part of or is
attached to the Agreement Material. 

  

	17.	Indemnity 

  

	 	(a)	The Recipient will at all times indemnify, hold harmless and defend the Commonwealth, its officers and employees including members of the CRC Advisory Committee and any independent experts used by the CRC Advisory
Committee (referred to in this clause 17 as “those indemnified”) from and against any loss or liability, including: 

  

	 	(i)	loss of, or damage to, property of the Commonwealth; 

  

	 	(ii)	claims by any person in respect of personal injury or death; 

  

	 	(iii)	claims by any person in respect of loss of, or damage to, any property; and 

  

	 	(iv)	costs and expenses including the costs of defending or settling any claim referred to in clause 17(a)(ii) or clause 17(a)(iii), 	 

 arising out of or as a consequence of: 

 

	 	(v)	use or disposal of Assets; 

  

	 	(vi)	an infringement, or an alleged infringement, of the Intellectual Property Rights of any person, which occurred by reason of an act done by the Commonwealth in relation to any part of the Project; 

 

	 	(vii)	any actual, likely or threatened breach of the Recipient’s, its Personnel’s or subcontractor’s obligations relating to Confidential Information or personal information; or 

 

	 	(viii)	without limiting the preceding paragraphs, any breach of this Agreement by the Recipient, or negligence on the part of the Recipient, its Personnel or subcontractors or wrongful or unlawful act or omission on the part
of the Recipient, its Personnel or subcontractors. 

  

	 	(b)	The Recipient’s liability to indemnify those indemnified under clause 17(a) will be reduced proportionally to the extent that any negligent act or omission of those indemnified contributed to the loss.

  

	18.	Insurance 

  

	18.1	Obligation to maintain insurance 

 Unless otherwise specified in item 18 of Schedule 1,
in connection with the Project, the Recipient must have and maintain: 
  

	 	(a)	Workers’ compensation insurance for an amount required by the relevant State or Territory legislation; 

  

	 	(b)	Public liability insurance for an adequate amount per claim, or occurrence giving rise to a claim, in respect of activities undertaken under this Agreement (where occurrence means either a single occurrence or a series
of occurrences if these are linked or occur in connection with one another from one original cause, as the case may be); 

  

	 	(c)	insurance over any Asset acquired pursuant to clause 14 of this Agreement for its full replacement value; and 

  

	 	(d)	any other insurance required by law or by the Commonwealth (acting reasonably). 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 25	 

	18.2	Certificates of currency 

 The Recipient must, on request by the Commonwealth, provide
current relevant confirmation of insurance documentation from its insurers or insurance brokers certifying that it has insurance as required by clause 18.1. 
  

	19.	Publicity 

 The Commonwealth reserves the right to publicise and report on the awarding of the
Funds, and may do this by, amongst other means, including the Participants’ names, the amount of Funds and the title and a brief description of the Project in media releases, general announcements about the Programme, annual reports, and in
order to fulfil its obligations under the Commonwealth Grants Rules and Guidelines. 
  

	20.	Confidentiality 

  

	20.1	Prohibition on disclosure 

  

	 	(a)	Subject to clause 20.4, the Recipient must not, without the prior written consent of the Commonwealth, disclose any Commonwealth’ Confidential Information to a third party, or use such Confidential Information
other than for the purpose of the Project. 

  

	 	(b)	Subject to clause 20.4, the Commonwealth must not, without the prior written consent of the Recipient, disclose any Recipient’ Confidential Information to a third party, or use such Confidential Information other
than for the purpose of the Project. 

  

	20.2	Conditions of approval 

 In giving written consent to use or disclose Commonwealth
Confidential Information, the Commonwealth may impose such conditions as it thinks fit. The Recipient must comply with any term or condition imposed by the Commonwealth under this clause 20.2. 

 

	20.3	Advisers and third parties 

 The Commonwealth may at any time require the Recipient to
arrange for: 
  

	 	(a)	its Advisers; 

  

	 	(b)	its Personnel, other employees and subcontractors or the Project Partners involved in the Project; or 

  

	 	(c)	any other third party, to whom Commonwealth Confidential Information may be disclosed pursuant to clause 20.4(a) or clause 20.4(b), 

to give a written undertaking relating to the use and non-disclosure of the Commonwealth’s
Confidential Information in the form approved by the Commonwealth. 
  

	20.4	Exceptions to obligations 

 The obligations on each party under clause 20.1 or 20.10 will
not be taken to have been breached to the extent that Confidential Information of the other party: 
  

	 	(a)	is disclosed by a party to its Advisers or employees solely in order to comply with obligations, or to exercise rights, under this Agreement; 

 

	 	(b)	is disclosed to a party’s internal management personnel, solely to enable effective management or auditing of activities related to this Agreement; 

 

	 	(c)	is disclosed by the Commonwealth to the responsible Minister; 

  

	 	(d)	is disclosed by the Commonwealth, in response to a request by a House or a Committee of the Parliament of the Commonwealth of Australia; 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 26	 

	 	(e)	is shared by the Commonwealth within the Department, or with another Commonwealth agency, where this serves the Commonwealth’s legitimate interests; 

 

	 	(f)	is disclosed by the Commonwealth to the Auditor-General, the Commonwealth Ombudsman or the Australian Information Commissioner; 

  

	 	(g)	is required by Law to be disclosed; 

  

	 	(h)	is shared by the Commonwealth to Innovation Australia or its delegates for the purposes of the administration of the R&D Tax Incentive; or 

 

	 	(i)	is in the public domain otherwise than due to a breach of this Agreement. 

  

	20.5	Obligation on disclosure 

 Where a party discloses Confidential Information of the other
party to another person: 
  

	 	(a)	pursuant to clauses 20.4(a), (b) or (e), the disclosing party must: 

  

	 	(i)	notify the receiving person that the information is Confidential Information; and 

  

	 	(ii)	not provide the information unless the receiving person agrees to keep the information confidential, including in the case of Commonwealth’ Confidential Information, the receiving person giving the Commonwealth a
legally binding undertaking to that effect in the form approved by the Commonwealth; or 

  

	 	(b)	pursuant to clauses 20.4(c), (d), (f) and (h), the disclosing party must notify the receiving party that the information is Confidential Information of the other party. 

 

	20.6	Additional confidential information 

  

	 	(a)	The parties may agree in writing after the date of this Agreement that certain additional information is to constitute Confidential Information for the purposes of this Agreement. 

 

	 	(b)	Where the parties agree in writing after the date of this Agreement that certain additional information is to constitute Confidential Information for the purposes of this Agreement, this documentation is incorporated
into, and becomes part of this Agreement, on the date by which both parties have signed this documentation. 

  

	20.7	Period of confidentiality 

 The obligations under this clause 20 continue,
notwithstanding the expiry or termination of this Agreement: 
  

	 	(a)	in relation to an item of information described in item 19 of Schedule 1, for the period set out in that Schedule in respect of that item; and 

 

	 	(b)	in relation to any information which the parties agree in writing after the date of this Agreement is to constitute Confidential Information for the purposes of this Agreement, for the period agreed by the parties in
writing in respect of that information. 

  

	20.8	No reduction in privacy obligations 

 Nothing in this Agreement derogates from any
obligation which either party may have under the Privacy Act 1988 (Cth) as amended from time to time, in relation to the protection of ‘personal information’ as defined in that Act or information that is protected by the Census
and Statistics Act 1905 (Cth), or any other Act, regulation or other legislative instrument requiring secrecy or confidentiality in dealing with information. 
  

	20.9	Return of information 

 At the Commonwealth’s request or on the expiry or
termination this Agreement, the Recipient must promptly return all of the Commonwealth’s physical and written records containing Commonwealth Confidential Information, and all documentation relating to that Commonwealth Confidential Information
(including copies), to the Commonwealth in a form reasonably requested by the Commonwealth. Alternatively, if requested by the Commonwealth, the Recipient must destroy such items in the manner specified by the Commonwealth and promptly certify to
the Commonwealth in writing that it has done so. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 27	 

	20.10	Confidential Agreement Provisions 

 Notwithstanding any other provision of this
Agreement, the Commonwealth may disclose the provisions of this Agreement. However, any provisions of this Agreement that are Confidential Information may only be disclosed in accordance with the Senate Order on Departmental and Agency Agreements,
and where such disclosure of Confidential Information is required a statement of reasons for the confidentiality may be included with the disclosure. 
  

	21.	  Work health and safety 

  

	21.1	  General safety obligations 

   The Recipient must: 

 

	 	(a)	ensure that the Project is undertaken in a safe manner; 

  

	 	(b)	ensure that the Participants and their respective Personnel do not, by act or omission place the Commonwealth in breach of its obligations under the WHS Laws; and 

 

	 	(c)	ensure that the Recipient, the Project Partners and their respective Personnel, if using or accessing the Commonwealth’s premises or facilities, comply with all reasonable instructions, directions, policies and
procedures relating to work health and safety in operation at those premises or facilities whether specifically drawn to the attention of the Recipient or might reasonably be inferred from the circumstances. 

 

	22.	  Protection of personal information 

  

	22.1	  Definitions 

 In this clause 22, the terms ‘agency’,
‘Australian Privacy Principle’ (APPs), ‘APP privacy policy’, ‘Australian Privacy Principle Code’ (APP code) and ‘contracted service provider’ have the same meaning as they have in section 6 of
the Privacy Act, and ‘personal information’, which also has the meaning it has in section 6 of the Privacy Act, means: 

‘information or an opinion about an identified individual, or an individual who is reasonably identifiable whether the information or
opinion is true or not and whether the information or opinion is recorded in a material form or not’. 
  

	22.2	  Application of this clause 

 This clause 22 applies only where the
Recipient deals with personal information provided to the Recipient by the Commonwealth, for the purpose of, completing the Project under this Agreement. 
  

	22.3	  Obligations 

 The Recipient acknowledges that to the extent this clause 22
applies it is a ‘contracted service provider’ and agrees in respect of the Project under this Agreement to take all necessary measures to ensure that personal information in its possession or control in connection with this Agreement is
protected against loss and unauthorised access, use, disclosure or modification. 
  

	 	(a)	The Recipient must, on request from the Commonwealth, provide to the Commonwealth: 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 28	 

	 	(i)	a copy of the Recipient’s and any subcontractor’s APP privacy policy which is compliant with APP 1; 

  

	 	(ii)	copies of the Recipient’s and any subcontractor’s security and data protection policies upon request by the Commonwealth; or 

 

	 	(iii)	details of the Recipient’s and any subcontractor’s processes and procedures implemented to ensure compliance with the Privacy Act. 

 

	 	(b)	The Recipient agrees in respect of the Project under this Agreement: 

  

	 	(i)	to use or disclose personal information obtained by the Recipient from the Commonwealth during the course of the Project under this Agreement, only for the purposes of this Agreement; 

 

	 	(ii)	not to do any act or engage in any practice that would breach an APP contained in schedule 1 of the Privacy Act, which if done or engaged in by an agency, would be a breach of that APP; 

 

	 	(iii)	to carry out and discharge the obligations contained in the APPs as if it were an agency under the Privacy Act; 

  

	 	(iv)	to notify individuals whose personal information the Recipient holds, that complaints about acts or practices of the Recipient may be investigated by the Privacy Commissioner who has power to award compensation against
the Recipient in appropriate circumstances; 

  

	 	(v)	not to use or disclose personal information or engage in an act or practice that would breach APP 7 (direct marketing) or a registered APP Code which is applicable to the Recipient, unless the use or disclosure is
necessary, directly or indirectly, to discharge an obligation of this Agreement; 

  

	 	(vi)	to follow any reasonable directions given by the Commonwealth to ensure compliance with the Privacy Act; 

  

	 	(vii)	to not transfer or transmit personal information outside of Australia except with the prior written approval of the Commonwealth, which will not be unreasonably withheld. In giving its approval the Commonwealth may
impose such conditions as it thinks fit. The Recipient must comply with any term or condition imposed by the Commonwealth under this clause 22.3(b)(vii); 

  

	 	(viii)	to disclose in writing to any person who asks, the content of the provisions of this Agreement (if any) that are inconsistent with an APP or a registered APP code which is binding on a party to this Agreement;

  

	 	(ix)	to immediately notify the Commonwealth if the Recipient becomes aware of a breach or possible breach of any of the obligations contained in, or referred to in, this clause 22, whether by the Recipient or any
subcontractor (including any complaints made about acts or practices of the Recipient in connection with personal information); 

  

	 	(x)	to notify the Commonwealth of any subpoena, warrant, order, demand or request made by a foreign court or other authority for the disclosure of personal information to which the Privacy Act applies and to not disclose
such information without the prior written approval of the Commonwealth, which will not be unreasonably withheld. In giving its approval the Commonwealth may impose such conditions as it thinks fit. The Recipient must comply with any term or
condition imposed by the Commonwealth under this clause 22.3(b)(x); 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 29	 

	 	(xi)	to comply with any directions, guidelines, determinations or recommendations of the Privacy Commissioner, notified to the Recipient by the Commonwealth to the extent that they are not inconsistent with the requirements
of this clause 22; and 

  

	 	(xii)	to ensure that any employee of the Recipient who is required to deal with personal information for the purposes of this Agreement is made aware of the obligations of the Recipient set out in this clause 22.

  

	22.4	Subcontracts 

 The Recipient must ensure that any subcontract entered into for the
purpose of fulfilling its obligations under this Agreement contains provisions to ensure that the subcontractor has the same awareness and obligations as the Recipient has under this clause 22, including the requirement in relation to
subcontracts. 
  

	22.5	Indemnity 

 The Recipient agrees to indemnify the Commonwealth in respect of any loss or
liability suffered or incurred by the Commonwealth which arises directly or indirectly from a breach of any of the obligations of the Agreement under this clause 22, or a subcontractor under the subcontract provisions referred to in clause 22,
or a subcontractor under the subcontract provisions referred to in clause 13.1. 
  

	23.	Conflict of interest 

  

	23.1	Warranty 

 The Recipient warrants that, to the best of its knowledge after making
diligent inquiry, at the date of signing this Agreement, no conflict of interest exists or is likely to arise in the performance of its obligations under this Agreement or the Participant’s Agreement. 

 

	23.2	Notification of a conflict of interest 

 If a conflict of interest arises, or appears
likely to arise, the Recipient must: 
  

	 	(a)	notify the Commonwealth immediately in writing; 

  

	 	(b)	make full disclosure of all relevant information relating to the conflict; and 

  

	 	(c)	take such steps as the Commonwealth requires to resolve or otherwise deal with the conflict. 

  

	24.	Books and records 

  

	24.1	Recipient to keep books and records 

 The Recipient must: 

 

	 	(a)	keep and require its subcontractors and the Project Partners to keep adequate books and records, in accordance with Accounting Standards, in sufficient detail to enable: 

 

	 	(i)	all receipts and payments related to the Project to be identified and reported in accordance with this Agreement; and 

  

	 	(ii)	the amounts payable by the Commonwealth under this Agreement to be determined; and 

  

	 	(b)	retain and require its subcontractors and the Project Partners to retain for a period of seven years after the expiry or termination of this Agreement, all books and records relating to the Project. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 30	 

	24.2	Costs 

 The Recipient must bear its own costs of complying with this clause 24. 

 

	24.3	Survival 

 This clause 24 applies for the Agreement Period and for a period of seven
years from the expiry or termination of this Agreement. 
  

	25.	Audit and access 

  

	25.1	Right to conduct audits 

 For the duration of this Agreement and for a period of 7 years
following the expiry or termination of this Agreement, the Commonwealth or a representative may conduct audits relevant to the performance of the Recipient’s obligations under this Agreement. Audits may be conducted of: 

 

	 	(a)	the Assets; 

  

	 	(b)	the Recipient’s operational practices and procedures as they relate to this Agreement; 

  

	 	(c)	the accuracy of the Recipient’s Reports; 

  

	 	(d)	the Recipient’s compliance with its confidentiality and privacy obligations under this Agreement; 

  

	 	(e)	Material (including books and records) in the possession of the Recipient relevant to the Project or this Agreement; and 

  

	 	(f)	any other matters determined by the Commonwealth to be relevant to the Project or this Agreement. 

  

	25.2	Access by the Commonwealth 

  

	 	(a)	The Commonwealth may, at reasonable times and on giving reasonable notice to the Recipient, to the extent relevant to the performance of this Agreement: 

 

	 	(i)	access the premises of the Recipient; 

  

	 	(ii)	require the provision by the Recipient, its employees, agents or subcontractors or by the Project Partners, of records and information in a data format and storage medium accessible by the Commonwealth by use of the
Commonwealth’s existing computer hardware and software; 

  

	 	(iii)	inspect and copy documentation, books and records, however stored, in the custody or under the control of the Recipient, its employees, agents or subcontractors or by the Project Partners; and 

 

	 	(iv)	require assistance in respect of any inquiry into or concerning the Project or this Agreement. For these purposes an inquiry includes any administrative or statutory review, audit or inquiry (whether within or external
to the Department), any request for information directed to the Commonwealth, and any inquiry conducted by Parliament or any Parliamentary Committee. 

  

	 	(b)	The Recipient must provide access to its computer hardware and software to the extent necessary for the Commonwealth to exercise its rights under this clause 25, and provide the Commonwealth with any reasonable
assistance requested by the Commonwealth to use that hardware and software. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 31	 

	25.3	Conduct of audit and access 

 The Commonwealth must use reasonable endeavours to ensure
that: 
  

	 	(a)	audits performed pursuant to clause 25.1; and 

  

	 	(b)	the exercise of the general rights granted by clause 25.2 by the Commonwealth, 

 do not
unreasonably delay or disrupt in any material respect the Recipient’s performance of its obligations under this Agreement or its business. 
  

	25.4	Costs 

 Unless otherwise agreed in writing, each party must bear its own costs of any
audits. 
  

	25.5	Auditor-General and Australian Information Commissioner 

 The rights of the Commonwealth
under clause 25.2(a)(i) to 25.2(a)(iii) apply equally to the Auditor-General or a delegate of the Auditor-General, or the Australian Information Commissioner or a delegate of the Australian Information Commissioner, for the purpose of performing the
Auditor-General’s or the Australian Information Commissioner’s statutory functions or powers. 
  

	25.6	Recipient to comply with Auditor-General’s requirements 

 The Recipient must do all
things necessary to comply with the Auditor-General’s or his or her delegate’s or the Australian Information Commissioner’s or his or her delegate’s requirements, notified under clause 25.2, provided such requirements are legally
enforceable and within the power of the Auditor-General, the Australian Information Commissioner, or his or her respective delegate. 
  

	25.7	No reduction in responsibility 

 The requirement for, and participation in, audits does
not in any way reduce the Recipient’s responsibility to perform its obligations in accordance with this Agreement. 
  

	25.8	Subcontractor requirements 

 The Recipient must ensure that any subcontract entered into
for the purpose of this Agreement contains an equivalent clause granting the rights specified in this clause 25. 
  

	25.9	No restriction 

 Nothing in this Agreement reduces, limits or restricts in any way any
function, power, right or entitlement of the Auditor-General or a delegate of the Auditor-General or the Privacy Commissioner or a delegate of the Office of the Australian Information Commissioner. The rights of the Commonwealth under this Agreement
are in addition to any other power, right or entitlement of the Auditor-General or a delegate of the Auditor-General or the Australian Information Commissioner or a delegate of the Australian Information Commissioner. 

Note: The effect of clause 28 of this Agreement is that this clause 25 applies for the Agreement Period and for a period of seven years from
the expiry or termination of this Agreement. 
  

	26.	Dispute resolution 

  

	26.1	No arbitration or court proceedings 

 If a dispute arises in relation to the conduct of
this Agreement (Dispute), a party must comply with this clause 26 before starting arbitration or court proceedings except proceedings for urgent interlocutory relief. After a party has sought or obtained any urgent interlocutory relief, that
party must follow this clause 26. 
  

	26.2	Notification 

 A party claiming a Dispute has arisen must give the other parties to the
Dispute notice setting out details of the Dispute. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 32	 

	26.3	Parties to resolve Dispute 

 During the 14 days after a notice is given under clause 26.2
(or longer period if the parties to the Dispute agree in writing), each party to the Dispute must use its reasonable efforts through a meeting of CEOs (or their nominees) to resolve the Dispute. If the parties cannot resolve the Dispute within that
period, they must refer the Dispute to a mediator if one of them requests. 
  

	26.4	Appointment of mediator 

 If the parties to the Dispute cannot agree on a mediator within
seven days after a request under clause 26.3, the chairperson of the Resolution Institute or the chairperson’s nominee will appoint a mediator. 
  

	26.5	Role of mediator and obligations of parties 

 The role of a mediator is to assist in
negotiating a resolution of the Dispute. A mediator may not make a binding decision on a party to the Dispute except if the party agrees in writing. Unless agreed by the mediator and parties, the mediation must be held within 21 days of the request
for mediation in clause 26.3. The parties must attend the mediation and act in good faith to genuinely attempt to resolve the Dispute. 
  

	26.6	Confidentiality 

 Any information or documents disclosed by a party under this clause 26:

  

	 	(a)	must be kept confidential; and 

  

	 	(b)	may only be used to attempt to resolve the Dispute. 

  

	26.7	Costs 

 Each party to a Dispute must pay its own costs of complying with this clause 26.
The parties to the Dispute must equally pay the costs of any mediator. 
  

	26.8	Termination of process 

 A party to a Dispute may terminate the dispute resolution
process by giving notice to each other party after it has complied with clauses 26.1 to 26.5. Clauses 26.6 and 26.7 survive termination of the dispute resolution process. 
  

	26.9	Breach of this clause 

 If a party to a Dispute breaches clauses 26.1 to 26.8, the other
party does not have to comply with those clauses in relation to the Dispute. 
  

	27.	Reduction, suspension and termination 

  

	27.1	Reduction 

 Without limiting any other right or remedy of the Commonwealth, the
Commonwealth may reduce the amount of any instalment of the Funds: 
  

	 	(a)	if by the date for payment of an instalment the Recipient has not spent Funds previously paid to the Recipient, by the amount that has not been spent; 

 

	 	(b)	if, in the Commonwealth’s opinion, Funds have been spent other than in accordance with this Agreement, by the amount that, in the Commonwealth’s opinion, was spent other than in accordance with this Agreement;

  

	 	(c)	if any Participant Contributions due to be provided before the date for payment of the instalment have not been provided, by an amount that represents the same proportion of the total Funds as those Participant
Contributions bear to the total Participant Contributions; or 

  

	 	(d)	as otherwise provided in this Agreement.  

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 33	 

	27.2	Suspension 

  

	 	(a)	Without limiting any other right or remedy of the Commonwealth, the Commonwealth may, in its sole discretion, suspend payment of the Funds (or any part of the Funds) if: 

 

	 	(i)	any Participant Contributions due to be provided before the date for payment have not been provided, until those Participant Contributions have been provided; 

 

	 	(ii)	the Recipient has not provided a Report due to be provided before the date for payment, until the Report is provided; 

  

	 	(iii)	a Report provided by the Recipient is not accurate or complete, until an accurate and complete replacement Report is provided; 

  

	 	(iv)	the Recipient has not achieved a Milestone that was due to be achieved before the date for payment, until the Milestone is achieved; 

 

	 	(v)	the Recipient has not spent Funds previously paid to the Recipient, until the Recipient has done so; 

  

	 	(vi)	the Commonwealth determines that the Recipient holds an excessive balance of Funds as a proportion of its total funds; 

  

	 	(vii)	the Recipient has not otherwise undertaken the Project to the satisfaction of the Commonwealth, until the Recipient remedies its performance; 

 

	 	(viii)	the Commonwealth determines, acting reasonably and in good faith, that the Recipient is not performing to the satisfaction of the Commonwealth; 

 

	 	(ix)	a certified copy of the Participants Agreement is not provided to the Commonwealth, within the timeframe stipulated at Schedule 2; or 

 

	 	(x)	as otherwise provided in this Agreement. 

  

	 	(b)	Despite any suspension, the Recipient must continue to perform its obligations under this Agreement. 

  

	27.3	Termination and reduction for convenience 

  

	 	(a)	The Commonwealth may, at any time, by Notice, terminate this Agreement or reduce the scope of the Project. 

  

	 	(b)	On receipt of a Notice of termination or reduction the Recipient must: 

  

	 	(i)	take all available steps to minimise loss resulting from that termination or reduction and to protect Commonwealth Material and Agreement Material; and 

 

	 	(ii)	continue to undertake any part of the Project not affected by the Notice. 

  

	 	(c)	If this Agreement is terminated under this clause 27.3, the Commonwealth is liable only for: 

  

	 	(i)	subject to clause 27.6(a)(i), payments under clause 7 in accordance with this Agreement before the effective date of termination; and 

 

	 	(ii)	subject to clause 27.3(e) and (f) reasonable costs actually incurred by the Recipient and directly attributable to the termination. 

 

	 	(d)	If the scope of the Project is reduced, the Commonwealth’s liability to pay the Funds or to provide Commonwealth Material abates in accordance with the reduction in the Project. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 34	 

	 	(e)	The Commonwealth is not liable to pay compensation under clause 27.3(c)(ii) for an amount which would, in addition to any amounts paid or due, or becoming due, to the Recipient under this Agreement, exceed the total
Funds payable under this Agreement. 

  

	 	(f)	The Recipient is not entitled to compensation for loss of prospective profits. 

  

	27.4	Termination for default 

  

	 	(a)	Without limiting any other rights or remedies the Commonwealth may have against the Recipient arising out of or in connection with this Agreement, the Commonwealth may terminate this Agreement effective immediately by
giving Notice to the Recipient if: 

  

	 	(i)	the Recipient breaches a material provision of this Agreement where that breach is not capable of remedy; 

  

	 	(ii)	the Recipient breaches any provision of this Agreement and fails to remedy the breach within 14 days after receiving Notice requiring it to do so; 

 

	 	(iii)	the Recipient fails to notify the Commonwealth of a conflict of interest, or in the opinion of the Commonwealth, a conflict of interest exists which would prevent the Recipient from performing its obligations under this
Agreement; 

  

	 	(iv)	the Recipient is unable to obtain Participant Contributions, or obtain them in time to enable completion of the Project by the End Date; 

 

	 	(v)	the Commonwealth is satisfied that any statement made in the Recipient’s application for funding (if any) is incorrect, incomplete, false or misleading in a way which would have affected the original decision to
approve the provision of the Funds; or 

  

	 	(vi)	an event specified in clause 27.4(c) happens. 

  

	 	(b)	Without limitation, for the purposes of clause 27.4(a)(i), each of the following constitutes a breach of a material provision: 

  

	 	(i)	breach of warranty under clause 4.3 (Warranties); 

  

	 	(ii)	a failure to comply with clause 5.4 (Breach of the Participants Agreement); 

  

	 	(iii)	breach of clause 9.1, 9.2 or 9.3 (Use of Funds); 

  

	 	(iv)	a failure to comply with clause 13 (Subcontractors and Personnel); 

  

	 	(v)	breach of or failure to comply with clause 11 (Monitoring progress) 

  

	 	(vi)	breach of or failure to comply with clause 12 (Performance); 

  

	 	(vii)	a failure to comply with clause 15 (Intellectual Property); 

  

	 	(viii)	a failure to comply with clause 18 (Insurance); 

  

	 	(ix)	a failure to comply with clause 20 (Confidentiality); 

  

	 	(x)	a failure to comply with clause 22 (Protection of personal information); and 

  

	 	(xi)	a failure to notify the Commonwealth of a conflict of interest, or where the Recipient is unable or unwilling to resolve or deal with the conflict as required under clause 23 (Conflict of interest). 

 

	 	(c)	The Recipient must notify the Commonwealth immediately if: 

  

	 	(i)	there is any Change in Control of the Recipient; 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 35	 

	 	(ii)	the Recipient disposes of the whole or any part of its assets, operations or business other than in the ordinary course of business; 

 

	 	(iii)	the Recipient ceases to carry on business; 

  

	 	(iv)	the Recipient ceases to be able to pay its debts as they become due; 

  

	 	(v)	proceedings are initiated with a view to obtaining an order for the winding up of the Recipient, or any person convenes a meeting for the purpose of considering or passing any resolution for the winding up of the
Recipient; 

  

	 	(vi)	the Recipient applies to come under, the Recipient receives a Notice requiring it to show cause why it should not come under, an order has been made for the purpose of placing the Recipient under, or the Recipient
otherwise comes under one of the forms of external administration referred to in Chapter 5 of the Corporations Act or Chapter 11 of the Corporations (Aboriginal and Torres Strait Islander) Act 2006 (Cth) or equivalent provisions in State or
Territory legislation in relation to incorporated associations; 

  

	 	(vii)	the Recipient being a natural person is declared bankrupt or assigns his or her estate for the benefit of creditors; 

  

	 	(viii)	where the Recipient is a partnership, any step is taken to dissolve that partnership; or 

  

	 	(ix)	anything analogous to an event referred to in clause 27.4(c)(v) – (viii) occurs in relation to the Recipient. 

  

	27.5	After termination 

 On termination of this Agreement the Recipient must deal with
Commonwealth Material and the Commonwealth’s Confidential Information in accordance with this Agreement and otherwise as reasonably directed by the Commonwealth. 
  

	27.6	Commonwealth rights 

  

	 	(a)	Without limiting any of the Commonwealth’s other rights or remedies, on termination of this Agreement, the Commonwealth: 

  

	 	(i)	is not obliged to pay to the Recipient any outstanding amount of the Funds, except to the extent that those monies have been legally committed for expenditure by the Recipient in accordance with this Agreement and
payable by the Recipient as a current liability (written evidence of which will be required) by the date the Recipient receives the Notice of termination; and 

  

	 	(ii)	is entitled to recover from the Recipient: 

  

	 	(A)	any Funds which have not been spent, or legally committed for expenditure by the Recipient in accordance with this Agreement and payable by the Recipient as a current liability (written evidence of which will be
required), by the date the Recipient receives the Notice of termination; and 

  

	 	(B)	the amount of any Funds which, in the Commonwealth’s opinion, have been spent other than in accordance with this Agreement. 

  

	 	(b)	The Commonwealth may give the Recipient a Notice requiring the Recipient to repay to the Commonwealth (or deal with as specified by the Commonwealth) an amount which the Commonwealth is entitled to recover under clause
27.6(a)(ii). 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 36	 

	 	(c)	If the Commonwealth gives a Notice under clause 27.6(b), the Recipient must repay the amount specified in the Notice in full (or deal with it as specified by the Commonwealth) within 30 days of the date of the Notice.

  

	27.7	Termination does not affect accrued rights 

 Termination of this Agreement does not
affect any accrued rights or remedies of a party. 
  

	28.	Survival 

 The following clauses survive the expiry or termination of this Agreement: 

 

	 	(a)	Clause 4.2 (Acknowledgment of support); 

  

	 	(b)	Clause 8 (GST and R&D Tax Incentive); 

  

	 	(c)	Clause 10 (Repayment); 

  

	 	(d)	Clause 11.2 (Reporting); 

  

	 	(e)	Clause 12.2 (Evaluation); 

  

	 	(f)	Clause 15 (Intellectual Property Rights); 

  

	 	(g)	Clause 16 (Moral Rights); 

  

	 	(h)	Clause 17 (Indemnity); 

  

	 	(i)	Clause 18 (Insurance); 

  

	 	(j)	Clause 20 (Confidentiality); 

  

	 	(k)	Clause 22 (Protection of personal information); 

  

	 	(l)	Clause 24 (Books and records); 

  

	 	(m)	Clause 25 (Audit and access) for a period of seven years from the expiry or termination of this Agreement; 

  

	 	(n)	Clause 27.6 (Commonwealth rights); and 

  

	 	(o)	Clause 30.2 (Amounts due to Commonwealth), 

 together with any provision of this Agreement which
expressly or by implication from its nature is intended to survive the expiry or termination of this Agreement. 
  

	29.	Notices and other communications 

  

	29.1	Service of Notices 

 A Notice must be: 

 

	 	(a)	in writing, in English and signed by a person duly authorised by the sender; and 

  

	 	(b)	hand delivered or sent by prepaid post or by electronic means (facsimile or email) to the Recipient’s address for Notices specified in item 20 of Schedule 1, as varied by any Notice given by the Recipient to the
sender. 

  

	29.2	Effective on receipt 

 A Notice given in accordance with clause 29.1 takes effect when it
is taken to be received (or at a later time specified in it), and is taken to be received: 
  

	 	(a)	if hand delivered, on delivery; 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 37	 

	 	(b)	if sent by prepaid post, on the second Business Day after the date of posting (or on the seventh Business Day after the date of posting if posted to or from a place outside Australia); or 

 

	 	(c)	if sent by facsimile, when the sender’s facsimile system generates a message confirming successful transmission of the entire Notice unless, within eight Business Hours after the transmission, the recipient informs
the sender that it has not received the entire Notice; 

  

	 	(d)	if sent by email, as provided under sections 14 and 14A of the Electronic Transactions Act 1999 (Cth), 

but if the delivery, receipt or transmission is not on a Business Day or is after 5.00 pm on a Business Day, the Notice is taken to be received
at 9.00am on the next Business Day. 
  

	30.	Miscellaneous 

  

	30.1	No security 

 The Recipient must not use any of the following as any form of security for
the purpose of obtaining or complying with any form of loan, credit, payment or other interest, or for the preparation of, or in the course of any litigation: 
  

	 	(a)	the Funds; 

  

	 	(b)	this Agreement or any of the Commonwealth’s obligations under this Agreement; or 

  

	 	(c)	any Assets or Agreement Material. 

  

	30.2	Amounts due to Commonwealth 

  

	 	(a)	Without limiting any other of the Commonwealth’s rights or remedies, any amount owed or payable to the Commonwealth (including by way of refund), or which the Commonwealth is entitled to recover from the Recipient,
under this Agreement will be recoverable by the Commonwealth as a debt due and payable to the Commonwealth by the Recipient. 

  

	 	(b)	The Commonwealth may set-off any money due for payment by the Commonwealth to the Recipient under this Agreement against any money due for payment by the Recipient to the
Commonwealth under this Agreement. 

  

	30.3	Ownership of Agreement 

 All copyright and other Intellectual Property Rights contained
in this Agreement remain the property of the Commonwealth. 
  

	30.4	Variation 

 No agreement or understanding varying or extending this Agreement is legally
binding upon either party unless the agreement or understanding is in writing and signed by both parties. 
  

	30.5	Approvals and consents 

 Except where this Agreement expressly states otherwise, a party
may, in its discretion, give conditionally or unconditionally or withhold any approval or consent under this Agreement. 
  

	30.6	Assignment and novation 

 A party may only assign its rights or novate its rights and
obligations under this Agreement with the prior written consent of the other party. 
  

	30.7	Costs 

 Each party must pay its own costs of negotiating, preparing and executing this
Agreement. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 38	 

	30.8	Counterparts 

 This Agreement may be executed in counterparts. All executed counterparts
constitute one document. 
  

	30.9	No merger 

 The rights and obligations of the parties under this Agreement do not merge
on completion of any transaction contemplated by this Agreement. 
  

	30.10 	Entire agreement 

 This Agreement constitutes the entire agreement between the parties in
connection with its subject matter and supersedes all previous agreements or understandings between the parties in connection with its subject matter. 
  

	30.11 	Further action 

 Each party must do, at its own expense, everything reasonably necessary
(including executing documents) to give full effect to this Agreement and any transaction contemplated by it. 
  

	30.12 	Severability 

 A term or part of a term of this Agreement that is illegal or
unenforceable may be severed from this Agreement and the remaining terms or parts of the terms of this Agreement continue in force. 
  

	30.13 	Waiver 

 Waiver of any provision of or right under this Agreement: 

 

	 	(a)	must be in writing signed by the party entitled to the benefit of that provision or right; and 

  

	 	(b)	is effective only to the extent set out in any written waiver. 

  

	30.14 	Relationship 

  

	 	(a)	The parties must not represent themselves, and must ensure that their officers, employees, agents and subcontractors do not represent themselves, as being an officer, employee, partner or agent of the other party, or as
otherwise able to bind or represent the other party. 

  

	 	(b)	This Agreement does not create a relationship of employment, agency or partnership between the parties. 

  

	30.15 	Governing law and jurisdiction 

 This Agreement is governed by the law of the Australian
Capital Territory and each party irrevocably and unconditionally submits to the non-exclusive jurisdiction of the courts of the Australian Capital Territory. 

 

	30.16 	False or misleading information 

  

	 	(a)	The Recipient acknowledges that giving false or misleading information to the Commonwealth is a serious offence under section 137.1 of the Criminal Code Act 1995 (Criminal Code). 

 

	 	(b)	The Recipient must ensure that all Project Partners and any subcontractor engaged in connection with the Agreement acknowledges the information contained in this clause. 

Note: Under section 137 of the Criminal Code giving false or misleading information to a Commonwealth entity is an offence, but only if the
Commonwealth entity took reasonable steps to inform the person of the offence.  

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 39	 

	30.17 	Safe and ethical research 

 When research in Australia is conducted on or involving
humans or animals, the Recipient, in relation to any such research conducted by it or any of the Project Partners, must 
  

	 	(a)	ensure that the research complies with, and that it observes, all relevant ethics codes and guidelines adopted by the National Health and Medical Research Council, the Office of the Gene Technology Regulator and all
other relevant regulatory agencies operating in Australia and any place in which the research is being conducted being codes and guidelines in force from time to time during the Agreement Period, including requirements to obtain prior approval in
writing (including from any relevant ethics committee) that the research to be undertaken is so compliant. 

  

	 	(b)	engage one or several higher education institution(s), or Federal or State research organisation(s), or medical institution(s) with a relevant ethics committee constituted in accordance with the codes and guidelines
referred to in clause 30.17(a) to oversee all ethical clearances which may be required under those codes and guidelines. 

  

	 	(c)	When conducting research in Australia which involves the use of ionising radiation, the Recipient must ensure that persons performing procedures involving ionising radiation are appropriately trained and hold a relevant
current licence from the appropriate State authority. 

  

	 	(d)	Whenever reasonably required by the Commonwealth, the Recipient must promptly provide to the Commonwealth written evidence of compliance with the requirements of this clause. 

 

	30.18 	Responsible conduct of research 

  

	 	(a)	The Recipient must ensure that research conducted by it and each Project Partner conforms to the principles outlined in the following and their successor documents: 

 

	 	(i)	the NHMRC/ARC/UA Australian Code for the Responsible Conduct of Research (2007); and 

  

	 	(ii)	if applicable, the NHMRC/ARC/AVCC National Statement on Ethical Conduct in Human Research (2007). 

  

	 	(b)	The Recipient must ensure that it and each Project Partner: 

  

	 	(i)	promote the responsible conduct of research; 

  

	 	(ii)	maintain high standards of responsible research; 

  

	 	(iii)	report research responsibly; 

  

	 	(iv)	respect all research participants; 

  

	 	(v)	respect animals used in research; 

  

	 	(vi)	respect the environment; and 

  

	 	(vii)	report research misconduct. 

  

	 	(c)	The Recipient must have, and must ensure that each Project Partner has, procedures in place for dealing with instances of suspected or alleged research misconduct which are consistent with the principles referred to at
clause 30.18(a). 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 40	 

 Schedule 1– Agreement Details 

 
  

							
	 Item

number
	  	Description	  	Clause
Reference	  	 Details

	1.	  	Commonwealth	  	1.1	  	 Commonwealth of Australia as represented by the Department of Industry, Innovation and Science

 
 Industry House

10 Binara Street
 Canberra City ACT 2601

 
 ABN 74 599 608 295

				
	2.	  	Recipient	  	1.1	  	 Novogen Ltd
 PO Box 2333,

Hornsby Westfield,
 Hornsby, NSW 1635

ABN 37 063 259 754

				
	3.	  	Commonwealth
Representative	  	1.1 and
11.1	  	 General Manager,
 Single Business Service
Programme and CRC Programme

				
	4.	  	Recipient
Representative	  	1.1 and
11.1	  	 Dr Stephen Palmer
 Program Director

Novogen Ltd

				
	5.	  	Project
Partners	  	1.1	  	 I C P – Firefly Pty Limited
 SME industry
participant
 Address: PO Box 6198
 Alexandria, NSW 2015

ABN: 66 071 626 358
  

University of New South Wales (UNSW)
 School of Medical
Sciences
 Research participant
 Address: Professor Peter
Gunning, School of Medical Sciences,
 Wallace Wurth Building West, Rm 254, UNSW Australia, NSW 2052

ABN: 57 195 873 179

				
	6.	  	Programme	  	1.1	  	The Cooperative Research Centres Programme (CRC Programme)
				
	7.	  	Commencement
Date	  	1.1 and 3	  	1 March 2017, or the date of execution of this Agreement, whichever is the later.
				
	8.	  	End Date	  	1.1 and 3	  	29 February 2020
				
	9.	  	Guidelines	  	4.1	  	The Cooperative Research Centres Programme Guidelines, and any related documentation developed to assist the management and administration of the CRC Programme, issued by the Commonwealth and as amended from time to time.

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 41	 

							
	 Item

number
	  	Description	  	Clause
Reference	  	 Details

	10.	  	Policy and
requirements	  	4.1	  	The National Principles of Intellectual Property Management for Publicly Funded Research
				
	11.	  	Acknowledgment
of support	  	4.2	  	Acknowledgement of support must be made in accordance with any relevant Guidelines issued by the Commonwealth from time to time, and as amended from time to time.
				
	12.	  	Subcontractors	  	13.1	  	 Prof. William Lehman, Boston University, Boston MA 02215 USA. (ABN not applicable)

 
 Sanoosa Pty. Ltd. Level 30, 35 Collins St, Melbourne VIC 3000

Australia (ABN: 39 610 409 455)
  

K&L Gates, Level 25, 525 Collins St, Melbourne VIC 3000

Australia (ABN: 81 310 965 026)
  

Dr Andrew Burgess, The Garvan Institute, Sydney, NSW 2010, Australia.

(ABN: 62 330 391 937)
  

ACRF Drug Discovery Centre, Children’s Cancer Institute Australia, PO Box 81, Randwick NSW 2031, Australia. (ABN 41 072 279 559)

 
 GVK Biosciences Private Ltd, Plot No. 28 A, IDA Nacharam, Hyderabad 500076, India.
(ABN not applicable)
  
 Jubilant Biosys Ltd, 2nd Stage, Yeshwanthpur, Bangalore-560022, Karnataka, India. (ABN not applicable)
  

Pluriomics B.V. Biopartner Building 3, Galileiweg 8, 2333 BD Leiden, The Netherlands. (ABN not applicable)

 
 Ricerca Biosciences, PO Box 932488, Cleveland, OH 44193 USA (ABN not
applicable)

				
	13.	  	Specified
Personnel	  	1.1 and 13	  	 Novogen
 Dr S Palmer Program Director
0.8xFTE
 Dr J Hook UNSW Research Officer 1.0xFTE
  

I C P - Firefly
 Dr I Meyer-Carrive 0.1xFTE

 
 UNSW

Prof. P Gunning 0.1xFTE

				
	14.	  	Commonwealth
Material	  	1.1, 15.3
and 15.4	  	 •       CRC Indicia:

 
 The license granted to the Recipient and Project Partners by the Commonwealth under
clause 15.3(b)(iii), in so far as it relates to CRC Indicia is subject to the following conditions, directions or restrictions:

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 42	 

							
	 Item

number
	  	Description	  	Clause
Reference	  	 Details

				
		  		  		  	 a)      The Recipient must ensure that where it grants a sub-license to the Project Partners under clause 15.3(b)(iii), that:
  

(i)     the Project Partners acknowledge that the Commonwealth owns all rights in the CRC
Indicia;
  
 (ii)    the term
of the sublicense ceases on or before the End Date;
  

(iii)  the Project Partners are bound by the same conditions imposed on the Recipient by the
Commonwealth;
  
 (iv)   the
sublicense does not include a further right of sublicense;
  

(v)    the sublicense is automatically revoked upon termination or expiration of this
Agreement.
  

b)      The Recipient must cease using the CRC Indicia by the End Date or from the date
the Agreement is otherwise terminated, except where acknowledgement of support under clause 4.2(a) or 4.2(c) is required where these publications or public announcements are not released until after the End Date.

				
	15.	  	Pre-existing
Material	  	1.1	  	 Recipient’s pre-existing material

 
 1.      All
pre-existing data generated by the Recipient’s sponsored research in pursuit of tropomyosin binding compounds that are relevant to the aims of the Project.
  

2.      All other techniques, know-how, software
and materials (regardless of the form or medium in which they are disclosed or stored) that are provided by or on behalf of the Recipient for use in the Project.

				
	16.	  	Intellectual
Property –
licences	  	1.1 and 15	  	 Period of licence to Commonwealth granted in clause 15.3(b)(i) is:

Perpetual

				
	17.	  	Moral
Rights –
Specified
Acts	  	1.1 and 16	  	Not Applicable

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 43	 

							
	 Item

number
	  	Description	  	Clause
Reference	  	 Details

	18.	  	Insurance	  	18	  	Not Applicable
				
	19.	  	Confidential
Information	  	1.1 and 20	  	 Recipient’s Confidential Information
  

1.      The Participants Agreement (period of time: in perpetuity)

 
 2.      All of the
Recipient’s Pre-existing Material
  

3.      All Agreement Material, other than the reports required to be provided to the
Commonwealth as detailed in Schedule 3.
  
 For the Agreement Material and Pre-existing Material, the period of confidentiality persists until; (1) notified by the Recipient that the contents therein have sufficient intellectual property protection to ensure that disclosure could
offer no detriment to commercial gain, or (2) notified by the Recipient that the contents therein are no longer subject to confidentiality because of prior disclosures or discontinuance of work on the subject matter.

				
	20.	  	Address for
Notices	  	29	  	 Commonwealth:
  

General Manager,
 Single Business Service Programme and CRC

Programme
  

GPO Box 9839
 Canberra ACT 2601

 
 Industry House

10 Binara Street
 Canberra City ACT 2601

 
 Email: crc.program@industry.gov.au

 
 Recipient:

Dr Stephen Palmer
 Program Director

Novogen Ltd
  

PO BOX 2333
 Hornsby Westfeild

Hornsby NSW 1635
  

Suite 502
 20 George Street

Hornsby NSW 2077
  

Email: stephen.palmer@novogen.com

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 44	 

 Schedule 2 – Project 

 
  

	1.	Project overview, Outcomes and impacts (clauses 1.1 and 4.1) 

 Cancer therapies have a global market value of
$50bn/year, growing 6%/annum with constant demand for new treatments. This project aims to provide improved chemotherapy for advanced metastatic disease through an Australian innovation to selectively destroy cancer cells using anti-tropomyosin
(ATM) drugs. Prototype ATMs have demonstrated proof of concept in model systems but CRC-P investment is needed to perfect this technology and create a clinical product with high commercial value. The key
activities include protein structure research and computer-aided modelling of the target protein, manufacture and screening of compounds designed to fit and to disrupt the function of the target protein, refinement of pharmaceutic properties and
drug delivery methods, advancement to screening and testing in animal models of cancer to demonstrate evidence of efficacy and completion of all of the standard toxicology tests required for submission of an Investigational New Drug (IND)
application to the FDA. The project outcomes will be a novel anti-cancer drug with a scalable manufacturing strategy, an established delivery route, an understanding of which cancer types are most susceptible to this drug (influencing clinical
strategy) and a comprehensive portfolio of preclinical evidence supporting treatment of advanced metastatic disease. At project end, the drug will have all of the regulatory compliance data required for entry into clinical trials, with the aim of
establishing clinical efficacy within a further 3 years (end of phase II) allowing subsequent licensing deals with multinational pharmaceutical companies to advance the product through phase III and on to market approval. 

 

	2.	Project activities (clause 1.1) 

 Tropomyosin proteins are divided into a diverse array of isoforms. For reasons
that are not fully understood, but may relate to high turnover properties, cancer cells selectively develop a strong bias towards expression of the low molecular weight tropomyosin isoform Tpm3.1, on which they become dependent for survival. This
provides a selective target for a novel form of anti-cancer treatment. All tropomyosins first form dimers and then assemble on the actin core through head-to-tail
interactions. This interaction domain is a site of vulnerability that we will target by drug interference. Professor William Lehman (Boston University) is a world expert in the ultrastructure of the actin-tropomyosin polymer and will use
combinations of protein structure research (e.g. X-ray crystallography) and computer-aided molecular analysis to develop a sophisticated model of the target site. Our Novogen chemistry experts will design
libraries of organic molecules predicted to fit the target site and disrupt its normal function. These libraries will enter a screening cascade that begins with basic cell culture screens to determine the relative potential efficacy of each
compound. At UNSW, high throughput screening and high-content microscopy systems will be used to test; (1) compound potency against multiple independent adult cancer cell lines, (2) on-target impact
on microfilament depolymerisation using detection of actin filaments and computer-aided analysis, (3) potency of synergistic effects with a variety of pre-existing anti-cancer drugs to determine the
potential utility of combination therapy and the potential to overcome resistance mechanisms. Flexible investigative studies will also be conducted to determine the binding dynamics and specificity of the compounds using functional biochemistry in
cell-free systems. A selection of the top performing compounds will be submitted for in vitro predictive absorption, distribution, metabolism, excretion and toxicology (ADMET) analysis. All of these data will be collated for quantitative structure
activity relationship (QSAR) analysis for further rounds of modelling, drug design, synthesis and screening. These cycles will continue until the structure is maximally refined to meet the expectations of the target product profile. Overlapping
studies will advance selected lead candidates to preclinical formulation studies, efficacy testing in simple in vivo cancer models, drug delivery route analysis and maximum tolerated dosage analysis (at ICP Firefly). More sophisticated analyses of
effects on tumour growth and metastasis will follow, using specialised cell lines that allow whole body imaging of cancer progression and animal cancer models that are based on patient-derived explants and orthotopic tumour development. During the
final stage, a lead drug product will be selected from the top performing compounds and manufactured to GLP standards to undergo the battery of in vivo toxicity compliance testing necessary to support an IND application to the FDA. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 45	 

	3.	Compliance Milestones (clauses 1.1, 4.1, 11 and 12) 

  

					
	 No.
	  	 Milestone
	  	 Due Date

	1.	  	Submission of completed Participants Agreement	  	Within 60 days of Commencement Date
			
	2.	  	Submission of Quarterly Report	  	Each Quarter in accordance with Guidelines
			
	3.	  	Submission of End of Project Report	  	After the End Date in accordance with Guidelines

  

	4.	Performance Milestones (clause 1.1 and 4.1) 

  

			
	 No.
	  	 Performance Milestone

	 1
	  	 Title:
             Anti-tropomyosin compound libraries designed and synthesised
  

Start date:     1 March 2017

End date:       31 August 2018

 
 Description:

 
 By end date: a broad library of molecules that bind to tropomyosin 3.1 with specificity
and the ability to disrupt its function in cells will be completed. The process is cyclical - feedback from the parallel in vitro screens (Milestone 2) will improve modelling and design, allowing refinement of the activity and pharmaceutical
properties.
  
 Methods: Protein structural research and computer-aided modelling
(Boston University) will dictate design of the new chemical entities (Novogen chemists), which will be manufactured by contract chemists with a strong existing Novogen relationship (GVK Hyderabad).

		
	 2
	  	 Title:             Compound
library in vitro screens completed
  
 Start
date:    1 March 2017
 End date:      28 February
2019
  
 Description:

 
 By end date: a set of lead candidate compounds
(5-10) from within the chemical library generated (Milestone 1) will have been selected, that have the most favourable (1) specificity (2) potency (3) synergy (4) pharmaceutic properties, with
respect to the target product profile. This will permit advancement to the in vivo screens (Milestone 3).
  

Methods: High-content screens using cultured cancer cell lines (UNSW) will be used to assess impact of drugs on actin microfilaments, cell killing potency and
synergy with pre-existing anti-cancer drugs. Cell-free systems will be used to assess protein binding dynamics and specificity (UNSW). A subset of the better-performing compounds will be screened for drug-like
properties such as solubility, absorption, metabolism and cell toxicity (GVK Hyderabad).

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 46	 

			
	 3
	  	 Title:              In vivo
screens of lead candidates completed and single lead compound selected
  

Start date:     1 March 2018

End date:       28 February 2019

 
 Description:

 
 By end date: a single lead compound from the
(5-10) lead candidate molecules will have been selected based on detailed evidence of compound efficacy in rodent models of cancer and the study of compound side-effects and pharmacokinetics in animals.

 
 Methods: Mice with engrafted cancer cell lines or patient-derived tumours will be
treated with lead candidates either alone or in combination with synergising compounds identified in the in vitro screens (I C P - Firefly). Delivery routes, behaviour (pharmacokinetics) of the drugs and potential toxicities will be carefully
monitored in rodents (I C P - Firefly). Some detailed analyses will investigate the biology of compound impact using more sophisticated analytical techniques (UNSW). A variety of in vitro and vivo techniques will explore the mechanisms of action for
synergism, the types of cancer that are most susceptible to the novel therapy and the response of cell lines that are resistant to other forms of treatment, in order to develop a detailed strategy for entry into clinical trials and beyond
(UNSW & Others).

		
	 4
	  	 Title:
             IND-enabling studies completed in readiness for clinical trials

 
 Start date:
    1 March 2019
 End date:       29 February
2020
  
 Description:

 
 By end date: all of the regulatory compliance studies required by the FDA for
investigational new drug (IND) application will have been completed in order to begin progression to clinical trials.
  

Methods: The lead compound will be manufactured to GLP standard for use in a battery of QA in vitro and in vivo tests, plus information on drug formulation,
delivery route (preferably oral) and pharmacokinetic performance. Most tests performed by I C P - Firefly but some specialist tests (e.g. cardiotoxicity and genotoxicity) performed at overseas centres.

		
	 5
	  	 Title:
             CRC-P students enrolled and CRC-P staff employed and trained

 
 Start date:
    1 March 2017
 End date:       29 February
2020
  
 Description:

 
 By end date: 1 PhD student will have been recruited, enrolled and will have completed
greater than 50% of their benchwork for award of their degree. At least 2 honours students will either have completed their degrees or will have been recruited to the program for thesis submission in late 2020. At least 2 members of staff, funded by
the CRC-P, will have been recruited to the program and trained to perform their required function within the project.
  

Methods: Search for recruitment of a competent PhD student will begin on the start date. Supervison will be by members of the
in-kind CRC-P team at UNSW and Novogen, and internal UNSW PhD review procedures will ensure adequate progress of the student. Medical research PhDs are typically 3.5-4yrs in duration. Regardless of the PhD enrolment date, Novogen will continue to support the PhD student beyond the life of the grant until thesis submission. Two honours students will be recruited sequentially
to avoid overcommitment to teaching. The honours period of study is usually March-October of each year, which precludes the possibility of recruitment in 2017. Ideally, the first honours student will be in 2018 and the second in 2019. Novogen will
support any enrolments that overrun the life of the grant until thesis submission. At least 2 members of staff will be recruited to the project as soon as practicable after execution of this contract, sited primarily at UNSW and at Novogen, and will
be trained by skilled members of the existing workforce to perform their required duties.

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 47	 

			
	 6
	  	 Title:             Completion of
the Project
 Due date:      29 February 2020

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 48	 

 Schedule 3 – Reporting 

 
  

	1.	Quarterly reports 

 Throughout the Agreement Period, the Recipient must provide to the
Commonwealth, in accordance with any relevant Guidelines, a quarterly report after the end of each Quarter incorporating: 
  

	 	(a)	an overview of any Project Milestones and Outcomes achieved in that Quarter, and/or an evaluation of progress in achieving upcoming, scheduled Milestones; 

 

	 	(b)	a list of any changes to Recipient and/or Project Partner structure/ownership/involvement, Agreement Material, key personnel, etc., that could affect compliance with this Agreement; 

 

	 	(c)	a cash (not accrual) report in respect of that Quarter indicating the sources of all cash contributions from Participants for the Project; 

 

	 	(d)	a report in respect of that Quarter on the in-kind contributions (FTE and non-staff in-kind)
contributed to the Project; 

  

	 	(e)	a cash (not accrual) report in respect of that Quarter on the expenditure of cash for the Project against each head of expenditure; and 

 

	 	(f)	a declaration by the Recipient certifying the accuracy of the particulars provided under paragraphs (a) to (e), including a statement that the Funds have been expended only for the Project and otherwise in
accordance with this Agreement. 

  

	2.	End of Project Reporting 

 Following the end of the Agreement Period, the Recipient must provide
the Commonwealth with an independent audit certificate covering all Project related income and expenditure in accordance with the Guidelines. 
  

	3.	Post-Project Reporting 

 The Commonwealth may request that the Recipient prepare and provide to
the Commonwealth a report after the end of the Agreement Period in accordance with the Guidelines. 
  

	4.	Ad hoc reports 

 The Recipient must provide ad-hoc
reports as required by the Commonwealth from time to time, at the time and in the manner reasonably required by the Commonwealth in relation to any significant developments concerning the Project or any significant delays or difficulties encountered
in undertaking the Project.  

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 49	 

 Schedule 4 – Funds, contributions and budget 

 
  

	1.	Funds (clause 1.1) 

 The total amount of the Funds is $3,000,000 (excluding GST).

  

	2.	Payment (clauses 1.1, 7 and 8.4) 

 Payment of Funds for the Project will be made quarterly by
the Commonwealth subject to satisfactory Project progress and other requirements under this Agreement (Clauses 7, 8, 9, 11 and 27). 
 The
initial payment will be a proportion of the first quarterly payment paid on commencement of this Agreement, subject to the Commonwealth being satisfied that significant progress has been made in finalising the Participants Agreement. The balance of
the first quarterly amount will be payable in arrears subject to the Participants Agreement having commenced and the provision of a satisfactory quarterly report to the Commonwealth. 

Subsequent quarterly payments will be made in arrears subject to the provision of a satisfactory quarterly report to the Commonwealth and
compliance with reporting requirements under this Agreement. Before the final payment is made, an independent audit certificate from the CRC Project will be required in accordance with any Guidelines issued by the Commonwealth. 

The schedule of quarterly payments is set out in the table below. 
  

															
	 Year
	  	 Quarter
	  	Instalment
(excl. GST)	 	  	GST
component	 	  	Total
(incl.
GST)	 
	 2016-17
	  	Jan-Mar (Q3) (initial)	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	Jan-Mar (Q3) (balance)	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	Apr-Jun (Q4)	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  	Total for 2016-17	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 2017-18
	  	Jul-Sep (Q1)	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	Oct-Dec (Q2)	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	Jan-Mar (Q3)	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	Apr-Jun (Q4)	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  	Total for 2017-18	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 2018-19
	  	Jul-Sep (Q1)	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	Oct-Dec (Q2)	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	Jan-Mar (Q3)	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	Apr-Jun (Q4)	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  	Total for 2018-19	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 2019-20
	  	Jul-Sep (Q1)	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	Oct-Dec (Q2)	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	Jan-Mar (Q3)	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  	Total for 2019-20	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total
	  	Total for all years	  	$	3,000,000	 	  	 	XXXXX	 	  	 	XXXXX	 
		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 50	 

	3.	Participant Contributions (clauses 1.1, 5.1 and 6.1) 

  

																					
	 Recipient/Lead Participant:
	  	 	Novogen Limited	 
						
	 Contribution type
	  	2016-17	 	  	2017-18	 	  	2018-19	 	  	2019-20	 	  	Total	 
	 Cash
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	$	1,000,000	 
	 FTE
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 FTE value
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 Non-staff
in-kind
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total value of contributions
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		
	 Participant:
	  	 	I C P - Firefly Pty Limited	 
						
	 Contribution type
	  	2016-17	 	  	2017-18	 	  	2018-19	 	  	2019-20	 	  	Total	 
	 Cash
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 FTE
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 FTE value
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 Non-staff
in-kind
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total value of contributions
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		
	 Participant:
	  	 	University of New South Wales	 
						
	 Contribution type
	  	2016-17	 	  	2017-18	 	  	2018-19	 	  	2019-20	 	  	Total	 
	 Cash
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	$	300,000	 
	 FTE
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 FTE value
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 Non-staff
in-kind
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total value of contributions
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		
	 TOTAL PARTICIPANT CONTRIBUTIONS
	  			
						
	 Contribution type
	  	2016-17	 	  	2017-18	 	  	2018-19	 	  	2019-20	 	  	Total	 
	 Cash
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 FTE
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 FTE value
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 Non-staff
in-kind
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total value of contributions
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 

 Note: FTE = Full-Time Equivalent as it relates to staff in-kind contributions. FTE
Value is calculated by multiplying the FTE value by XXXX. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 51	 

	4.	Budget (clauses 1.1 and 9.1) 

  

																					
	 Heads of expenditure
	  	2016-17	 	  	2017-18	 	  	2018-19	 	  	2019-20	 	  	Total	 
	 Employee
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 Supplier
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 Capital
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 Other
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total expenditure
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 52	 

 Signing page 

 
 EXECUTED as an agreement. 

 

			
	 Signed for and on behalf of the 

Commonwealth of Australia as
 represented by the
Department of
 Industry, Innovation and Science by its

duly authorised delegate in the presence of

 

							
		 	f	  		  	f
	  
 Signature of witness

 
	 		  	  
 Signature of delegate

 
	  	
	  
 Name of witness (print)

 
	 		  	  
 Name of delegate (print)

 
	  	
		 		  	  
 Position of delegate (print)

 
	  	
	  
 Date

 
	 		  	  
 Date
	  	
	 Executed by Novogen Ltd in accordance with section 127 of the Corporations Act 2001 in the presence of

 
	 	f	  		  	f
	  
 Signature of director

 
	 		  	  
 Signature of director/company
secretary/sole director and sole company secretary
 (delete as applicable)

 
	  	
	  
 Name of director (print)

 
	 		  	  
 Name of director/company
secretary/sole director and sole company secretary (print)
  
	  	
	  
 Date
	 		  	  
 Date¬
	  	

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	CRC-P Funding Agreement CRC-P53981 | Novogen Limited | March 2017	  	 	page 53

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]